The Weekly Term Sheet (2026-W13)
W13 (March 23-28, 2026) opened with a striking signal for the autoimmune T-cell engager space. On Monday, Gilead Sciences announced a $2.175 billion acquisition of Ouro Medicines—adding a clinical-stage BCMAxCD3 T-cell engager with an intricate Galapagos co-development structure including 20-23% royalties on global net sales—while Sanofi simultaneously committed $1.23 billion to license Kali Therapeutics' masked tri-specific CD19/BCMA/CD3 antibody KT501. Over $3.4 billion in autoimmune TCE deal value on a single day underscores the modality's emergence as the hottest licensing category in 2026 biopharma.
On Tuesday, Merck announced the week's largest new deal: a $6.7 billion acquisition of Terns Pharmaceuticals ($53/share, ~$5.7 billion net of acquired cash) for TERN-701, an oral allosteric BCR::ABL1 inhibitor in Phase 1/2 for chronic myeloid leukemia.
TERN-701 carries a notably light upstream royalty obligation of 0.75-1.25% to Hansoh on ex-Greater China net sales---among the cleanest royalty profiles in any major 2026 acquisition. On Friday, Novartis announced a $2 billion acquisition of Excellergy, adding the first-in-class anti-IgE ECRI Exl-111 to its immunology portfolio, while Otsuka Pharmaceutical announced a $1.225 billion acquisition of Transcend Therapeutics, securing a Breakthrough Therapy-designated MDMA analog for PTSD.
Also on Friday, AnaptysBio approved a spin-off of First Tracks Biotherapeutics backed by a $145 million private placement, restructuring itself into a royalty-management entity overseeing Jemperli (GSK) and imsidolimab (Vanda) economics---a move underscored by the appointment of Susannah Gray, former CFO of Royalty Pharma, to the AnaptysBio board.
Combined with the prior week's $3 billion Synnovation deal, Novartis committed up to $5 billion in acquisitions within eight days. The FDA approved Novo Nordisk's Awiqli (insulin icodec) on March 26---the first-ever once-weekly basal insulin for type 2 diabetes---adding a fifth FDA approval to the week alongside Lynavoy (linerixibat, approved March 17 ahead of its March 24 PDUFA), Lifyorli, AVLAYAH, and Kresladi. The Lynavoy approval triggered a $100 million FDA approval milestone from Alfasigma to GSK under their $690 million licensing agreement.
Abbott completed its previously announced $21 billion acquisition of Exact Sciences on March 23, closing the largest diagnostics M&A transaction in history. Cencora acquired EyeSouth Partners' retina business from Olympus Partners for $1.1 billion, and Pfizer and Valneva reported mixed Phase 3 results for their Lyme disease vaccine candidate—sending Valneva shares down 37% despite 73.2% demonstrated efficacy.
Mid-week deal flow included MSD's $2.2 billion IBD target discovery alliance with Quotient Therapeutics, Shionogi's $100 million buyout of Apnimed's sleep disorder JV stake, and Everest Medicines' $50 million acquisition of Greater China rights to CARDAMYST (etripamil). Alteogen signed a Hybrozyme SC reformulation license with Biogen worth up to $579 million, extending a platform portfolio that now spans Merck, Pfizer, Sandoz, and Teva. Maze Therapeutics received a $20 million milestone from Shionogi on first patient dosing in the ESPRIT Phase 2 trial of its oral Pompe disease candidate MZE001.
On the financing side, Earendil Labs raised $787 million anchored by Sanofi and the Pfizer/Hillhouse Biotech Development Fund---though the company's IP provenance warrants scrutiny: Earendil is a Delaware entity affiliated with Helixon Therapeutics (China), using HXN-prefixed compound designations, and the IP relationship between the two entities is not publicly detailed, creating questions about clean IP transfer and regulatory constraints.
Apogee Therapeutics closed a $403 million upsized public offering at $70/share on the back of strong Phase 2 atopic dermatitis data. UCB announced a $2 billion investment to build its first U.S. biologics manufacturing facility in Gwinnett County, Georgia.
Tuesday delivered two significant FDA approvals. Corcept Therapeutics received full approval for Lifyorli (relacorilant) in platinum-resistant ovarian cancer---3.5 months ahead of the PDUFA date---with a 35% reduction in risk of death and a $37,900/cycle WAC.
The drug carries zero royalty obligations in this indication, making it a strong synthetic royalty financing candidate.
Denali Therapeutics received accelerated approval for AVLAYAH (tividenofusp alfa) in Hunter syndrome, triggering a $200 million Royalty Pharma closing, an F-star regulatory milestone, and a Rare Pediatric Disease PRV worth an estimated $150-160 million---roughly $350-400 million+ in immediate economic value from a single approval.
Karyopharm reported mixed Phase 3 SENTRY myelofibrosis data---selinexor nearly doubled spleen volume responses (50% vs. 28%) but missed the symptom co-primary---while simultaneously securing a $30 million RA Capital placement tied to its upcoming endometrial cancer readout. Maze Therapeutics reported positive Phase 2 proof-of-concept for its APOL1 inhibitor MZE829 in kidney disease (35.6% uACR reduction broadly, 61.8% in FSGS), though shares fell 30% on breadth-of-response concerns.
The week closed with Rocket Pharma's Kresladi receiving FDA approval for LAD-I gene therapy two days early---triggering a PRV worth an estimated $150-160 million---AstraZeneca's tozorakimab delivering a landmark dual Phase 3 success in COPD (the first anti-IL-33 biologic to achieve confirmatory Phase 3 results, with $3-5 billion peak sales potential)---and the AAD 2026 annual meeting delivering landmark Phase 3 validations for both Alumis (envudeucitinib) and Takeda (zasocitinib) in psoriasis, plus AbbVie's first Phase 3 vitiligo data for Rinvoq.
Running in the background: Gilead's $7.8 billion tender offer for Arcellx (including a $5/share CVR tied to $6 billion in anito-cel sales) remained active throughout the week, and Arbutus Biopharma disclosed its $2.25 billion Moderna LNP patent settlement ($950 million upfront plus a $1.3 billion contingent Federal Circuit payment). The AD/PD 2026 congress delivered the definitive Phase 3 failure of Novo Nordisk's oral semaglutide in Alzheimer's disease, alongside encouraging 5-year prasinezumab data in Parkinson's.
Deal Closings
Abbott / Exact Sciences: $21 Billion Acquisition Closes
On March 23, 2026, Abbott (NYSE: ABT) completed its acquisition of Exact Sciences Corporation—closing the largest diagnostics M&A transaction in history. The deal was originally announced on November 20, 2025, and its transaction economics ($105 per share in cash, ~$21 billion equity value, ~$23 billion enterprise value) are attributed to that period. The March 23 event marks the formal closing following receipt of all regulatory clearances and Exact Sciences shareholder approval (obtained February 20, 2026, with 99.6% of votes cast in favor).
Deal Terms (Previously Announced, November 2025)
$105 per share in cash (~$21 billion equity value, ~$23 billion enterprise value including ~$1.8 billion net debt absorption). Financed via a $20 billion senior notes offering across eight tranches at 3.7-5.6% coupons (2029-2066 maturities), completed March 9, 2026.
The SEC 424B5 prospectus reveals a 16-bank syndicate across three tiers: four lead joint book-running managers (Morgan Stanley, Barclays, BofA Securities, and J.P. Morgan); five additional JBRMs on select tranches (BNP Paribas, Citigroup, Deutsche Bank Securities, MUFG, and Société Générale); and eleven co-managers on all notes (HSBC, Mizuho, Santander, Standard Chartered, Goldman Sachs, RBC Capital Markets, Siebert Williams Shank, Academy Securities, BBVA, ING, and US Bancorp). Termination fee: $628.7 million payable by Exact Sciences.
Abbott expects the deal to add ~$3 billion in incremental 2026 sales and dilute adjusted EPS by ~$0.20 through 2027 before turning accretive in 2028.
Advisors
| Role | Firm |
|---|---|
| Abbott financial advisor | Morgan Stanley |
| Abbott M&A legal counsel | Wachtell, Lipton, Rosen & Katz (David K. Lam) |
| Abbott antitrust counsel | Weil, Gotshal & Manges (Kristin Sanford, John Scribner) |
| Exact Sciences financial advisor (lead) | Centerview Partners (delivered fairness opinion) |
| Exact Sciences financial co-advisor | XMS Capital Partners |
| Exact Sciences legal counsel | Skadden, Arps, Slate, Meagher & Flom (Richard C. Witzel Jr., Rachel E. Cohn) |
Strategic Context
Exact Sciences' portfolio---Cologuard/Cologuard Plus (colorectal cancer screening), Oncotype Dx (breast cancer genomic profiling), Cancerguard (multi-cancer early detection), and Oncodetect (molecular residual disease monitoring)---creates the most comprehensive cancer diagnostics platform in the industry under Abbott's umbrella. Abbott valued the combined market at $60 billion. Regulatory clearances were secured from all jurisdictions (HSR, German Bundeskartellamt, EU, UK CMA) with no divestitures required. March 20, 2026 was the last day of Exact Sciences trading on NASDAQ. The deal carries no external licensing or royalty arrangements.
Thermo Fisher Scientific / Clario Holdings: $8.875 Billion Clinical Data Acquisition Closes
On March 24, 2026, Thermo Fisher Scientific (NYSE: TMO) completed its acquisition of Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials, for $8.875 billion in cash at close. The deal was originally announced in late 2025.
Deal Terms
| Term | Detail |
|---|---|
| Acquirer | Thermo Fisher Scientific (NYSE: TMO) |
| Target | Clario Holdings, Inc. |
| Sellers | Astorg (co-lead), Nordic Capital (co-lead), Novo Holdings, Cinven |
| Cash at close | $8.875 billion |
| Deferred payment | $125 million (due January 2027) |
| Performance earn-out | Up to $400 million (tied to 2026--2027 business performance) |
| Total potential consideration | Up to $9.4 billion |
| Expected accretion | Immediately accretive to adjusted EPS in year one |
| Synergies | ~$175 million adjusted operating income by year five |
| Segment | Laboratory Products and Biopharma Services |
Advisors
| Role | Firm |
|---|---|
| Thermo Fisher financial advisor | Not yet disclosed (historically J.P. Morgan and Goldman Sachs on major acquisitions including Life Technologies and PPD; confirmation pending 8-K or deal database) |
| Thermo Fisher deal counsel | WilmerHale |
| Thermo Fisher regulatory counsel | Axinn and Freshfields |
| Clario financial advisor | Evercore (lead) |
| Clario deal counsel | Latham & Watkins |
Strategic Context
Clario's platform integrates clinical trial endpoint data from devices, sites, and patients, supporting approximately 70% of FDA/EMA novel drug approvals over the prior decade. The acquisition strengthens Thermo Fisher's position as an integrated partner across the clinical development value chain. Management guided to high single-digit revenue growth, double-digit internal rates of return, and margin accretion in year one. The deal carries no direct licensing or royalty arrangements but reflects the increasing value of clinical trial infrastructure assets in the pharma ecosystem.
Active CVR Transactions and Major Settlements
Gilead Sciences / Arcellx: $7.8 Billion CAR-T Acquisition with $5/Share CVR (Tender Offer Active During W13)
The Gilead Sciences acquisition of Arcellx (NASDAQ: ACLX), announced February 23, 2026, was the only biopharma CVR-bearing transaction with active deal mechanics during the W13 window. Gilead's tender offer---launched March 6 via Ravens Sub, Inc.---was running throughout March 22--26, with an expiration date of one minute after 11:59 PM ET on April 2, 2026. No material amendments, new filings, or complications were identified during the W13 window specifically.
Deal Structure
| Term | Detail |
|---|---|
| Acquirer | Gilead Sciences (NASDAQ: GILD) |
| Target | Arcellx, Inc. (NASDAQ: ACLX) |
| Cash consideration | $115.00 per share |
| CVR | One non-transferable CVR per share, paying $5.00 if cumulative worldwide net sales of anito-cel exceed $6 billion from launch through December 31, 2029 |
| Total potential consideration | Up to $120.00 per share (~$7.8 billion equity value) |
| Tender offer expiration | April 2, 2026 |
| CVR payment date | March 31, 2030 (if triggered) |
| CVR agent | Computershare Trust Company, N.A. |
| Board recommendation | Unanimous recommendation to tender |
Asset and CVR Trigger Analysis
Anito-cel (anitocabtagene autoleucel) is a fully human BCMA-targeted, D-domain-based chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma. The FDA PDUFA date is December 23, 2026—meaning the drug has not yet been approved, and the $6 billion cumulative sales threshold must be achieved within approximately three years of a potential late-2026 launch.
For context, Johnson & Johnson's Carvykti (ciltacabtagene autoleucel) generated approximately $1.5 billion in its first full year on the US market, and Bristol Myers Squibb's Abecma (idecabtagene vicleucel) peaked at ~$500 million annually before losing share.
Advisors
| Role | Firm |
|---|---|
| Gilead financial advisor | Not yet disclosed (historically J.P. Morgan on major acquisitions including Immunomedics $21B; confirmation pending SC TO-T filing on EDGAR) |
| Gilead legal counsel | Not yet disclosed (historically Wachtell, Lipton, Rosen & Katz; confirmation pending SC TO-T filing) |
| Arcellx financial advisor | Not yet disclosed (confirmation pending SC 14D-9 filing on EDGAR, which will contain the fairness opinion) |
| Arcellx legal counsel | Not yet disclosed (confirmation pending SC 14D-9 filing) |
Upstream IP on Anito-cel (D-Domain CAR-T Platform)
Arcellx's proprietary D-domain technology uses synthetic binding domains based on modified human fibronectin scaffolds rather than traditional single-chain variable fragment (scFv) antibody constructs. Potential upstream obligations include: foundational CAR-T platform IP (University of Pennsylvania holds key patents on CAR-T constructs from Carl June's laboratory), lentiviral vector manufacturing technology licenses, and any D-domain scaffold IP from academic collaborators. Arcellx's 10-K "License Agreements" section and the SC 14D-9 filing's "Material Contracts" exhibit are the authoritative sources for confirming specific obligations and royalty rates. No material upstream royalty has been publicly characterized in Arcellx's SEC filings to date, but the absence of disclosure does not confirm absence of obligation---the SC 14D-9 typically provides the most comprehensive IP encumbrance disclosure.
The CVR's non-transferable structure means it will not trade on any exchange---unlike the legacy BMS/Celgene CVR (ticker: CELG-R), which traded on NYSE and provided continuous market-implied probability pricing. Arcellx shareholders who tender cannot sell their CVR position independently. Gilead's choice of a non-transferable CVR follows the dominant 2025--2026 trend: approximately 27 biopharma deals in 2025 included CVR components (up from 7 in 2024), and nearly all recent CVRs are non-transferable, reducing transparency and price discovery.
Context for Royalty Investors
The Gilead/Arcellx CVR is structurally relevant to the royalty ecosystem in two ways. First, CVRs are increasingly functioning as synthetic milestone-sharing instruments in biopharma M&A---economically equivalent to a milestone payment but structured as a registered security owed to target shareholders rather than a contractual payment to a licensor.
For royalty fund managers modeling target company economics, the distinction matters: CVR obligations sit on the acquirer's balance sheet alongside (and sometimes competing with) upstream royalty and milestone obligations.
Second, the $6 billion cumulative sales trigger creates a specific, publicly observable threshold that can be used to benchmark anito-cel's commercial trajectory against other BCMA CAR-T franchises.
Gilead's broader autoimmune T-cell engager strategy---including the Ouro Medicines acquisition announced the same week (see above)---positions the company as the most active acquirer in the TCE space in 2026, with combined deal value exceeding $10 billion across Arcellx and Ouro.
Arbutus Biopharma / Moderna: $2.25 Billion Global Settlement with Contingent Payment (Filed During W13)
On March 23, 2026, Arbutus Biopharma (NASDAQ: ABUS) filed an 8-K disclosing its previously announced $2.25 billion global settlement with Moderna Inc. resolving all patent disputes related to Arbutus's lipid nanoparticle (LNP) delivery technology used in Moderna's COVID-19 vaccine (Spikevax).
The settlement includes a $1.3 billion contingent payment conditioned on a favorable Federal Circuit ruling---structurally analogous to a CVR in its binary, milestone-like payout profile, though technically a litigation settlement instrument rather than a registered security.
| Term | Detail |
|---|---|
| Upfront payment | $950 million (received) |
| Contingent payment | $1.3 billion (conditioned on Federal Circuit ruling) |
| Total potential settlement | $2.25 billion |
| License | Moderna receives worldwide, non-exclusive license to Arbutus LNP patents |
| Genevant (subsidiary) | Settlement resolves all Genevant-related claims; Arbutus retains full Genevant ownership |
The $1.3 billion contingent tranche is one of the largest binary-outcome payment instruments in biopharma outside of a formal CVR. For the royalty community, Arbutus's LNP patent estate---which covers foundational lipid nanoparticle technology used across the mRNA therapeutics industry---represents a potentially durable royalty-generating asset if the company pursues licensing beyond Moderna. Arbutus reported the settlement in its FY2025 annual results filed during the W13 window.
Other Active CVR Instruments During W13
Lisata Therapeutics / Kuva Labs (announced March 6, 2026): $5.00 per share in cash plus up to $1.00 per share in a non-tradeable CVR tied to NDA filing and/or acceptance for certepetide within seven years of closing. The tender offer was active during the W13 window. Total potential consideration of $6.00 per share.
M&A and Asset Transactions
Merck / Terns Pharmaceuticals: $6.7 Billion CML Acquisition with Hansoh Upstream Royalty
On March 25, 2026, Merck (NYSE: MRK) announced a definitive agreement to acquire Terns Pharmaceuticals (NASDAQ: TERN), a clinical-stage oncology company, for $53.00 per share in cash, representing an approximate equity value of $6.7 billion (~$5.7 billion net of acquired cash). The deal adds TERN-701, an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor, to Merck's expanding hematology pipeline.
Deal Structure
| Term | Detail |
|---|---|
| Acquirer | Merck & Co. (NYSE: MRK) |
| Target | Terns Pharmaceuticals (NASDAQ: TERN) |
| Price per share | $53.00 (cash) |
| Equity value | ~$6.7 billion |
| Net of acquired cash | ~$5.7 billion |
| Premium (60-day VWAP) | ~31% |
| Premium (90-day VWAP) | ~42% |
| Structure | Tender offer followed by merger |
| Accounting treatment | Asset acquisition |
| Expected charge | ~$5.8 billion (~$2.35/share), included in Q2 and FY2026 GAAP and non-GAAP results |
| Expected close | Q2 2026, subject to HSR review and customary conditions |
| Termination fee | $235 million (payable by Terns) |
| Reverse termination fee | $270 million (payable by Merck) |
Advisors
| Role | Firm |
|---|---|
| Terns financial advisors | Centerview Partners and Jefferies |
| Terns legal counsel | Freshfields |
| Merck financial advisor | Not yet disclosed (historically Goldman Sachs on major acquisitions including Acceleron $11.5B and Prometheus $10.8B; confirmation pending SC TO-T filing on EDGAR) |
| Merck legal counsel | Not yet disclosed (historically Cravath, Swaine & Moore; confirmation pending SC TO-T filing on EDGAR) |
Upstream Licensing and Royalty Obligations
TERN-701 originated from a July 2020 Exclusive Option and License Agreement between Terns and Hansoh (Shanghai) Healthtech Co., Ltd., under which Terns granted Hansoh exclusive rights to TERN-701 in mainland China, Taiwan, Hong Kong, and Macau. In January 2026, the agreement was amended to convert Terns' prior non-exclusive, royalty-free license to certain Hansoh-invented patents into an exclusive, sublicensable, royalty-bearing, perpetual worldwide license (excluding the Hansoh Territory). Under the amendment:
| Term | Detail |
|---|---|
| Licensor | Hansoh (Shanghai) Healthtech Co., Ltd. |
| Licensee | Terns Pharmaceuticals (via CaspianTern, LLC) |
| Upfront license fee | $1.0 million |
| Royalties (ex-Greater China) | Tiered 0.75%-1.25% on annual net sales of TERN-701 products, subject to reductions (this rate is substantially below typical out-licensing royalties for comparable geographic scope, which generally range from mid-single to low-double digits; the low rate likely reflects Hansoh's contribution of specific patent improvements rather than the core compound IP, which originated within Terns' own program) |
| Hansoh retained rights | Exclusive development and commercialization in mainland China, Taiwan, Hong Kong, and Macau |
| License scope | Exclusive, sublicensable, perpetual, worldwide (ex-Hansoh Territory) |
The upstream royalty burden is notably light at 0.75-1.25% of net sales---among the lowest royalty obligations in a major 2026 pharma acquisition. This reflects the asset's origin within Terns' own research program (with Hansoh contributing improvements during the collaboration), rather than an in-licensed external asset. For Merck, the clean royalty profile means near-complete retention of commercial economics on global (ex-Greater China) TERN-701 sales, a structural advantage compared to acquisitions where stacked upstream royalties can consume 15-25%+ of net sales (compare the Gilead/Ouro/Galapagos/Keymed structure in this same issue, where combined royalty burdens likely exceed 25%).
Clinical Data and Mechanism
TERN-701 is a novel oral allosteric BCR::ABL1 inhibitor designed to bind the ABL myristoyl pocket---the same mechanism as Novartis' Scemblix (asciminib), the first approved allosteric TKI for CML. TERN-701 is being evaluated in the CARDINAL trial (NCT06163430), a global Phase 1/2 study in patients with Ph+ chronic phase CML who failed or were intolerant to at least one prior TKI. Key clinical milestones:
- Dose escalation completed January 2025 with no dose-limiting toxicities up to 500mg QD
- Dose expansion initiated April 2025 (320mg or 500mg QD, up to 40 patients per arm)
- January 2026: additional cohort added for patients with BCR::ABL1 resistance mutations including T315I, M244V, and F359I/C/V
- Phase 1 data showed a 75% cumulative major molecular response (MMR) rate by 24 weeks, including responses in heavily pretreated patients and those who had previously received allosteric TKIs
- Majority of adverse events were low-grade; no clinically meaningful blood pressure changes; low rates of lipase elevation
Competitive Context and Royalty Implications
The deal is Merck's third multibillion-dollar acquisition in the past year as the company diversifies its oncology portfolio ahead of Keytruda's 2028 patent expiration. Scemblix (asciminib), marketed by Novartis since October 2021, generated $238 million in Q1 2025 sales (up 76% year-over-year) and is projected to reach approximately $2.4 billion by 2030. Scemblix received a positive CHMP opinion for frontline CML in Europe in October 2025 and is approved in the first-line setting in the US, Japan, and China. Novartis CEO Vas Narasimhan has acknowledged that Scemblix growth in first-line CML has plateaued somewhat due to the rarity of CML and physician hesitancy to switch from imatinib.
For royalty investors and the broader pharma transaction ecosystem, this deal offers several valuation benchmarks:
- Phase 1/2 oncology asset acquisition at $5.7 billion (net): sets a high-water mark for allosteric TKI valuations and validates the CML market as a multi-billion-dollar opportunity worth significant premiums
- Minimal upstream royalty burden (0.75-1.25%): contrasts sharply with the trend of stacked royalties seen in other major 2026 acquisitions, providing Merck with a cleaner commercial profile
- Orphan Drug Designation: FDA granted ODD for TERN-701 in CML in March 2024, providing potential market exclusivity benefits
- Hansoh retained Greater China rights: Hansoh's retained territory creates a natural geographic split that could serve as a template for future royalty structures in China-originated assets
- Keytruda patent cliff context: Merck's willingness to pay $6.7 billion for a Phase 1/2 asset reflects the urgency and scale of portfolio diversification required when a $25B+ franchise faces biosimilar competition
- No CVR component: Unlike many 2025--2026 biopharma acquisitions (including Gilead's concurrent Arcellx deal), Merck chose a clean all-cash structure with no contingent value rights despite TERN-701's Phase 1/2 stage---signaling high conviction in the asset's approvability and willingness to pay full value upfront rather than share upside via a CVR
Gilead Sciences / Ouro Medicines: $2.175 Billion Acquisition with Galapagos Collaboration
On March 23, 2026, Gilead Sciences (NASDAQ: GILD) announced a definitive agreement to acquire Ouro Medicines, a privately held clinical-stage biotechnology company developing T-cell engager therapies for autoimmune diseases. The deal adds OM336 (gamgertamig), a clinical-stage BCMAxCD3 bispecific T-cell engager with Fast Track and Orphan Drug Designation, to Gilead's inflammation portfolio.
Deal Structure
| Term | Detail |
|---|---|
| Acquirer | Gilead Sciences (NASDAQ: GILD) |
| Target | Ouro Medicines (San Francisco; founded 2025 by Monograph Capital in partnership with GSK) |
| Upfront cash consideration | $1,675 million |
| Contingent milestone payments | Up to $500 million (contractual earnouts, not tradeable CVRs---unlike Gilead's concurrent Arcellx acquisition, which uses a registered non-transferable CVR for its contingent component) |
| Total potential consideration | Up to $2,175 million |
| Closing conditions | HSR review, customary conditions |
Galapagos Strategic Collaboration
Critically, Gilead simultaneously disclosed advanced discussions with Galapagos NV (EURONEXT: GLPG) on a strategic collaboration that would fundamentally reshape the economics of the acquisition:
| Term | Detail |
|---|---|
| Galapagos cost share (upfront) | 50% of the $1,675 million upfront (~$837.5 million) |
| Galapagos cost share (milestones) | 50% of up to $500 million in contingent milestones |
| Operating assets | Galapagos would absorb substantially all of Ouro's operating assets and retain its employees |
| Development costs | Galapagos responsible through registrational study initiation; registrational costs shared equally |
| Commercialization rights | Gilead retains sole worldwide commercialization (excluding Greater China, licensed to Keymed Biosciences) |
| Royalties | Galapagos receives 20-23% of net sales from Gilead |
| OLCA amendment | Galapagos' legacy Option License and Collaboration Agreement amended to free up to $500 million of Galapagos' cash, including up to $150 million for share repurchases |
This structure is remarkable for several reasons. It effectively uses Galapagos as an R&D subsidiary---Galapagos funds the early development, absorbs the operating team, and bears the pre-registrational risk, while Gilead retains commercial control and pays Galapagos a 20-23% royalty on sales.
Critically, by splitting all costs 50/50, Gilead's net acquisition cost is reduced to approximately $837.5 million upfront and up to $250 million in contingent milestones---less than half the headline figure. The specific sales thresholds that trigger escalation from 20% to 23% remain undisclosed, and no definitive agreement had been filed on EDGAR as of March 25.
The OLCA amendment freeing $500 million in Galapagos cash (including $150 million for buybacks) appears designed to make the arrangement palatable to Galapagos shareholders by creating immediate capital return capacity.
Advisors
| Role | Firm |
|---|---|
| Gilead financial advisors | Centerview Partners and TD Cowen |
| Gilead legal counsel | Covington & Burling, Mayer Brown, and Arnold & Porter Kaye Scholer |
| Ouro Medicines financial advisor | Goldman Sachs & Co. (exclusive) |
| Ouro Medicines legal counsel | Goodwin Procter |
| Galapagos financial advisor | Morgan Stanley & Co. |
| Galapagos legal counsel | Paul Weiss and Linklaters |
Mechanism, Clinical Data, and Upstream Licensing
OM336 (gamgertamig) is a BCMAxCD3 bispecific T-cell engager designed to redirect a patient's T cells toward BCMA-expressing plasma cells, achieving rapid and deep B-cell depletion following a limited subcutaneously administered treatment course. In ongoing Phase 1/2 studies, OM336 has demonstrated what Gilead described as "transformative efficacy and a differentiated safety profile" after a single treatment cycle in severe antibody-mediated orphan diseases including autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP).
The FDA has granted both Fast Track and Orphan Drug Designation for AIHA and ITP. Registrational studies are expected in 2027.
OM336 was originally developed in-house by Keymed Biosciences (HKEX: 2162) as CM336 and licensed to Ouro's subsidiary Platina Medicines in November 2024 under an exclusive license for all territories outside Greater China. The upstream deal terms:
| Term | Detail |
|---|---|
| Licensor | Keymed Biosciences (Chengdu, China; HKEX: 2162) |
| Licensee | Platina Medicines Ltd. (wholly owned by Ouro Medicines) |
| Upfront and near-term payments | $16 million |
| Milestone payments | Up to $610 million (clinical, regulatory, and commercial) |
| Royalties | Tiered royalties on net sales of CM336/OM336 and related products |
| Equity component | Keymed received a minority equity interest in Ouro Medicines (~15% as of the Gilead acquisition announcement), which converts to approximately $250 million in cash from the closing payment |
| Retained rights | Keymed retains Greater China development and commercialization rights |
The Keymed upstream economics create a triple-layered royalty structure: Keymed receives tiered royalties on global (ex-China) net sales under the original license; Galapagos receives 20-23% of net sales under the proposed Gilead collaboration; and Gilead retains the residual commercial economics.
The combined royalty burden---20-23% to Galapagos plus an undisclosed tiered rate to Keymed---likely exceeds 25% of net sales, an unusually high figure that reflects Gilead's willingness to pay premium economics for a validated BCMAxCD3 autoimmune asset approaching registrational stage.
Keymed's ~15% equity stake in Ouro will also be cashed out at approximately $250 million given the $1,675 million upfront consideration. Keymed is concurrently studying CM336 in an ongoing Phase 2 expansion study in multiple myeloma in China.
Ouro Medicines: Founding and Investors
Ouro was founded in 2025 by Monograph Capital (42% equity on a fully diluted basis at the time of the Keymed license) in partnership with GSK, and is backed by TPG (via TPG Life Sciences Innovations), NEA, and Norwest Venture Partners. Keymed holds approximately 15% equity. CEO Jaideep Dudani, Ph.D. is co-founder. The board includes representatives from TPG (Shinichiro Fuse), NEA (Matt McAviney), Norwest (Brian Matesic), Monograph (Tim Funnell), and Keymed (Bo Chen).
Competitive Context and Royalty Implications
The deal arrives on the same day as the Sanofi/Kali Therapeutics TCE license—over $3.4 billion in autoimmune T-cell engager deals in one day. The competitive landscape for BCMA-targeted autoimmune therapies includes BMS/2Seventy Bio (CAR-T), and the Kali Therapeutics tri-specific (CD19/BCMA/CD3) now licensed to Sanofi.
Gilead's existing inflammation pipeline includes filgotinib (Jyseleca, JAK inhibitor) and its CAR-T cell therapy platform (Yescarta, Tecartus), and the Ouro acquisition bridges the company's cell therapy expertise with an off-the-shelf bispecific approach.
For royalty investors, the 20-23% royalty rate payable to Galapagos on global net sales represents one of the highest disclosed royalty rates in a recent autoimmune deal. The Galapagos structure also creates a novel template: a mid-cap biotech functioning as a development-stage royalty investor, bearing pre-registrational costs in exchange for double-digit royalties on a big-pharma-commercialized asset.
Cencora / EyeSouth Partners: $1.1 Billion Retina Business Acquisition
On March 23, 2026, Cencora, Inc. (NYSE: COR) announced a definitive agreement to acquire the retina business of EyeSouth Partners from Olympus Partners for $1.1 billion in cash. Olympus will retain ownership of EyeSouth's Anterior segment business.
Deal Structure
| Term | Detail |
|---|---|
| Seller | Olympus Partners (via EyeSouth Partners) |
| Buyer | Cencora, Inc. (NYSE: COR) |
| Asset | Retina business of EyeSouth Partners |
| Transaction value | $1.1 billion cash |
| Retained by Olympus | Anterior segment business |
| Expected close | Subject to HSR review; not expected within Cencora's FY2026 |
Advisors
| Role | Firm |
|---|---|
| Cencora financial advisors | BofA Securities (lead) and Citi |
| Cencora legal counsel | Sidley Austin |
| EyeSouth/Olympus financial advisor | Jefferies |
| EyeSouth/Olympus legal counsel | Kirkland & Ellis (Matt Goulding, Matt Dunnet) |
Strategic Context
The acquisition folds EyeSouth's retina physicians into Cencora's existing Retina Consultants of America (RCA) platform, more than doubling Cencora's retina physician count from approximately 300 to over 700 and increasing retina market share from roughly 1-2% to over 3%. BofA analyst Allen Lutz estimated a $70M+ EBIT opportunity in CY2027 from the Eylea biosimilar launch alone, and noted this acquisition more than doubles that estimate. The deal is expected to be slightly accretive to adjusted diluted EPS in the first 12 months.
Under Olympus' ownership (since September 2022, acquired from Shore Capital Partners), EyeSouth increased its physician base by more than 130 doctors and expanded into three new states (Michigan, North Carolina, and South Carolina). EyeSouth operates 60+ practice affiliations with 400+ doctors across 276 locations in 14 states, including 26 surgery centers. The Olympus deal team included Griffin Barstis (Partner), Jim Conroy, Sam Greenberg, Heather Deng, and Lester Coleman.
Regulatory Approvals
Corcept Therapeutics: Lifyorli (Relacorilant) FDA Approval in Platinum-Resistant Ovarian Cancer (March 25)
On March 25, 2026, Corcept Therapeutics (NASDAQ: CORT) announced that the U.S.
Food and Drug Administration has approved Lifyorli (relacorilant) in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist (SGRA) and Corcept's second approved product after Korlym (mifepristone) for Cushing's syndrome. The approval came approximately 3.5 months ahead of the July PDUFA target date.
Clinical Data
| Parameter | Relacorilant + nab-paclitaxel | Nab-paclitaxel alone |
|---|---|---|
| Median PFS (BICR) | 6.5 months | 5.5 months |
| PFS hazard ratio | 0.70 (95% CI: 0.54--0.91; p=0.0076) | --- |
| Median OS | 16.0 months | 11.9 months |
| OS hazard ratio | 0.65 (95% CI: 0.51--0.83; p=0.0004) | --- |
| Trial | Phase 3 ROSELLA, 381 patients | --- |
The 35% reduction in risk of death represents a clinically meaningful survival benefit in a difficult-to-treat population. Lifyorli is administered orally on the day before, the day of, and the day after each nab-paclitaxel infusion. No biomarker requirement.
Commercial Profile
| Term | Detail |
|---|---|
| Wholesale acquisition cost | $37,900 per 28-day cycle |
| Estimated eligible U.S. patients | ~10,000 new patients annually starting a new therapy |
| European regulatory status | MAA submitted to EMA; EC Orphan Drug Designation |
| Additional indications in development | Endometrial, cervical, pancreatic, and prostate cancers |
| Cushing's syndrome status | CRL received December 2025; FDA cited need for additional evidence despite successful Phase 3 |
Royalty Financing Relevance: High
Lifyorli is fully proprietary to Corcept with no known third-party royalty obligations---relacorilant is protected by composition-of-matter, method-of-use, and other patents. The compound was discovered entirely in-house as part of Corcept's portfolio of 1,000+ proprietary selective cortisol modulators.
The only disclosed third-party license is with the University of Chicago, covering use-of-cortisol-modulators patents for triple-negative breast cancer and castration-resistant prostate cancer (expiring 2031 and 2033)---this license does not cover ovarian cancer, Lifyorli's approved indication.
Corcept's FY2024 10-K states: "We believe we are not obligated to pay royalties relating to the use of intellectual property to any third parties except the University of Chicago." A historical Stanford University license covers mifepristone/Korlym for psychiatric indications—completely unrelated to relacorilant.
This confirmed zero-royalty-burden profile makes Corcept a strong candidate for synthetic royalty financing, where an investor provides upfront capital in exchange for a percentage of future Lifyorli revenues. The demonstrated OS benefit, clear regulatory pathway, and predictable commercial profile (WAC ~$37,900/cycle, ~10,000 eligible patients annually) create the type of revenue stream royalty investors favor.
Corcept reported FY2025 revenue of $757 million (from Korlym alone), $756 million in cash, and no long-term debt---suggesting the company could pursue synthetic royalty financing from a position of strength rather than necessity.
Notably, the December 2025 CRL in Cushing's syndrome---where the FDA acknowledged a successful Phase 3 but requested additional evidence---means Corcept's near-term revenue diversification relies heavily on Lifyorli's oncology launch. Corcept has proven commercial infrastructure and a second approved product, but its growth trajectory is now more dependent on Lifyorli's execution than it otherwise would be.
Denali Therapeutics: AVLAYAH (Tividenofusp Alfa) Accelerated Approval for Hunter Syndrome (March 25)
On March 25, 2026, Denali Therapeutics (NASDAQ: DNLI) announced that the U.S.
Food and Drug Administration has granted accelerated approval for AVLAYAH (tividenofusp alfa-eknm), an enzyme replacement therapy for the treatment of neurologic manifestations of Hunter syndrome (mucopolysaccharidosis type II, or MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment.
AVLAYAH is the first FDA-approved biologic specifically designed to cross the blood-brain barrier and the first new treatment for Hunter syndrome in approximately 20 years. Approval came approximately 11 days ahead of the April 5 PDUFA date.
Clinical Data and Mechanism
| Parameter | Detail |
|---|---|
| Platform | TransportVehicle (transferrin receptor-mediated BBB crossing) |
| Trial | Phase 1/2, published in NEJM (January 1, 2026) |
| CSF heparan sulfate reduction | 91% by week 24 |
| Patients reaching normal CSF HS levels | 93% |
| Administration | Intravenous, weekly |
| Confirmatory trial | Phase 2/3 COMPASS (ongoing; includes young adults) |
| Continued approval contingent on | Verification of clinical benefit in confirmatory trial |
AVLAYAH uses Denali's proprietary TransportVehicle platform to ferry iduronate-2-sulfatase across the blood-brain barrier via binding to the transferrin receptor. This represents the first clinical validation of the TransportVehicle platform, which has broader applications across neurodegenerative diseases including Parkinson's, ALS, and frontotemporal dementia.
Commercial and Regulatory Details
| Term | Detail |
|---|---|
| List price | $5,200 per 150 mg single-use vial |
| U.S. patient population | ~500 patients (almost exclusively male, X-linked) |
| U.S. availability | Within two weeks of approval |
| Priority Review Voucher | Rare Pediatric Disease PRV awarded (potentially worth >$100M if sold) |
| FDA designations | Breakthrough, Fast Track, Priority Review, Orphan Drug |
Royalty Financing Relevance: High
AVLAYAH presents multiple royalty-relevant dimensions. As a rare disease therapy for ~500 U.S. patients, annual per-patient treatment costs will be substantial---weekly IV infusion at $5,200/vial suggests annualized costs potentially exceeding $250,000 per patient.
The Rare Pediatric Disease PRV provides immediate monetization value. Recent PRV sales have transacted at $150-160 million (Bavarian Nordic $160M in June 2025, Abeona $155M in May 2025, Zevra $150M in February 2025). Denali reported cash and investments of approximately $1.3 billion at year-end 2025, so the PRV represents a meaningful but not critical non-dilutive event.
Most strategically, the TransportVehicle platform validation creates potential for significant future licensing and partnership economics across Denali's broader neuroscience pipeline---including programs in Parkinson's disease and frontotemporal dementia---each of which could generate royalty-bearing agreements.
Milestone Payments Triggered by Approval
The AVLAYAH approval was the single largest milestone-triggering event of W13, activating at least $200 million in confirmed contractual payments and likely more:
| Payment | Payer | Recipient | Amount | Trigger |
|---|---|---|---|---|
| Royalty Pharma synthetic royalty closing | Royalty Pharma | Denali Therapeutics | $200 million (confirmed) | U.S. FDA accelerated approval (closing condition met March 25) |
| F-star TransportVehicle regulatory milestone | Denali Therapeutics | invoX Pharma (F-star) | Low-to-mid tens of millions (estimated, from ~$243M remaining aggregate pool) | First FDA approval under license (milestones only---no royalties on sales) |
| Rare Pediatric Disease PRV | FDA | Denali Therapeutics | $150--160 million (estimated if sold) | PRV awarded alongside approval |
Under the Royalty Pharma funding agreement announced December 4, 2025, Denali receives $200 million at closing (triggered by U.S. accelerated approval) plus a further $75 million upon EMA approval by December 31, 2029. In exchange, Royalty Pharma receives a 9.25% royalty on worldwide AVLAYAH net sales, capped at a 3.0x return on total funding received (~$825 million cap if full $275 million is drawn), or 2.5x if achieved by Q1 2039.
The F-star (invoX Pharma) license underlying the TransportVehicle platform carries milestones from an aggregate pool of approximately $243 million remaining (reduced from the original $447 million after research-phase milestones were paid in earlier years). First FDA approval clearly constitutes a regulatory milestone from this pool, though the specific amount is redacted.
Critical finding: The F-star/invoX Pharma license includes NO ongoing royalties on product sales. Denali's 2018 exercise of its buy-out option to acquire F-star Gamma eliminated what would have been tiered sales royalties under the license-only pathway. Denali's 10-K repeatedly states: "There are no royalty payments on net sales from future products." Only milestone payments remain from the $243 million aggregate pool.
This is a material distinction for royalty investors: AVLAYAH's only ongoing royalty burden is the 9.25% synthetic royalty owed to Royalty Pharma. There is no additional upstream royalty stack from the platform licensor. No academic institution obligations were identified for tividenofusp alfa specifically—the IDS enzyme is a natural human protein, Denali developed the recombinant ETV:IDS fusion internally, and the transferrin receptor binding technology came through the F-star collaboration, which Denali now owns outright.
Combined, the AVLAYAH approval generated roughly $350-400 million+ in immediate economic value across the Royalty Pharma closing, F-star regulatory milestone, and PRV---making it by far the most consequential contractual trigger of the W13 window.
The accelerated approval pathway introduces confirmatory-trial risk (the COMPASS study must verify clinical benefit), but the 91% biomarker reduction and NEJM publication provide strong scientific backing. For royalty investors, the combination of ultra-rare disease economics, platform validation, Royalty Pharma's 9.25% royalty stake, and PRV optionality makes Denali's commercial trajectory one of the most closely watched positions in the rare disease royalty landscape.
Novartis / Excellergy: Up to $2 Billion Acquisition of First-in-Class Anti-IgE ECRI (March 27)
On March 27, 2026, Novartis (SIX: NOVN; NYSE: NVS) announced a definitive agreement to acquire Excellergy, Inc., a private biotechnology company developing next-generation anti-IgE therapies, for up to $2 billion in upfront and milestone payments.
Deal Structure
| Term | Detail |
|---|---|
| Acquirer | Novartis AG |
| Target | Excellergy, Inc. (Palo Alto, CA; private) |
| Total potential consideration | Up to $2 billion (upfront + milestones) |
| Upfront/milestone split | Not disclosed |
| Lead asset | Exl-111, half-life extended, high-affinity anti-IgE antibody |
| Stage | Phase 1 (DISARM trial; first subjects dosed February 2026) |
| Mechanism | Trifunctional allergic Effector Cell Response Inhibitor (ECRI): dissociates receptor-bound IgE, intercepts circulating IgE, drives FcεRIα downregulation |
| Indications | Food allergy (lead), chronic spontaneous urticaria, chronic inducible urticaria, allergic asthma, other IgE-mediated diseases |
| Expected close | H2 2026 |
| Excellergy investors | Red Tree Venture Capital, Samsara BioCapital, Decheng Capital ($70M Series A) |
| Excellergy financial advisor | J.P. Morgan Securities |
| Excellergy legal counsel | Wilson Sonsini Goodrich & Rosati |
| Novartis financial advisor | Not yet disclosed (announced March 27; historically Goldman Sachs, J.P. Morgan, or Morgan Stanley on major acquisitions; confirmation pending 8-K or EDGAR filing) |
| Novartis legal counsel | Not yet disclosed (historically Wachtell, Lipton, Rosen & Katz or Linklaters; confirmation pending filing) |
Strategic Context
Exl-111 is mechanistically differentiated from existing anti-IgE approaches: conventional omalizumab (Xolair) blocks free IgE but does not remove receptor-bound IgE, whereas Exl-111 is designed to dissociate IgE already bound to FcεRI receptors and drive receptor downregulation---potentially enabling faster symptom relief and deeper pathway suppression. This builds on Novartis's deep history with IgE biology (Xolair was originally co-developed by Novartis/Genentech and generated $4.4 billion in 2024 sales for Roche's franchise).
The acquisition is Novartis's second multi-billion deal in eight days: the company announced a $3 billion acquisition of Synnovation Therapeutics (SNV4818, a pan-mutant-selective PI3Kα inhibitor for HR+/HER2-- breast cancer) on March 20.
Combined, Novartis committed up to $5 billion in acquisitions within a single week, signaling aggressive portfolio-building across immunology and oncology ahead of key patent cliffs. Royalty financing relevance: moderate. Exl-111 is wholly owned by Excellergy with no disclosed upstream licensing obligations.
If the asset advances to registration, the clean IP profile and large addressable market (global IgE-mediated disease market exceeds $15 billion, anchored by the $4.4 billion Xolair franchise) could make it attractive for synthetic royalty financing. However, Phase 1 stage implies substantial development risk before commercial economics materialize.
Upstream University License Obligations: Stanford and University of Bern (Undisclosed but Near-Certain)
Research into the foundational IP reveals a material undisclosed obligation. The key patent underlying Exl-111's ECRI technology (WO2022061236A1, "High affinity anti-IgE antibodies") is assigned to Stanford University and Universitaet Bern, not to Excellergy. The inventors---Theodore Jardetzky (Stanford), Alexander Eggel (Bern), Luke Pennington, and Pascal Gasser---are all Excellergy co-founders. Excellergy's own Series A press release (October 2025) states the company was "built on scientific advances into the structural binding of IgE to its receptor from Stanford University and the University of Bern."
This strongly implies Excellergy holds an exclusive license from both universities. Critically, the underlying research was funded by NIH grants AI115469 and HL141493, triggering Bayh-Dole Act obligations including federal march-in rights—an additional encumbrance beyond standard university licensing terms.
Standard university license terms typically include upfront fees, regulatory milestone payments, and running royalties of 1-5% on net sales, and this dual-university co-assignment structure means both Stanford and Bern receive separate royalty streams, compounding the burden. As a private company with no SEC filings, Excellergy's specific license terms are not publicly available. No investor (Red Tree Venture Capital, Samsara BioCapital, Decheng Capital) holds royalty rights---these are standard equity investments.
Key monitoring item: The Novartis 8-K filing (expected within days of the March 27 announcement) should disclose assumed upstream obligations, including any university licenses. Upon closing, Novartis would assume these obligations on future Exl-111 commercial sales. The practical impact is modest at current stage---university royalty rates rarely exceed 5%---but the obligation will compound if Exl-111 reaches the multi-billion-dollar Xolair-class commercial scale that Novartis's $2 billion valuation implies.
Otsuka Pharmaceutical / Transcend Therapeutics: $1.225 Billion Neuroplastogen Acquisition (March 27)
On March 27, 2026, Otsuka Pharmaceutical announced a definitive agreement to acquire Transcend Therapeutics, a clinical-stage company developing non-hallucinogenic neuroplastogens for psychiatric disorders.
Deal Structure
| Term | Detail |
|---|---|
| Acquirer | Otsuka Pharmaceutical Co., Ltd. |
| Target | Transcend Therapeutics (private) |
| Upfront cash consideration | $700 million |
| Sales-based milestones | Up to $525 million |
| Total potential consideration | Up to $1.225 billion |
| Lead asset | TSND-201 (methylone), a non-hallucinogenic rapid-acting neuroplastogen for PTSD |
| Stage | Phase 3 enrollment underway |
| Designations | FDA Breakthrough Therapy Designation (July 2025) |
| Key data | Phase 2 published in JAMA Psychiatry (February 2026) |
| Expected close | Q2 2026 |
Strategic Context
The acquisition extends Otsuka's dominant position in psychiatry (Abilify/Rexulti franchise) into the emerging neuroplastogen class. TSND-201 is an MDMA analog engineered to retain rapid-acting neuroplasticity-inducing properties while eliminating hallucinogenic effects, addressing the regulatory and commercial challenges that derailed Lykos Therapeutics' MDMA-assisted therapy for PTSD (FDA CRL in August 2024). The Breakthrough Therapy designation and JAMA Psychiatry publication provide strong clinical and regulatory validation.
The $525 million in sales milestones create a milestone-based contingent structure (not a CVR) that is economically relevant for royalty investors modeling acquirer cash flow obligations. No upstream academic or third-party royalty obligations have been publicly identified for TSND-201.
Advisors
| Role | Firm |
|---|---|
| Otsuka financial advisor | Not yet disclosed (announced March 27; confirmation pending 8-K or merger filing on EDGAR) |
| Otsuka legal counsel | Not yet disclosed |
| Transcend financial advisor | Not yet disclosed (private company; disclosure may come through Otsuka's 8-K exhibit or merger agreement) |
| Transcend legal counsel | Not yet disclosed |
Upstream IP Considerations for TSND-201 (Methylone)
Methylone (3,4-methylenedioxy-N-methylcathinone) is a Schedule I controlled substance (permanently scheduled in 2013 under the Synthetic Drug Abuse Prevention Act). The molecule itself, first synthesized by Peyton Jacob III and Alexander Shulgin, is not broadly patentable for composition of matter.
Transcend's IP position likely rests on formulation patents, method-of-use patents for PTSD treatment protocols, and proprietary manufacturing processes for GMP-grade methylone production. Whether Transcend holds academic licenses from institutions studying entactogens remains unconfirmed.
The MAPS/Lykos IP (focused on MDMA-assisted therapy protocols) covers a distinct compound, though method-of-treatment patents covering entactogen-assisted psychotherapy could raise freedom-to-operate questions. Detailed IP disclosures should appear in the merger agreement filed as an exhibit to Otsuka's acquisition 8-K.
Royalty financing relevance: moderate. If approved, the combination of a large PTSD addressable market, milestone-based economics, and Otsuka's established psychiatry commercial infrastructure could support future synthetic royalty transactions.
Eli Lilly / Insilico Medicine: $2B GLP-1 Licensing Deal and FTC HSR Early Termination (March 26--29)
The Deal
According to the Financial Times (March 29), Eli Lilly will sign a deal worth up to $2 billion with Insilico Medicine for exclusive rights to an AI-designed oral GLP-1 receptor agonist for diabetes. The deal includes a $115 million upfront payment and could exceed $2 billion if future regulatory and sales milestones are met. The formal announcement is expected later on March 29. Both companies declined to comment to the FT.
Separately, on March 26, the FTC granted Hart-Scott-Rodino Early Termination (Transaction #20261000) for Eli Lilly and Company's acquisition of InSilico Medicine Cayman TopCo, covering four entities: Insilico Medicine IP Limited, Insilico Medicine Ltd., InSilico Medicine Hong Kong Limited, and InSilico Medicine US Inc.
| Term | Detail |
|---|---|
| Licensee | Eli Lilly and Company |
| Licensor | Insilico Medicine (HKEX: 3696.HK) |
| Asset | Oral GLP-1 receptor agonist for diabetes (likely from Insilico's cardiometabolic portfolio disclosed at BIO-Europe November 2025) |
| Upfront | $115M |
| Total deal value | Up to $2B+ (regulatory and sales milestones) |
| Royalties | Not yet disclosed (terms expected with formal announcement) |
| Lilly equity position | Eli Lilly's Asian venture arm is among Insilico's 10 largest shareholders |
| HSR filing structure | Full acquisition of all four entities including the Cayman holding company |
| FTC ET granted | March 26, 2026 |
| Public listing | HKEX: 3696.HK (IPO December 30, 2025; raised HK$2.28B / ~$292M) |
| IPO price | HK$24.05 per share |
| Market cap (indicative) | ~HK$31.3B (~$4.0B) at HK$49.24 as of March 23; 52-week range HK$29.98--80.90 |
The GLP-1 Asset
At BIO-Europe in November 2025, Insilico unveiled a cardiometabolic portfolio of eight AI-designed oral small molecules. At the center were two oral small-molecule GLP-1 receptor agonists at preclinical candidate stage: one designed for once-daily dosing and one engineered for once-weekly dosing. The once-weekly candidate was described as offering high solubility, extremely low metabolic and systemic clearance, and weight-loss efficacy comparable or superior to existing daily oral GLP-1 agonists. Insilico
The FT reports the licensed asset is a GLP-1 drug for diabetes. Lilly already has tirzepatide (Mounjaro/Zepbound) and orforglipron (Phase 3 oral GLP-1, discovered by Chugai) in its metabolic portfolio. An AI-designed, structurally novel oral GLP-1 agonist from Insilico would provide Lilly with a next-generation molecule with potentially differentiated IP protection and pharmacokinetic properties, as well as combination potential with Insilico's broader cardiometabolic portfolio (GIPR antagonist ISM0676, amylin, APJ, Lp(a), NR3C1, NLRP3 assets).
HSR Filing: Licensing Deal or Something More?
The HSR filing structure is notably broad for a single-asset licensing deal. The FTC filing names all four Insilico entities including the Cayman TopCo holding company -- a structure more consistent with a corporate acquisition or a very large transaction involving IP transfers across multiple jurisdictions. There are several possible explanations:
The $2B headline value likely triggers the HSR notification threshold on its own (current threshold: $119.5M), so the filing may simply reflect Lilly's need to notify regulators of a large licensing transaction. Alternatively, the deal may include broader rights beyond the single GLP-1 asset reported by the FT -- potentially options on additional cardiometabolic assets, expanded platform access, or an equity component building on Lilly's existing shareholder position. The fact that Lilly's Asian venture arm is already among Insilico's top 10 shareholders adds another dimension.
The FT noted that "additional details about the deal could not immediately be learned," leaving open the possibility that the full scope extends beyond what has been reported.
Relationship Timeline
The Lilly-Insilico relationship has deepened in clear stages:
2023: Software licensing deal (not publicly disclosed at the time) giving Lilly access to Insilico's Pharma.AI suite.
November 2025: Research and licensing collaboration valued at over $100 million including upfront, milestones, and tiered royalties on net sales, with Insilico using its Pharma.AI platform to generate and optimize candidate compounds against Lilly-defined targets. PR Newswire
November 2025: When asked whether Insilico could envision being acquired by Lilly, Zhavoronkov stated that the company could not comment on M&A speculation but was committed to current collaborations. Genengnews
March 26, 2026: FTC grants HSR Early Termination for Lilly's filing covering all four Insilico entities.
March 29, 2026: FT reports $2B licensing deal for GLP-1 diabetes asset, $115M upfront, announcement expected same day.
Upstream Royalty Exposure and Partner Impact
Insilico maintains an extensive network of active partnerships with disclosed royalty obligations. An exclusive license to Lilly for a GLP-1 asset – even without a full acquisition – would create new royalty economics, and the HSR filing raises questions about whether the full transaction involves broader rights that could affect Insilico's other partnerships:
Menarini/Stemline: Up to $550M in milestones for ISM3091 (USP1 inhibitor, oncology); MEN2501 (ISM9682, KIF18A inhibitor) has achieved IND approval and first patient dosing, triggering $3M and $5M milestone payments. Royalty terms undisclosed.
Exelixis: $80M deal for multi-target oncology collaboration; royalty terms undisclosed.
Qilu Pharmaceutical: Near-$120M collaboration (January 2026) for cardiometabolic small molecule inhibitors, with single-digit royalties on net sales. Insilico This deal directly overlaps with Insilico's cardiometabolic portfolio and may include assets related to the Lilly GLP-1 license.
Tenacia Biotechnology: Expanded CNS collaboration announced March 26 (same day as HSR ET grant), valued at up to $94.75M. Finanznachrichten
Hygtia Therapeutics (Fosun Pharma JV): Co-development of ISM8969 (NLRP3 inhibitor for Parkinson's), 50/50 global rights, Insilico eligible for upfront and milestones totaling over HK$500M. FDA IND clearance received January 2026.
Fosun Pharma: Co-developing ISM8207 (QPCTL inhibitor) for advanced tumors; Phase I (NCT06445517).
Sanofi, Pfizer, Servier, Boehringer Ingelheim: Active AI-driven drug discovery collaborations; terms undisclosed.
In aggregate, Insilico has secured software licensing agreements with 13 of the world's top 20 multinational pharmaceutical companies, and its pipeline out-licensing deals with Exelixis and Menarini alone carry total transaction values exceeding $2 billion. Yahoo Finance
Royalty Financing Relevance
High. This deal is significant for the royalty financing market on multiple dimensions:
First, the $115M upfront and $2B+ milestone structure on a preclinical AI-designed GLP-1 asset establishes a new valuation benchmark for AI-discovered drug candidates in the cardiometabolic space. The asset is likely preclinical (based on the BIO-Europe November 2025 disclosure of PCC-stage GLP-1 molecules), meaning Lilly is paying a substantial premium for AI-designed chemistry and differentiated pharmacokinetic properties – a signal for how the market values AI-native drug discovery.
Second, the tiered royalty obligations Insilico has across its partnership network -- particularly the single-digit royalties in the Qilu deal and the tiered royalties in the November 2025 Lilly research collaboration -- represent quantifiable future cash flow streams that are attractive to royalty financing investors. If the GLP-1 license generates commercial revenues, Insilico's retained royalty economics (if any) would be directly financeable.
Third, the ambiguity around the HSR filing structure means the market should watch for whether the formal announcement reveals broader rights or equity components that would change Insilico's corporate structure and affect the entire royalty portfolio. A full acquisition by Lilly would consolidate all of Insilico's partnership royalty obligations under Lilly's balance sheet -- a fundamentally different outcome for royalty investors than a single-asset license.
Lilly CFO Lucas Montarce noted at a March conference that the company is investing heavily in AI for R&D but acknowledged it will take more time to advance AI drugs from research to clinical testing. Lilly's 2025 annual report added new risk language warning of significant risks in developing and deploying AI, and that AI may enable new competitors in drug discovery.
Licensing and Partnerships
Sanofi / Kali Therapeutics: $1.23 Billion Tri-Specific T-Cell Engager License
On March 23, 2026, Kali Therapeutics announced a worldwide exclusive license agreement with Sanofi (EURONEXT: SAN) for KT501, a novel tri-specific T-cell engager designed to treat B cell-mediated autoimmune diseases.
Deal Structure
| Term | Detail |
|---|---|
| Licensor | Kali Therapeutics (San Mateo, CA; incorporated April 2024) |
| Licensee | Sanofi |
| Asset | KT501, IgG-like tri-specific antibody (CD3/CD19/BCMA) |
| Indication | B cell-mediated autoimmune diseases (RA, lupus, and others) |
| Stage | Phase 1a (first-in-human, NCT07234773, RA patients, enrolled March 2026) |
| Upfront and near-term payments | $180 million |
| Development and commercial milestones | Up to $1.05 billion |
| Total potential deal value | Up to $1.23 billion |
| Royalties | Tiered, high-single digits to double digits on global net sales (implying a range likely spanning ~8-9% at the low end through the low-to-mid teens) |
| Rights | Exclusive worldwide |
| Development obligations | Clean out-license: Sanofi assumes full responsibility for all development and commercialization globally; Kali retains no operational role post-closing |
| Sanofi financial advisor | Not disclosed (license deal---advisor names for licensing transactions are rarely disclosed in press releases; Sanofi's 6-K or annual report is the primary source) |
| Sanofi legal counsel | Not disclosed |
| Kali Therapeutics financial advisor | Not disclosed (Kali is a private company incorporated April 2024; no SEC filings exist) |
| Kali Therapeutics legal counsel | Not disclosed |
Mechanism and Competitive Context
KT501 simultaneously binds CD3 (T-cell recruitment), CD19 (B cells broadly), and BCMA (plasma cells)---targeting both the B cell lineage and the terminally differentiated plasma cell compartment that produces autoantibodies. Kali's proprietary CD3 masking technology is designed to decouple T-cell activation potency from cytokine release, a critical challenge for T-cell engager approaches in autoimmune indications where the therapeutic window must be wider than in oncology.
Preclinical data presented at ACR Convergence 2025 showed KT501 was more potent in B-cell killing with lower cytokine release than blinatumomab. In cynomolgus monkeys, a single 1 mg/kg subcutaneous dose induced rapid depletion of peripheral CD20+ B cells within 24 hours. The Phase 1a trial has an estimated completion date of August 2027.
Team and Investors
Kali Therapeutics was founded in 2024. Management includes CEO Weihao Xu (formerly CBO at Harbour BioMed), CSO and co-founder John Wang, CTO and co-founder Jay Zhao, and CMO and co-founder Min Bao, M.D. The company has not announced formal venture rounds; funding sources are undisclosed.
Kali's broader pipeline includes KT502 (CD19xCD3 bispecific, IND-enabling) and KT209 (CD19xCD20xCD3 tri-specific for B-cell malignancies, IND-enabling).
No upstream academic IP has been identified for KT501---the platform appears proprietary. However, the trispecific TCE format (CD3/CD19/BCMA) operates in a heavily patented landscape with Amgen (BiTE), Genentech, and others holding broad bispecific/multispecific antibody patents, creating potential FTO considerations that would be material to any royalty investor evaluating the downstream economics.
Strategic Implications
The deal marks Sanofi's return to the T-cell engager space after acquiring TCE-focused Amunix for $1 billion in 2021 and subsequently selling three clinical-stage TCEs to Vir Biotechnology in 2024. Sanofi's March 2026 spending spree---Kali ($1.23B), Sino Biopharm/rovadicitinib ($1.53B, announced March 4), plus earlier deals with Dren Bio and Blueprint Medicines---represents over $13 billion in total deal commitments within the past year as the company rebuilds its immunology portfolio ahead of Dupixent's loss of exclusivity in the early 2030s.
Comparables include Sanofi/Dren Bio ($600M upfront, up to $1.9B for a CD20-directed bispecific, March 2025), BMS/Janux ($50M upfront, up to $850M for an undisclosed TCE, January 2026), and the Astellas/CytomX termination covered in W12. Direct competitors with overlapping biology include Oblenio Bio's LBL-051 (same CD19xBCMAxCD3 target combination), GSK/Chimagen's CMG1A46, and Regeneron's REGN7257.
Alteogen / Biogen: Hybrozyme SC Formulation License (Up to $579M)
On March 25, 2026, Alteogen (KOSDAQ: 196170) and Biogen (NASDAQ: BIIB) announced an exclusive license agreement for Alteogen's Hybrozyme (ALT-B4 / berahyaluronidase alfa) platform to enable subcutaneous formulations of two Biogen biologics, with an option for a third product.
Deal Structure
| Term | Detail |
|---|---|
| Licensor | Alteogen, Inc. (Daejeon, South Korea) |
| Licensee | Biogen Inc. |
| Platform | Hybrozyme (ALT-B4 / berahyaluronidase alfa), recombinant human hyaluronidase enabling SC delivery |
| Products covered | Two Biogen biologics (undisclosed); option for a third |
| Upfront payment | $20 million |
| Second-product initiation payment | $10 million |
| Development, regulatory, and sales milestones | Up to $549 million (two products combined) |
| Total potential deal value | Up to $579 million |
| Royalties | Tiered on net sales (rate not disclosed) |
Strategic Context
The Alteogen/Biogen deal is the week's most commercially significant unrecognized licensing transaction and extends Hybrozyme's status as a competitive platform in the subcutaneous reformulation market.
Alteogen has previously licensed Hybrozyme to Pfizer, Sandoz, and Teva, accumulating over $1 billion in potential deal value across its partnering portfolio, anchored by the landmark Merck/Keytruda SC license announced in 2023 (approximately $1.24 billion in total potential value, ~$50 million upfront) -- the platform's most visible commercial validation to date.
The Biogen deal's lower headline ($579M vs. Merck's $1.24B) likely reflects Biogen's smaller IV biologic portfolio and the two-product scope confirmed by the $10 million second-product initiation payment.
The most probable candidates are Tysabri (natalizumab) -- Biogen's IV-administered multiple sclerosis therapy -- and potentially Leqembi (lecanemab), where a subcutaneous initiation-dosing sBLA is already pending at FDA with a PDUFA date of May 24, 2026.
The platform competes directly with Halozyme's ENHANZE technology (rHuPH20), which underpins SC formulations of blockbusters including Roche's Herceptin SC, J&J's Darzalex SC, and AstraZeneca/Merck's Keytruda SC program.
Biogen's two undisclosed biologics likely include late-stage or marketed assets where SC formulations offer lifecycle extension and patient-convenience differentiation. The milestone structure is back-loaded, consistent with royalty-bearing platform licenses where value accrues primarily upon commercial launch.
Royalty Economics and Upstream IP
The $579M headline almost certainly understates total economic value. All Hybrozyme platform licenses to date include tiered royalties on net sales in addition to milestones -- estimated in the low-to-mid single digits (2-5%) based on comparable Halozyme ENHANZE deals. If either licensed biologic achieves blockbuster-scale SC commercial sales, the royalty stream could exceed the milestone pool in cumulative value.
ALT-B4 (berahyaluronidase alfa) appears to be entirely internally developed by Alteogen with no publicly disclosed upstream academic licensing obligations -- a structurally clean profile. The principal IP risk is the Halozyme patent overhang: Halozyme holds extensive patents on rHuPH20-based subcutaneous delivery, and while Alteogen claims structural and functional differentiation for ALT-B4, no cross-licensing agreement or formal freedom-to-operate resolution has been publicly confirmed. This unresolved question is the single most material diligence item for any investor considering the Hybrozyme royalty portfolio.
Royalty financing relevance: high. The Hybrozyme platform royalty portfolio across 8-12+ licensees -- Merck, Pfizer, Biogen, Sandoz, Teva, and others -- with blue-chip counterparties represents a classic platform royalty monetization opportunity, comparable structurally to Halozyme's ENHANZE portfolio. Optimal timing for a synthetic royalty transaction would be 2027-2029, as the first Hybrozyme-enabled products approach commercial launch. The Halozyme FTO question and the first licensee commercial milestone are the key gating events to watch.
GlycoNex / Nippon Kayaku: Preclinical ADC Collaboration
On March 23, 2026, GlycoNex, Inc. (TPEX: 4168) and Nippon Kayaku Co., Ltd. (TYO: 4272) announced a collaboration to jointly advance GNX201-ADC, a next-generation antibody-drug conjugate for solid tumors. Financial terms were not disclosed. The collaboration centers on ADC construct optimization and preclinical data generation to support regulatory submissions.
GNX201-ADC leverages GlycoNex's "Antibody Lock" protease-activated pro-ADC technology---a masked antibody that remains inactive in systemic circulation and activates selectively in the tumor microenvironment. The ADC targets tumor-associated glycan antigens, a broadly expressed but therapeutically underexploited class of tumor markers. GlycoNex's more advanced program, GNX1021 (glycan-targeted ADC for gastric cancer), has IND filings planned for Taiwan and Japan with Phase 1 targeted for mid-2026.
Bio-Thera Solutions / Intas Pharmaceuticals: BAT2506 Biosimilar License for India
On March 23, 2026, Bio-Thera Solutions announced a further expansion of its partnership with Intas Pharmaceuticals through an exclusive commercialization and license agreement in India for BAT2506, a proposed biosimilar referencing Simponi (golimumab), Johnson & Johnson's anti-TNF monoclonal antibody approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
Financial terms were not disclosed.
Golimumab generated approximately $2.8 billion in global sales in 2025. The India biosimilar market is one of the fastest-growing globally, and this deal expands on an existing Bio-Thera/Intas relationship.
For benchmarking, their earlier US deal (February 2025) included a $21 million upfront and up to $143.5 million in milestones (total $164.5 million)---given India's substantially smaller branded biologic market, the India deal is likely a fraction of these figures. No financial terms were disclosed for the India license in any English-language filing.
Bio-Thera Solutions, headquartered in Guangzhou, China, is a clinical-stage biopharmaceutical company focused on biosimilars and novel antibodies. Intas Pharmaceuticals, headquartered in Ahmedabad, India, is one of India's largest privately held pharmaceutical companies with significant domestic distribution infrastructure.
Maze Therapeutics / Shionogi: $20 Million Phase 2 Milestone for MZE001 in Pompe Disease (March 25)
The $20 million milestone payment triggered by first patient dosing in the ESPRIT Phase 2 trial of MZE001 represents one of three near-term milestone tranches structured into the original Maze/Shionogi collaboration.
Under the September 2022 agreement -- estimated total value in the $600-900 million range -- Shionogi licensed rights to MZE001 for Japan and select Asian territories, while Maze retained the US, EU, and rest of world.
The milestone structure includes three $10 million tranches tied to IND-related activities and clinical initiation (the first triggered in Q4 2025; this second tranche triggered March 2026 on Phase 2 FPD; a third tranche anticipated later in 2026), followed by up to $475 million in development and regulatory milestones and up to $475 million in sales-based milestones -- leaving approximately $530-830 million outstanding across the remaining deal life.
Shionogi owes Maze tiered royalties on net sales in the licensed territory, estimated in the low-to-mid teens (10-18%) based on comparable rare disease licensing benchmarks.
MZE001 is an oral small molecule GAA activator / pharmacological chaperone for late-onset Pompe disease -- a first-in-class oral approach in a space currently dominated by IV enzyme replacement therapies (Sanofi's Nexviazyme, $1.5B+ franchise globally).
An oral disease-modifying agent would be transformative for patients receiving biweekly IV infusions, with rare disease pricing precedent of $200-400K+ per patient per year. The compound was discovered entirely in-house by Maze through its genetics-informed platform; no upstream academic royalty or third-party license has been identified.
The ESPRIT trial milestone did not trigger any payment obligations from Maze to any licensor -- all milestone flows in this deal move from Shionogi to Maze.
Royalty financing relevance: moderate, improving. The Shionogi royalty stream is geographically limited to Japan/Asia and the asset is Phase 2, making it premature for traditional royalty financing today. However, as MZE001 advances through Phase 2 data and into Phase 3, the combination of rare disease economics, oral differentiation advantage, and creditworthy counterparty (Shionogi) positions this stream as increasingly attractive. A synthetic royalty transaction is most plausible at Phase 3 initiation or upon positive pivotal data, likely 2027-2028.
Lexicon Pharmaceuticals / Novo Nordisk: LX9851 Phase 1 Milestone
On March 23, 2026, Lexicon Pharmaceuticals (NASDAQ: LXRX) and Novo Nordisk announced the initiation of a Phase 1 study of LX9851, a first-in-class oral non-incretin ACSL5 inhibitor for obesity, triggering a $10 million milestone payment from Novo Nordisk to Lexicon.
This is the second milestone under the March 2025 exclusive worldwide license agreement, which has a total potential value of up to $1 billion in upfront and milestone payments plus tiered royalties on net sales. The 96-participant Phase 1 trial has expected completion in Q1 2027.
Deal Economics (from Lexicon FY2025 10-K, filed March 5, 2026)
Lexicon's annual report provides granular detail on the March 28, 2025 agreement structure:
| Term | Detail |
|---|---|
| Upfront payment | $45 million (received April 2025) |
| Near-term milestones | Up to $30 million in three $10M tranches tied to IND-related activities and clinical initiation (first $10M received Q4 2025; second $10M triggered March 2026 upon Phase 1 dosing; third $10M expected later in 2026) |
| Regulatory and launch milestones | Up to $475 million |
| Sales-based milestones | Up to $475 million (triggered by cumulative or annual net sales thresholds) |
| Royalties | Tiered, escalating from single-digit to low-double-digit percentages of annual net sales (exact tiers redacted) |
| Development responsibility | Novo Nordisk assumes full responsibility for IND filing, all development, regulatory activities, manufacturing (after transition period), and global commercialization |
| Supply | Lexicon provides clinical material at agreed transfer price for a defined period |
LX9851 acts through a mechanistically distinct pathway from GLP-1 agonists, inhibiting acyl-CoA synthetase long-chain family member 5 (ACSL5), which plays a key role in intestinal lipid absorption.
LX9851 was discovered entirely in-house through Lexicon's proprietary Genome5000 genomics platform---no upstream licensor, no academic institution, and no third-party royalty obligation was identified. Lexicon's other collaborations (BMS neuroscience, Ipsen/XERMELO, Viatris/sotagliflozin) are all unrelated to LX9851.
The $10 million flows one-way from Novo Nordisk to Lexicon as the second of three near-term milestones under the March 2025 exclusive license.
Preclinical data showed LX9851 combined with semaglutide reduced body weight beyond semaglutide alone and mitigated weight regain after treatment discontinuation---positioning it as a potential combination partner for Novo Nordisk's semaglutide franchise.
MSD / Quotient Therapeutics: $2.2 Billion IBD Target Discovery Alliance
On March 24, 2026, MSD (Merck & Co. in the US and Canada) activated an alliance with Quotient Therapeutics, a Flagship Pioneering company, to discover new therapeutic targets in inflammatory bowel disease (IBD) using Quotient's somatic genomics platform.
Deal Structure
| Term | Detail |
|---|---|
| Licensor/Partner | Quotient Therapeutics (Cambridge, MA; Flagship Pioneering company) |
| Licensee | MSD (Merck & Co.) |
| Upfront payment | $20 million |
| Development, regulatory, and commercial milestones | Up to $2.2 billion |
| Therapeutic focus | Inflammatory bowel disease (ulcerative colitis, Crohn's disease) |
| Stage | Target discovery (preclinical) |
| Advisors | Not disclosed |
Platform and Strategic Context
Quotient's platform uses proprietary single-molecule genome sequencing to identify somatic genetic mutations---random DNA changes that accumulate in cells over time and can confer resistance or vulnerability to disease. By building a library of natural genetic variations, Quotient aims to discover gene variants that inform entirely new drug targets. Marc Levesque, head of discovery at Merck Research Laboratories, noted that Quotient's approach "has the potential to provide us with unique biological insights into genomic changes that are naturally occurring within patients with IBD."
IBD is a key R&D focus for MSD, whose pipeline in the indication is led by tulisokibart, an anti-TL1A antibody in Phase 3 for ulcerative colitis and Crohn's disease and mid-stage trials for other inflammatory conditions including rheumatoid arthritis.
Since emerging from stealth in late 2023, Quotient has disclosed agreements with Pfizer (2024, cardiovascular and renal disease targets, under Flagship's $7 billion strategic alliance with Pfizer) and GSK (2025, respiratory and liver disease targets, under the Flagship-GSK framework which carries a $150 million combined upfront and up to $720 million per program in milestones across up to 10 medicines).
The MSD deal is notably Quotient's first standalone collaboration outside a Flagship umbrella framework, which likely explains its more detailed financial disclosure.
Given the preclinical/target discovery stage, the $2.2 billion headline is heavily milestone-loaded and contingent on successful drug development from any targets identified---but the deal reflects the increasing premium pharma places on novel target identification infrastructure rather than individual clinical-stage assets.
Biodexa Pharmaceuticals / Tanner Pharma Group: eRapa Early Access Program
On March 23, 2026, Biodexa Pharmaceuticals (NASDAQ: BDRX) partnered with Tanner Pharma Group to launch a global Early Access Program for eRapa (proprietary encapsulated rapamycin formulation) in patients with Familial Adenomatous Polyposis (FAP). No financial terms were disclosed. Biodexa's Phase 3 registrational trial (168 patients, 30 US/EU sites) is ongoing, supported by a $20 million CPRIT grant.
Everest Medicines / Corxel Pharmaceuticals: Etripamil Greater China Asset Purchase
On March 23, 2026, Everest Medicines (HKEX: 1952.HK) announced an Asset Purchase Agreement with Corxel Pharmaceuticals Hong Kong Limited for the rights to develop, manufacture, and commercialize CARDAMYST (etripamil) nasal spray in Greater China (Chinese Mainland, Hong Kong, Macao, and Taiwan).
Deal Structure
| Term | Detail |
|---|---|
| Acquirer | Everest Medicines (HKEX: 1952.HK) |
| Seller | Corxel Pharmaceuticals Hong Kong Limited |
| Asset | CARDAMYST (etripamil) nasal spray---Greater China rights |
| Upfront payment | $30 million |
| Development milestones | Up to $20 million |
| Total potential deal value | Up to $50 million |
| Regulatory status (China) | NDA accepted by NMPA (January 17, 2025); approval expected Q3 2026 |
| Regulatory status (US) | FDA approved December 2025 |
| Original developer | Milestone Pharmaceuticals Inc. (NASDAQ: MIST) |
| Upstream license | Corxel (formerly Jixing) licensed Greater China rights from Milestone in May 2021 |
Mechanism and Clinical Context
Etripamil is a novel, rapid-acting calcium channel blocker administered as a self-administered nasal spray for the acute termination of paroxysmal supraventricular tachycardia (PSVT). It became the first and only self-administered nasal spray in over 30 years capable of converting PSVT to sinus rhythm in adults when FDA approved it in December 2025.
The global Phase 3 RAPID trial demonstrated 64% conversion to sinus rhythm within 30 minutes versus 31% for placebo (N=184). The China Phase 3 JX02002 trial met its primary endpoint with a hazard ratio of 3.02 (p=0.0005). No serious adverse events were reported within 24 hours of administration in either Phase 3 trial.
PSVT affects approximately 2.3 to 4 per 1,000 individuals, representing an estimated 3 to 6 million patients in China. Etripamil is also under clinical development for atrial fibrillation with rapid ventricular response (AFib-RVR), where Phase 2 data showed 58.3% of patients achieving ventricular rate below 100 bpm versus 4% for placebo.
Strategic Context
The transaction strengthens Everest's cardiovascular franchise and represents a near-commercial asset acquisition---the NMPA accepted the NDA in January 2025, with approval expected in Q3 2026. From a deal archaeology perspective, the chain of title runs from Milestone Pharmaceuticals (original developer) to Corxel/Jixing (Greater China licensee since May 2021) to Everest Medicines (acquirer of Corxel's Greater China rights in March 2026). Milestone retains rights for all territories outside Greater China.
Upstream Milestone Pharmaceuticals License (Inherited Obligations)
Per Milestone's SEC filings (FY2022 10-K), the original May 2021 license to Ji Xing (now Corxel) carried economics that Everest now inherits in full:
| Term | Detail |
|---|---|
| Upfront payment | $15 million non-refundable (paid to Milestone, 2021) |
| Equity subscription | $5 million RTW Investments subscription in Milestone |
| Development milestones | Up to $15.5 million (at least $5M triggered by end of 2022) |
| Sales/commercial milestones | Up to $92 million |
| Royalties | Tiered from low double-digit to high double-digit percentages of Greater China net sales |
| Total potential consideration | Up to $107.5 million in milestones (plus royalties) |
The royalty band described as "low-to-high double digits" is unusually wide for a regional license, potentially spanning roughly 10% to as high as 19% of Greater China net sales.
These upstream obligations to Milestone Pharmaceuticals are a material consideration for Everest's unit economics---in addition to the $50 million paid to Corxel, Everest inherits the full remaining milestone and royalty stack owed to Milestone on every dollar of Chinese etripamil sales.
For reference, Milestone's separate US royalty purchase agreement with RTW Investments discloses tiered rates of 7% on net sales up to $500 million (rising to 9.5% if certain revenue thresholds are missed), with higher tiers above $500 million and $800 million---providing a comparable benchmark for the commercial-stage royalty economics on etripamil.
Corxel's broader pipeline includes CX11, an oral small molecule GLP-1 RA under clinical development for obesity and T2DM, and CX12, an oral amylin RA in preclinical development---the etripamil divestiture appears designed to concentrate Corxel's resources on its cardiometabolic small molecule programs.
Shionogi / Apnimed: $150 Million Sleep Disorder JV Buyout with Royalties
On March 24, 2026, Shionogi & Co., Ltd. (TYO: 4507) announced a definitive agreement to acquire Apnimed's 50% ownership stake in Shionogi-Apnimed Sleep Science, LLC (SASS), a joint venture originally established in 2023 to develop oral pharmacologic treatments for sleep disorders. Upon closing, SASS will become a wholly owned subsidiary of Shionogi.
Deal Structure
| Term | Detail |
|---|---|
| Acquirer | Shionogi & Co., Ltd. (TYO: 4507) |
| Seller | Apnimed, Inc. (Cambridge, MA) |
| Asset | 50% equity stake in Shionogi-Apnimed Sleep Science, LLC |
| Upfront payment | $100 million |
| Development milestone | $50 million (tied to SASS-002/sulthiame) |
| Royalties | Tiered royalties on future commercial sales of SASS products |
| Total potential value | $150 million + royalties |
| Expected close | Q2 2026 |
| Key programs acquired | SASS-001 (undisclosed target); SASS-002 (sulthiame, licensed from Desitin Arzneimittel) |
Strategic Context
SASS was established in 2023 to combine Apnimed's expertise in obstructive sleep apnea (OSA) with Shionogi's small molecule drug discovery engine. The JV's pipeline includes SASS-001---which combines Shionogi's sivopixant (P2X3 antagonist) with an undisclosed second compound, with Phase 2a RESTEADY trial results expected H1 2026---and SASS-002 (sulthiame), a differentiated carbonic anhydrase inhibitor that completed a positive Phase 2 FLOW trial (~300 patients) with results published in The Lancet in 2025.
Upstream Desitin Arzneimittel License for Sulthiame
Sulthiame was licensed by Apnimed from Germany's Desitin Arzneimittel GmbH on April 25, 2025, granting Apnimed exclusive global rights to sulthiame for sleep apnea. Financial terms are limited to "undisclosed upfront payment, future milestone payments and royalties on future sales"---no dollar amounts or royalty rates have been made public.
Shionogi subsequently paid Apnimed a separate one-time fee for joint ownership of sulthiame IP within the SASS JV. Whether the Desitin royalty obligation passes through to Shionogi via the SASS entity following this buyout remains unclear from public disclosures. Shionogi retains exclusive negotiation rights for Japan, Korea, Taiwan, and China under the SASS framework.
The buyout allows both parties to sharpen focus. Apnimed described the sale as a "strategic monetization" to strengthen its balance sheet ahead of an expected NDA submission for AD109, its wholly owned lead program, in Q2 2026. AD109---a combination therapy targeting a root cause of upper airway collapse in OSA---reported two Phase 3 wins in 2025 and is not part of the SASS JV. Apnimed disclosed a separate $35 million financing in December 2025.
For Shionogi, consolidating SASS as a wholly owned subsidiary positions sleep disorders as a core therapeutic pillar in its quality-of-life portfolio. The board resolution was dated March 23, 2026.
Notably, Shionogi disclosed two separate bridge loan facilities from Sumitomo Mitsui Banking Corporation during the W13 window, totaling JPY 660 billion (~$4.4 billion):
| Facility | Amount | Purpose | Announced | Disbursement | Maturity |
|---|---|---|---|---|---|
| RADICAVA bridge loan | JPY 360 billion | Acquisition of global RADICAVA (edaravone) rights from Tanabe Pharma ($2.5B deal, announced Dec 2025) | March 23, 2026 | May 27, 2026 | ~May 2027 |
| ViiV Healthcare bridge loan | JPY 300 billion | Additional $2.125B investment in ViiV Healthcare (HIV JV) to increase economic interest from ~10% to 21.7% following Pfizer's exit | March 27, 2026 | March 31, 2026 | March 26, 2027 |
Both facilities are unsecured. The ViiV Healthcare stake increase---announced January 20, 2026 alongside Pfizer's $1.875 billion exit from the JV---represents a strategically significant transaction for royalty investors: ViiV's HIV franchise (anchored by Cabenuva/Apretude/dolutegravir) generates substantial licensing and royalty-like economics that Shionogi's increased ownership stake now captures at a higher rate. Neither bridge loan is connected to the SASS/Apnimed buyout ($150M + royalties), which is modest enough to fund from existing cash.
Royalty Implications
The tiered royalty retained by Apnimed on all SASS-derived products creates a long-duration royalty stream linked to Shionogi's development and commercialization of oral sleep disorder therapies. If sulthiame advances through registrational development in OSA---a market affecting tens of millions globally with limited pharmacologic options---these royalties could become meaningful. The structure echoes a broader trend of biotechs monetizing JV stakes while retaining royalty economics on divested assets.
Yatiri Bio / Oscotec: Denfivontinib Global Option-to-License in AML
On March 24, 2026, Yatiri Bio (San Diego, CA) announced an exclusive global option to in-license denfivontinib (SKI-G-801), a potent FLT3/AXL dual multikinase inhibitor, from South Korea's Oscotec, Inc. for the treatment of acute myeloid leukemia (AML). Financial terms were not disclosed.
Denfivontinib targets both wild-type and mutant FLT3 forms (FLT3-ITD and FLT3-D835Y), a validated therapeutic pathway in AML. Oscotec completed a Phase 1 trial in relapsed/refractory AML (NCT03564288; 14 patients, 2018--2021). Yatiri Bio plans to apply its proprietary ProteoCharts platform---which uses deep neural networks to integrate unbiased proteomic profiling with clinical data---to identify a biomarker-defined AML patient population highly responsive to denfivontinib. This AI-driven patient selection approach aims to improve clinical trial success rates by targeting identified responder populations rather than broad AML patient cohorts.
OSR Holdings / BCM Europe: VXM01 Licensing Deal Restructured at Parent Level
On March 23, 2026, OSR Holdings (NASDAQ: OSRH) announced a restructuring of its previously disclosed binding term sheet (dated January 13, 2026) with BCM Europe AG for the global exclusive licensing of VXM01, an oral DNA-based immunotherapy targeting VEGFR-2 developed by OSR's Swiss subsidiary Vaximm AG.
This is not a new transaction but a structural amendment to an existing arrangement between related parties. For a comprehensive analysis of BCM Europe AG's corporate structure, leadership, investment thesis, and the VXM01 clinical profile, see our earlier deep-dive: Fund of the Week: BCM Europe AG.
What Changed on March 23
The deal has been through multiple iterations since November 2025---a non-binding term sheet, a shortened exclusivity amendment in December, and the binding term sheet in January 2026 that proposed a $30 million upfront (originally structured as 50% cash and 50% digital assets via the TAC token framework) plus up to $815 million in aggregate milestones. The March 23 restructuring makes four material changes:
| Term | Previous Structure | Revised Structure (March 23) |
|---|---|---|
| Counterparty | Vaximm AG (subsidiary) | OSR Holdings becomes direct counterparty alongside Vaximm |
| Milestone flow | Up to $815M payable to Vaximm | Up to $815M payable directly to OSR Holdings (parent) |
| Upfront funding | $30M direct payment to Vaximm (50% cash, 50% digital assets) | $30M development financing facility (drawdown-based) from OSR to Vaximm; digital asset provisions deferred |
| Equity option | Not previously disclosed | OSR may issue up to $15M of common stock at $10/share to the BCM fund, exercisable 6 months post-definitive agreement, at OSR's sole discretion |
The target date for execution of a definitive agreement has been pulled forward from end of May to April 30, 2026, subject to board approval and an independent fairness opinion. OSRH shares rose approximately 9.6% on the announcement.
Reading Between the Lines
The restructuring reveals several dynamics worth tracking. First, the deferral of the digital asset provisions---which were a defining feature of the original structure and central to BCM's "Decentralized Science" positioning---signals that the practical realities of operating a NASDAQ-listed entity with crypto-denominated deal components proved harder than anticipated. The press release diplomatically attributes this to "pending further regulatory clarity applicable to public companies holding and transacting in digital assets."
Second, the shift from a $30M upfront payment to a $30M drawdown facility is economically significant. Under the original structure, BCM Europe's investment fund ("BCM Decentralized Science Investors I, LP") would have transferred $30 million to Vaximm at signing. Under the new structure, OSR Holdings itself provides the development capital to its own subsidiary on an as-needed basis---effectively converting an external funding commitment into an internal capital allocation. For a company that was granted a 180-day NASDAQ minimum-bid compliance extension in March 2026, the question of where the $30 million drawdown facility is funded from is material.
Third, the equity option allowing OSR to issue $15 million of common stock at $10 per share to the BCM fund is notable given that OSRH has been trading well below that level---making the option currently deep out-of-the-money and the $10 strike price aspirational rather than immediately dilutive. It functions more as a signaling mechanism for long-term value expectations than as near-term financing.
Context for Royalty Investors
BCM Europe AG is the largest shareholder of OSR Holdings (~36.4%), and BCM's chairman, Kuk Hyoun "Peter" Hwang, simultaneously serves as CEO of OSR Holdings and Chairman of Vaximm AG---creating a related-party structure where the licensor, licensee, and majority shareholder are effectively controlled by the same individual. No independent financial or legal advisors were disclosed for the March 23 restructuring.
VXM01 itself is a genuine clinical-stage asset with Phase 2a data in recurrent glioblastoma showing 11.1-month median overall survival (versus 6-9 month historical benchmarks) in combination with Merck KGaA's avelumab. The oral T-cell vaccination platform---using attenuated Salmonella Typhi Ty21a as a bacterial vector to deliver VEGFR-2 antigens---represents a mechanistically differentiated approach to cancer immunotherapy. However, the $815 million milestone headline should be evaluated against the reality that no registrational study has been initiated, no major pharma partner is funding development, and the definitive licensing agreement has not yet been signed.
For the pharma royalty community, the OSR/BCM arrangement is most instructive as a case study in how emerging deal structures---DeSci fund vehicles, tokenized payment mechanisms, SPAC-acquired clinical assets, and related-party licensing---are testing the boundaries of conventional pharmaceutical transaction architecture. Whether this particular structure ultimately delivers value will depend on VXM01's clinical progression and whether the April 30 definitive agreement materializes with terms that can withstand independent fairness scrutiny.
It is worth noting that the only equity research coverage identified for OSRH is a company-sponsored report from Emerging Growth Research (December 4, 2025), which carries a $10.00 price target and "Buy-Emerging" rating.
The report was paid for by OSRH ($1,500 per the disclosure) and notes that its "heavily-discounted valuation is dependent on projections provided by management and modeling assumptions." The report references BCM Europe's fund structure as being "anchored by a strategic pharmaceutical investor (currently confidential)"---an unnamed anchor that has been cited across multiple press releases since November 2025 but never identified.
As of that December 2025 report, OSRH had a market capitalization of $16.3 million---making the $815 million milestone headline approximately 50 times the company's entire market value.
Tempus AI / Daiichi Sankyo: Strategic AI Collaboration for ADC Biomarker Discovery (March 25)
On March 25, 2026, Daiichi Sankyo announced a strategic collaboration with Tempus AI to leverage Tempus's PRISM2 multimodal foundation model---which combines pathology images and clinical data---to advance biomarker discovery, patient stratification, and clinical differentiation across an antibody-drug conjugate (ADC) program in oncology.
Financial terms were not disclosed. Royalty financing relevance: low. This is a data/AI services arrangement, not a traditional licensing deal with milestone or royalty economics.
However, the deal underscores the growing role of AI-powered biomarker platforms in ADC clinical development---a trend that could influence future deal structures by enabling more precise patient selection and potentially improving the risk profiles of royalty-financed assets.
Purple Biotech / Converge Bio: Generative AI Antibody Design Collaboration (March 25)
On March 25, 2026, Converge Bio announced it will apply generative AI to design and optimize next-generation tri-specific antibodies from Purple Biotech's CAPTN-3 platform for solid tumor oncology. Terms undisclosed. Royalty financing relevance: negligible. Preclinical discovery collaboration.
CDMO and Services Partnerships (March 26)
Aragen Life Sciences / Thermo Fisher Scientific announced a manufacturing partnership on March 26 to strengthen biologics manufacturing capabilities. Terms undisclosed. Royalty financing relevance: negligible. CDMO/services deal.
SK pharmteco / Prozomix announced a biocatalysis partnership on March 26 to accelerate sustainable biocatalysis in small-molecule manufacturing. Royalty financing relevance: negligible.
Verana Health / Guardant Health announced a clinicogenomic data partnership on March 26 to advance real-world clinicogenomic data for cancer research. Royalty financing relevance: low. Data/diagnostics arrangement, not licensing.
Clinical Data Readouts
Pfizer / Valneva: Lyme Disease Vaccine Phase 3 VALOR Results
On March 23, 2026, Pfizer and Valneva announced topline results from the Phase 3 VALOR trial of PF-07307405 (LB6V), their investigational 6-valent OspA-based Lyme disease vaccine candidate.
Key Results
| Endpoint | Result |
|---|---|
| Efficacy from 28 days post-dose 4 (season 2) | 73.2% (95% CI: 15.8, 93.5) |
| Efficacy from 1 day post-dose 4 (season 2) | 74.8% (95% CI: 24.7, 94.0) |
| Primary statistical endpoint met? | No (lower CI bound of 15.8% fell below required >20% threshold in first pre-specified analysis) |
| Safety | Well tolerated; no safety concerns identified |
The statistical miss was attributed to fewer-than-expected Lyme disease cases accrued over the study period. However, the second pre-specified analysis showed a confidence interval lower bound above 20%, and Pfizer stated it is confident in the vaccine's potential and is planning regulatory submissions. Valneva shares fell approximately 37% on the news.
Licensing and Royalty Structure
Pfizer and Valneva entered a collaboration and license agreement in April 2020, under which Pfizer obtained exclusive rights to manufacture and commercialize PF-07307405 globally. The agreement was materially amended in June 2022. Key deal terms include:
| Term | Detail |
|---|---|
| Original agreement | April 2020 Collaboration and License Agreement; amended June 2022 |
| Upfront payment | $130 million (to Valneva) |
| Equity investment | ~$95 million (Pfizer purchased ~8.1% equity stake in Valneva at €9.49/share, June 2022) |
| Development milestones | Up to $35 million |
| Commercialization milestones | Up to $143 million |
| Sales-based milestones | Up to $100 million (added in 2022 amendment) |
| Total potential cash payments | Up to $408 million (excluding royalties and equity investment) |
| Royalties | Tiered 14-22% on net sales (revised from an original flat 19% floor in the 2022 amendment; specific sales thresholds triggering escalation within the 14-22% range remain redacted in all Valneva 20-F filings) |
| Development cost share | 60% Pfizer / 40% Valneva (revised from original 70/30 in 2022 amendment; Valneva's contributions completed Q2 2024) |
| Manufacturing | Pfizer has exclusive manufacturing rights; Valneva contributes manufacturing and regulatory support |
If approved, PF-07307405 would be the first human Lyme disease vaccine in over two decades (Lymerix, SmithKline Beecham, was voluntarily withdrawn in 2002). The CDC estimates approximately 476,000 people are diagnosed and treated for Lyme disease annually in the United States, with an estimated 132,000 cases per year in Europe.
RBC Capital models adjusted peak sales at approximately $525 million following the mixed Phase 3 data, well below Valneva's own prior estimate of over $1 billion---a downward revision that, if sustained, would keep Valneva's royalty rate closer to the 14% floor of the tiered range rather than the 22% ceiling.
Theriva Biologics: FDA Agreement on VCN-01 Phase 3 Design
On March 23, 2026, Theriva Biologics (NASDAQ: TOVX) announced positive FDA End-of-Phase 2 meeting results for VCN-01, an oncolytic adenovirus for first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). The FDA endorsed Theriva's proposed Phase 3 trial design: randomized, double-blind, with overall survival as the primary endpoint. Shares surged approximately 50% on the news. Theriva had $15.2 million in cash as of late February 2026, with runway into Q1 2027.
VCN-01 is a genetically modified oncolytic adenovirus engineered to replicate selectively in tumor cells with dysregulated Rb pathway signaling and to express hyaluronidase, which degrades the hyaluronic acid-rich tumor stroma that forms a physical barrier to drug penetration in pancreatic cancer. Phase 2 data showed VCN-01 plus gemcitabine/nab-paclitaxel improved overall survival compared to chemotherapy alone in first-line mPDAC.
Galderma: Restylane Contour FDA Approval for Temple Hollowing
On March 23, 2026, Galderma received FDA approval for Restylane Contour as the first and only hyaluronic acid filler specifically indicated for correction of temple hollowing in adults aged 22 and older.
The approval was based on a 274-patient pivotal study demonstrating a 91% responder rate at 3 months with durability up to 18 months. Galderma retains full commercial rights globally.
No upstream royalty or milestone obligations exist: Galderma acquired 100% of Q-Med AB (the Swedish developer of NASHA technology and the Restylane brand) in 2011 for approximately SEK 10.6 billion (~$1.7 billion)---a complete corporate acquisition, not a license, under which all IP, manufacturing, and patents transferred outright.
Original NASHA patents from the 1990s-2000s have largely expired. The FDA approval is a supplemental PMA label expansion for a wholly owned product.
Basilea Pharmaceutica: BAL2420 Phase 1 Initiated
On March 23, 2026, Basilea Pharmaceutica (SIX: BSLN) announced first-in-human dosing of BAL2420, a first-in-class LptA inhibitor antibiotic targeting severe Gram-negative infections including multidrug-resistant strains.
The development is supported by CARB-X funding totaling $8.2 million. BAL2420 targets the lipopolysaccharide transport pathway (Lpt), a novel mechanism with no cross-resistance to existing antibiotic classes.
Upstream obligations: confirmed clean. All milestones owed to Basilea's upstream licensor Spexis for the BAL2420 program were fully paid upon drug candidate nomination in late 2024. The Asset Purchase Agreement (January 2024) structured CHF 2 million in total payments with the final milestone at candidate nomination.
Basilea's December 23, 2024 press release confirms: "The successful completion of these activities resulted in the nomination of BAL2420 as a drug candidate and also led to a final milestone payment from Basilea to Spexis." FIH dosing triggers no additional Spexis payment.
Low-single-digit royalties to upstream licensors (assumed from Spexis) apply only upon future commercialization.
The FIH dosing event is a high-probability disbursement trigger under CARB-X's milestone-based funding structure---CARB-X awarded an initial $0.9 million in April 2024 followed by $7.3 million in December 2024 specifically to support progression toward FIH studies, suggesting an estimated $1--3 million tranche was unlocked by this event (note: the CARB-X funding was awarded to support progression toward FIH, not triggered by FIH dosing itself).
Insmed: ARIKAYCE Phase 3b ENCORE—Positive Topline Results in MAC Lung Disease
On March 23, 2026, Insmed Incorporated (NASDAQ: INSM) reported positive topline results from the Phase 3b ENCORE study of ARIKAYCE (amikacin liposome inhalation suspension) plus multidrug therapy versus placebo plus multidrug therapy in patients with a new occurrence of Mycobacterium avium complex (MAC) lung infection who had not previously received antibiotics.
Key Results
| Endpoint | ARIKAYCE + MDT | Placebo + MDT | Result |
|---|---|---|---|
| Respiratory Symptom Score change (Month 13, primary) | 17.77 points | 14.66 points | Met (difference 3.11; p=0.0299) |
| Culture conversion by Month 6 | 87.8% | 57.0% | Met |
| Culture conversion by Month 12 | Significantly higher | --- | Met |
| Durable culture conversion (Month 15) | Significantly greater proportion | --- | Met |
| Study completion rate | 90.6% | 93.4% | --- |
| Treatment discontinuation | 18.3% | 11.8% | --- |
These results fulfill the FDA post-marketing requirement for ARIKAYCE, strengthening the clinical foundation for the therapy. INSM shares rose approximately 11% on the news. Insmed plans to file a supplemental NDA in H2 2026 to support potential U.S. label expansion from refractory to treatment-naive MAC lung disease and to convert the existing accelerated approval to traditional approval. A parallel submission to Japan's PMDA is also planned for H2 2026.
ARIKAYCE is a novel inhaled liposomal formulation of amikacin using Insmed's proprietary PULMOVANCE technology, delivered via the Lamira Nebulizer System (manufactured by PARI Pharma GmbH).
Under their licensing arrangement (originating 2008, amended multiple times), PARI receives mid-single-digit royalties on ARIKAYCE commercial net sales subject to specified annual minimum royalty payments, plus aggregate milestone payments of up to €4.3 million tied to regulatory filings and approvals (US and EU milestones triggered in 2018 and 2020, respectively).
Patent rights covering the Lamira device extend through January 18, 2034. Separately, Insmed carries a royalty financing obligation to OrbiMed of 4.0% of global ARIKAYCE net sales (rising to 4.5% after September 2025), plus 0.75% on brensocatib (BRINSUPRI) global net sales.
The combined PARI plus OrbiMed royalty burden on ARIKAYCE thus approaches high-single-digits when both layers are stacked---a material margin consideration as the franchise scales.
The positive ENCORE Phase 3b data did not trigger a milestone payment under either the PARI or OrbiMed agreements---these are structured as royalties on ongoing commercial sales and regulatory-event milestones (US and EU milestones already triggered in 2018 and 2020, respectively).
The planned sNDA filing in H2 2026 for treatment-naive MAC lung disease could, however, trigger an additional milestone from PARI's remaining €4.3 million regulatory pool. It is approved in the US, EU, and Japan for refractory MAC lung infection.
The ENCORE data, if accepted by regulators, would significantly expand ARIKAYCE's addressable patient population to include treatment-naive patients---a substantially larger commercial opportunity.
Wave Life Sciences: WVE-007 Phase 1 INLIGHT Obesity Data (March 26)
On March 26, 2026, Wave Life Sciences (NASDAQ: WVE) reported positive interim Phase 1 data from the INLIGHT study for WVE-007, a GalNAc-conjugated siRNA targeting INHBE (inhibin subunit beta E, also known as Activin E), in adults with overweight or obesity.
Key Results
| Parameter | WVE-007 240mg | Placebo | Change (placebo-adjusted) |
|---|---|---|---|
| Visceral fat reduction (6 months) | Reported | --- | --14.3% (p<0.05) |
| Total fat mass | Reduced | --- | --5% |
| Lean mass | Increased | --- | +2% |
| Waist circumference | Reduced | --- | --3% |
| Total body weight loss | Reported | --- | --1% |
| Activin E suppression | Durable | --- | Up to 88% at 6 months |
A single 240mg dose produced statistically significant visceral fat reduction with durable Activin E suppression. However, total body weight loss of only --1% triggered a ~50% decline in Wave's stock price, reflecting market skepticism about the commercial viability of a body composition profile without meaningful scale-weight reduction.
Context
WVE-007 is mechanistically differentiated: INHBE is a liver-expressed member of the TGF-beta superfamily that suppresses lipolysis and promotes visceral fat accumulation.
The hypothesis is that selective INHBE inhibition remodels fat distribution toward a metabolically healthier profile (less visceral, more lean mass) even with modest total weight reduction---analogous to tirzepatide's lean-mass-preserving profile versus older GLP-1 agents.
The disconnect between favorable body composition metrics and minimal scale weight nonetheless represents a commercial challenge in a market dominated by GLP-1/GIP agonists producing 15-25% total body weight loss.
Phase 2a enrollment in higher-BMI patients is planned for Q2 2026 to assess whether dosing optimization yields additive weight reduction on top of body composition improvements.
IP and Upstream Licensing
WVE-007 uses Wave's stereopure antisense oligonucleotide chemistry with GalNAc conjugation.
Critically, this is an ASO, not an siRNA, which likely places it outside the core scope of Alnylam's dominant GalNAc-siRNA patent portfolio -- Alnylam's IP enforcement actions have targeted siRNA-specific platforms (Dicerna, Arrowhead, Silence Therapeutics), and no known patent dispute exists between Wave and Alnylam.
Wave's proprietary PN backbone chemistry and stereopure synthesis represent a fundamentally different oligonucleotide modality. Wave's foundational stereopure oligonucleotide platform was licensed from Takeshi Wada's laboratory at Tokyo University of Science (not Harvard, as sometimes misattributed)---the core platform royalties flow to Japanese academic institutions. Wave may carry additional narrower upstream academic royalties (potentially including Harvard for specific target-related IP), but the primary platform obligation is to Tokyo University of Science, estimated at low single digits (1-3%); newer PN backbone chemistry may be largely Wave-proprietary.
WVE-007 is not part of the GSK collaboration ($80M upfront, up to $3.3B milestones, focused on genetic disorders) nor the terminated Takeda CNS collaboration -- it is wholly owned with no corporate co-development partner. Total estimated upstream royalty burden: 3-5% across all academic and potential platform licenses.
Royalty financing relevance: low at current stage. WVE-007 is wholly owned by Wave with no identified upstream corporate royalty. The enormous addressable obesity/metabolic market, first-in-class INHBE positioning, and genetically validated mechanism create significant future potential. A synthetic royalty transaction becomes viable at Phase 2 with compelling metabolic data, likely 2027 at the earliest.
AstraZeneca: Tozorakimab Dual Phase 3 Success in COPD—First-in-Class IL-33 Validation (March 27)
On March 27, 2026, AstraZeneca (LSE: AZN; NASDAQ: AZN) announced that tozorakimab, a potential first-in-class anti-IL-33 monoclonal antibody, met the primary endpoint in both OBERON and TITANIA, replicate Phase III trials in approximately 2,306 patients with chronic obstructive pulmonary disease (COPD).
Key Results
| Parameter | Detail |
|---|---|
| Primary endpoint | Statistically significant reduction in rate of moderate-to-severe COPD exacerbations vs. placebo (former smokers) |
| Key secondary endpoint | Met (overall population including current smokers) |
| Eosinophil independence | Efficacy observed across all blood eosinophil counts and all lung function severity stages |
| Effect size | Not disclosed; AstraZeneca described results as "statistically significant and highly clinically meaningful" |
| Peak sales estimate | $3--5 billion annually (AstraZeneca); $2.5 billion risk-adjusted (Leerink, probability of success raised from 40% to 75%) |
| Additional trials | MIRANDA (Q2W dosing) and PROSPERO (long-term extension) results expected H1 2026 |
| Regulatory plan | Filing based on OBERON + TITANIA without waiting for additional trials |
Mechanism and Competitive Context
Tozorakimab uniquely inhibits both reduced and oxidized forms of IL-33, blocking signaling through both the ST2 and RAGE/EGFR pathways. This dual-form inhibition differentiates it mechanistically from competitors targeting only reduced IL-33 or its receptor. The results represent the first successful replicate Phase III program for any IL-33-targeting biologic in COPD, following multiple competitor failures: Sanofi/Regeneron's itepekimab split Phase III results in May 2025 (AERIFY-1 hit, AERIFY-2 missed), and Roche's astegolimab failed its Phase III ARNASA primary endpoint in July 2025 with only a 14.5% numerical reduction.
Critically, tozorakimab's efficacy across all eosinophil counts differentiates it from existing COPD biologics (Dupixent, Nucala, Tezspire) that require eosinophilic or type 2 inflammatory phenotypes, potentially addressing a substantially broader COPD population. AstraZeneca shares rose approximately 3.4% in London on the news. Jefferies described the success as "a notable shift in sentiment" for the IL-33 mechanism.
Upstream IP and Royalty Obligations
Tozorakimab was developed entirely in-house by AstraZeneca (originally as MEDI-3506 within MedImmune). No upstream academic IP, licensing partners, or third-party royalty obligations have been identified. The compound is wholly owned with no disclosed encumbrances.
Royalty financing relevance: low at current stage. AstraZeneca has no need for synthetic royalty financing at its scale, and the absence of upstream royalties means no existing streams to acquire. However, the validation of IL-33 biology in COPD has significant implications for the broader respiratory royalty landscape---competitor IL-33 programs (itepekimab, astegolimab) and downstream licensing deals in this pathway may see revised valuations. The $3--5 billion peak sales estimate, if realized, would make tozorakimab one of the largest wholly owned respiratory assets in the industry.
Karyopharm Therapeutics: Phase 3 SENTRY Trial in Myelofibrosis—Mixed Results and $30 Million RA Capital Placement
On March 24, 2026, Karyopharm Therapeutics (NASDAQ: KPTI) reported topline results from the Phase 3 SENTRY trial (NCT04562389), a randomized, double-blind, placebo-controlled study of 60 mg selinexor in combination with ruxolitinib versus placebo plus ruxolitinib in JAK inhibitor-naive frontline myelofibrosis (n=353). Data cutoff was February 20, 2026.
Key Results
| Endpoint | Selinexor + Ruxolitinib | Ruxolitinib Alone | Result |
|---|---|---|---|
| SVR35 at Week 24 (co-primary) | 50% | 28% | Met (p<0.0001; OR 2.58, 95% CI 1.60--4.17) |
| Abs-TSS change at Week 24 (co-primary) | -9.89 points | -10.86 points | Not met (not statistically significant) |
| SVR35 at Week 12 | 49% | 20% | Supportive |
| SVR35 at Week 36 | 47% | 23% | Supportive |
| Overall survival (exploratory) | HR 0.43 | --- | Nominally significant; >50% risk reduction |
| VAF reduction ≥20% at Week 24 | 32% | 24% | Evidence of potential disease modification |
The trial met the spleen volume co-primary endpoint---a near doubling of patients achieving SVR35---but did not meet the symptom score co-primary, as patients in both arms achieved similar symptom improvement relative to baseline. The overall survival signal (HR 0.43, nominally significant) is particularly striking given the modest follow-up period, though the trial was not powered for OS. The VAF (variant allele frequency) reductions---32% of combination patients achieving ≥20% reduction at Week 24 versus 24% for ruxolitinib alone---suggest potential disease modification rather than symptomatic benefit alone, a mechanistically distinct claim from existing JAK inhibitor monotherapy.
KPTI shares initially surged approximately 15% in pre-market trading on the SVR35 hit, then reversed to close down approximately 12.7% as the market digested the missed symptom endpoint. Karyopharm plans to meet with the FDA to discuss the totality of the data and a potential supplemental NDA filing.
RA Capital Management $30 Million Private Placement
On the same morning, Karyopharm announced a $30 million private placement with RA Capital Management, with potential additional proceeds of approximately $44 million if all accompanying warrants are exercised.
| Term | Detail |
|---|---|
| Investor | RA Capital Management |
| Common shares | 1,030,354 at $6.785/share |
| Pre-funded warrants | 3,391,164 at $6.7849/warrant ($0.0001 exercise price, no expiration) |
| Accompanying warrants | 4,421,518 shares at $10.00/share exercise price |
| Warrant expiration | 30 days following topline results from Phase 3 XPORT-EC-042 (endometrial cancer, expected mid-2026) |
| Gross proceeds at close | ~$30 million |
| Potential additional proceeds | ~$44 million (full warrant exercise) |
| Pricing | At-the-market under Nasdaq rules |
| Placement agent | Jefferies and Piper Sandler |
| Expected close | On or about March 26, 2026 |
| Registration obligation | Resale registration statement due within 45 days of closing |
| Shares outstanding (March 23) | 19,618,032 |
The financing extends Karyopharm's cash runway into late Q3 2026 and satisfies a key capital-raise condition in its amended credit and forbearance agreements. Karyopharm also raised approximately $9.6 million through its at-the-market program earlier in March 2026. Management still cites substantial doubt about continuing as a going concern---the company's near-term survival is contingent on upcoming clinical catalysts.
DLBCL Indication Voluntary Withdrawal
Also in March 2026, Karyopharm agreed to voluntarily withdraw XPOVIO's accelerated approval for diffuse large B-cell lymphoma (DLBCL) at the FDA's request, after concluding the required confirmatory trial was no longer feasible in an evolving treatment landscape. The indication generates only immaterial revenue, and the withdrawal leaves XPOVIO's other approvals (multiple myeloma) intact---the move is a resource reallocation to concentrate on myelofibrosis and endometrial cancer.
Context for Royalty Investors
Selinexor (XPOVIO/NEXPOVIO) is marketed by Karyopharm in the US and has received regulatory approvals in over 50 countries and territories, including the EU (as NEXPOVIO), the UK, and China. The global ex-US commercial rights are managed through four active licensing arrangements that generate royalty-relevant economics:
| Partner | Territory | Upfront | Milestones | Royalties |
|---|---|---|---|---|
| Menarini Group | EU, UK, Latin America | $75M | Up to $202.5M | Tiered double-digit |
| Antengene | China, Macau (expanded) | $12M + $12M (amendment) | Up to $150M | Tiered double-digit (selinexor); single-to-double-digit (other compounds) |
| FORUS Therapeutics | Canada | ~$5M | Undisclosed | Double-digit |
| Promedico/Neopharm | Israel, Palestinian Authority | Undisclosed | Undisclosed | Double-digit |
A historical Ono Pharmaceutical deal (October 2017, Japan/Asia, ~$22M upfront, up to ~$171M milestones, low double-digit royalties) appears terminated based on its absence from Karyopharm's 2025 SEC filings. Karyopharm also entered a $75 million synthetic royalty financing with HealthCare Royalty Partners in September 2019 (expandable to $150 million).
Importantly, the mixed SENTRY Phase 3 data did not trigger milestone payments under any of these partner agreements---historical milestone recognitions across the Menarini, Antengene, and FORUS deals consistently align with regulatory submissions and approvals rather than Phase 3 readouts.
The real milestone triggers lie downstream: sNDA filing, FDA approval, and ex-US regulatory approvals for the myelofibrosis indication.
If the FDA accepts a supplemental filing for myelofibrosis based on SENTRY, it would meaningfully expand XPOVIO's addressable market---myelofibrosis is a larger commercial opportunity than the company's current multiple myeloma franchise, particularly in the frontline setting where the combination could become the first approved add-on to ruxolitinib.
The RA Capital financing structure is notable for its event-driven construction: the warrant expiration is tied to the endometrial cancer Phase 3 readout (expected mid-2026), creating a natural catalyst window. The $10.00 exercise price represents approximately 50% above the March 24 trading range, meaning substantial additional capital flows to Karyopharm only if the stock appreciates on positive pipeline developments. RA Capital's willingness to deploy $30 million on the day of a mixed Phase 3 readout signals conviction in the broader selinexor franchise value across multiple indications.
Upcoming catalysts include: (1) FDA meeting on potential myelofibrosis sNDA; (2) Phase 3 XPORT-EC-042 topline data in TP53 wild-type endometrial cancer (mid-2026); and (3) Phase 2 SENTRY-2 60 mg cohort data (H2 2026).
Ionis Pharmaceuticals: Zilganersen NDA Accepted with FDA Priority Review
On March 23, 2026, Ionis Pharmaceuticals (NASDAQ: IONS) announced that the FDA accepted the NDA for zilganersen, an antisense oligonucleotide targeting GFAP mRNA, for the treatment of Alexander disease (AxD), with Priority Review and a PDUFA target date of September 22, 2026.
Pivotal Data
The NDA is supported by a Phase 1-3 study (NCT04849741) in 54 participants (ages 1.5--53, mostly children), randomized 2:1 to zilganersen 50 mg or placebo administered once every 12 weeks for 60 weeks. The study met its primary endpoint with a statistically significant 33.3% mean difference in gait speed versus control at Week 61 (p=0.0412). Results across key secondary and exploratory endpoints (adaptive function, communication, GI symptoms, sleep, seizures) consistently favored zilganersen.
Designations and Context
Zilganersen holds Breakthrough Therapy Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation from the FDA, plus EMA Orphan Drug Designation.
Alexander disease is a rare, progressive, and often fatal neurological condition (prevalence ~1 per 1--3 million) caused by GFAP gene variants, leading to progressive motor and cognitive dysfunction with death typically 14--25 years after symptom onset.
If approved, zilganersen would be the first disease-modifying therapy for Alexander disease and a significant commercial milestone for Ionis's growing rare disease franchise.
Zilganersen is wholly owned by Ionis with no upstream academic IP obligations, licensing partners, or royalty-bearing arrangements identified in SEC filings---Ionis retains full global commercial rights.
Notably, zilganersen is not part of any Biogen, Novartis, or AstraZeneca collaboration, and no Royalty Pharma interest exists (their Ionis deal covers only SPINRAZA and pelacarsen).
Daiichi Sankyo / AstraZeneca: Enhertu Dual Japan Approvals
On March 23, 2026, Japan's Ministry of Health, Labour and Welfare (MHLW) granted two separate approvals for Enhertu (trastuzumab deruxtecan), the blockbuster HER2-directed antibody-drug conjugate jointly developed by Daiichi Sankyo (TYO: 4516) and AstraZeneca (LSE: AZN):
1. Pan-tumor HER2-positive indication: Enhertu was approved for advanced or recurrent HER2-positive (IHC 3+) solid tumors refractory or intolerant to standard treatments---making it the first HER2-directed therapy and first ADC with a tumor-agnostic indication in Japan. The approval was based on four Phase 2 trials including HERALD (Japanese investigator-initiated), DESTINY-PanTumor02, DESTINY-CRC02, and DESTINY-Lung01. In the HERALD study, the confirmed objective response rate was 56.5% across multiple tumor types (cervical, pancreatic, gastric, colorectal, NSCLC, and others).
2. Gastric cancer second-line expansion: Enhertu's label was expanded from third-line to second-line treatment of HER2-positive unresectable advanced or recurrent gastric cancer, based on Phase 3 data showing a 30% reduction in risk of death (median OS 14.7 months vs. 11.4 months).
Royalty and Licensing Context
Under the March 2019 global collaboration, Daiichi Sankyo and AstraZeneca jointly develop and commercialize Enhertu worldwide, except in Japan where Daiichi Sankyo retains exclusive rights. AstraZeneca paid Daiichi Sankyo up to $6.9 billion in upfront and milestone payments under the original agreement, structured as follows:
| Term | Detail |
|---|---|
| Upfront payment | $1.35 billion (paid in two equal $675M installments, 12 months apart) |
| Regulatory milestones | Up to $3.8 billion |
| Sales-related milestones | Up to $1.75 billion |
| Milestones paid/triggered to date | Over $1.14 billion, including a $600M sales milestone (Q4 2024), $175M for HER2-low/ultralow breast cancer approval (January 2025), and $150M for first-line HER2+ metastatic breast cancer approval (December 2025). The March 2026 Japan tumor-agnostic approval does not trigger an AstraZeneca milestone because Daiichi Sankyo retains exclusive Japan rights; AZ milestones apply only to ex-Japan approvals and sales |
| Profit sharing (ex-Japan) | 50/50 split of development costs, commercialization costs, and profits worldwide excluding Japan |
| Japan economics | Daiichi Sankyo retains exclusive rights; AstraZeneca receives mid-single-digit royalties on Japanese net sales |
| Revenue recording | Daiichi Sankyo books US revenue (AZ recognizes share as "Alliance Revenue"); AstraZeneca books sales in markets where it holds commercial infrastructure |
Japan approval milestone analysis: Because Japan is excluded from AstraZeneca's licensed territory under the 2019 collaboration, the March 2026 Japan tumor-agnostic and gastric cancer 2L approvals very likely trigger no AstraZeneca milestone payments.
All documented milestone payments from the $3.8 billion regulatory and $1.75 billion sales milestone pools correspond exclusively to US FDA or EU EMA approvals---every AstraZeneca press release announcing a US/EU approval includes a "Financial considerations" section specifying the milestone amount, while Japan approval announcements from Daiichi Sankyo never contain such disclosures.
The only financial flow triggered by increased Japan sales is the ongoing mid-single-digit percentage royalty that Daiichi Sankyo pays AstraZeneca on Japanese Enhertu net sales.
Enhertu generated $3.75 billion in FY2024 sales and approximately $3.6 billion through nine months of 2025, with analyst peak sales estimates of $10-12 billion.
The tumor-agnostic approval in Japan---the first such approval for any HER2-directed ADC in any market---has potential royalty implications for assets in the Daiichi Sankyo/AstraZeneca collaboration as well as for competing ADC programs. The U.S.
FDA also granted Priority Review for Enhertu's tumor-agnostic sBLA (decision expected July 2026) and for its breast cancer neoadjuvant/adjuvant application (July 7, 2026 PDUFA).
The separate Datopotamab Deruxtecan (Datroway) collaboration between the same partners follows an identical 50/50 structure with $1 billion upfront (staged over 24 months) and up to $5 billion in milestones.
Apogee Therapeutics: Zumilokibart (APG777) Phase 2 APEX 52-Week Data in Atopic Dermatitis
On March 23, 2026, Apogee Therapeutics (NASDAQ: APGE) reported 52-week data from Part A of the Phase 2 APEX trial of zumilokibart (APG777), an anti-OX40 ligand antibody, in moderate-to-severe atopic dermatitis.
Among Week 16 responders, EASI-75 was maintained in 75% (every 3-month dosing) and 85% (every 6-month dosing); overall EASI-75 rates across all treated patients reached 88% (Q3M) and 81% (Q6M). The extended dosing intervals (3--6 months) represent a significant potential competitive advantage versus existing biologics requiring more frequent administration.
Phase 2 Part B 16-week data are expected Q2 2026, with Phase 3 initiation planned for H2 2026.
Zumilokibart is licensed from Paragon Therapeutics under an April 2023 exclusive license.
Per Apogee's 10-K, the Paragon license carries up to $28 million in development and clinical milestones for the first licensed product, of which $3 million was paid in October 2024 upon development candidate nomination and $5 million is owed upon first patient dosed in Phase 1.
Royalties are a low-single-digit percentage of net sales on a product-by-product, country-by-country basis, lasting the later of 12 years after first commercial sale or patent expiry. Paragon retains a nonexclusive license-back for multispecific antibodies.
The 52-week Phase 2 data readout did not trigger a Paragon milestone---the remaining milestone obligations are tied to later regulatory and clinical events (Phase 1 FPD, which is owed but separate from this data event, plus additional development triggers). Only low-single-digit royalties on future sales remain as the primary ongoing economic obligation.
Ocugen: OCU410 Phase 2 ArMaDa 12-Month Data in Dry AMD
On March 24, 2026, Ocugen (NASDAQ: OCGN) reported that its modifier gene therapy OCU410 (AAV5-RORA) achieved a statistically significant 31% reduction in geographic atrophy lesion growth versus control at 12 months (p<0.05) in the Phase 2 ArMaDa trial in dry age-related macular degeneration (n=51). Photoreceptor structure was preserved with no serious adverse events. A Phase 3 registrational trial is planned for Q3 2026.
OCU410 is developed under an exclusive worldwide license from the Schepens Eye Research Institute (SERI), part of Massachusetts Eye and Ear/Harvard Medical School, originally executed in December 2017 and amended in January 2021. Per Ocugen's SEC filings, the SERI license carries aggregate milestone obligations of $16.5 million across regulatory and commercial triggers, with low-single-digit royalties on annual net sales. CanSinoBIO holds Greater China rights under a September 2021 sublicense amendment.
Anavex Life Sciences: Blarcamesine Phase IIb/III AD-004 Data at AD/PD 2026
On March 23, 2026, Anavex Life Sciences (NASDAQ: AVXL) presented new data from the Phase IIb/III AD-004 trial at the AD/PD 2026 conference in Copenhagen, showing that oral blarcamesine treatment correlated with preservation of brain volume in early Alzheimer's disease, with long-term data demonstrating 77.4 weeks of cognitive time saved versus natural history controls after 144 weeks of treatment.
NKGen Biotech: Troculeucel Combined Phase 1 Data in Alzheimer's Disease
On March 23, 2026, NKGen Biotech (NASDAQ: NKGN) presented pooled Phase 1 data for troculeucel (autologous NK cell therapy) at AD/PD 2026, showing 92% of Alzheimer's disease patients stable or improved in cognitive function.
In the moderate AD subgroup (n=6), 100% were stable or improved at 3 months, with 50% improving from moderate to mild. Dose-responsive GFAP biomarker correlations (r up to 0.76, p<=0.009) were observed with no treatment-related adverse events.
BioNTech: Lung Cancer Data at ELCC 2026
On March 24, 2026, BioNTech (NASDAQ: BNTX) presented updated data at the European Lung Cancer Congress (ELCC 2026, March 25--28, Copenhagen) for pumitamig (BNT327), a PD-L1/VEGF-A bispecific antibody, showing encouraging survival outcomes when combined with chemotherapy in first-line extensive-stage small cell lung cancer, as well as new Phase 1b/2a findings in first-line NSCLC demonstrating preliminary activity irrespective of PD-L1 expression.
These data advance BioNTech's differentiated late-stage oncology portfolio beyond its established mRNA vaccine platform.
Sarepta Therapeutics: First Clinical Data from siRNA Platform in FSHD1 and DM1 (March 25)
On March 25, 2026, Sarepta Therapeutics (NASDAQ: SRPT) reported the first clinical results from two siRNA programs licensed from Arrowhead Pharmaceuticals: SRP-1001 for facioscapulohumeral muscular dystrophy type 1 (FSHD1) and SRP-1003 for myotonic dystrophy type 1 (DM1).
Key Results
Early data from Phase 1/2 ascending dose studies of both programs demonstrated dose-dependent muscle siRNA exposure with no saturation of muscle uptake, early biomarker effects including proof-of-concept target knockdown (DUX4 protein reduction for SRP-1001; DMPK mRNA silencing for SRP-1003) after single doses, and favorable tolerability with no dose-limiting toxicity.
The majority of adverse events were mild to moderate and not dose dependent. Specific quantified knockdown percentages were not disclosed in the press release. Sarepta described the results as reinforcing scientific confidence in the αvβ6 integrin-targeted delivery platform that underpins both programs.
SRP-1001 is designed to reduce DUX4 protein production in skeletal muscle via a proprietary αvβ6 integrin-targeted ligand that enables siRNA to penetrate muscle tissue. Study 1001-101 is a combined Phase 1/2 SAD/MAD randomized, placebo-controlled trial in FSHD1 patients aged 16-70. FSHD affects approximately 16,000 diagnosed individuals in the US.
SRP-1003 targets and silences DMPK mRNA in DM1. Study SRP-1003-101 is a first-in-human Phase 1/2 SAD/MAD randomized, placebo-controlled trial in DM1 patients aged 18-65. DM1, the most common adult-onset muscular dystrophy, affects approximately 40,000 diagnosed individuals in the US. Neither FSHD nor DM1 has any approved disease-modifying treatment.
Arrowhead Pharmaceuticals Upstream License
Both programs are developed under a November 2024 exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals (NASDAQ: ARWR)---one of the largest siRNA licensing transactions in industry history. The agreement covers four clinical-stage and three preclinical-stage programs plus a discovery partnership for up to six additional targets:
| Term | Detail |
|---|---|
| Licensor | Arrowhead Pharmaceuticals (NASDAQ: ARWR) |
| Licensee | Sarepta Therapeutics (NASDAQ: SRPT) |
| Upfront payment | $500 million cash |
| Equity investment | $325 million in Arrowhead common stock (priced at 35% premium to 30-day VWAP) |
| Deferred payments | $250 million ($50 million annually over 5 years) |
| Near-term enrollment milestones | Up to $300 million (a $200 million milestone was triggered in November 2025 upon SRP-1003 DM1 enrollment target achievement) |
| Development milestones | $110-410 million per program (across 7 licensed programs + up to 6 discovery targets) |
| Total potential milestones | Up to approximately $10 billion |
| Royalties | Tiered up to low double-digit percentages on commercial sales |
| Manufacturing | Arrowhead manufactures clinical drug supply for all programs and commercial drug product for preclinical-stage programs |
| Programs covered | SRP-1001 (FSHD1), SRP-1002 (IPF), SRP-1003 (DM1), SRP-1004 (SCA2), SRP-1005 (Huntington's disease), plus preclinical SCA1, SCA3, and up to 6 discovery targets |
| Arrowhead legal advisor | Gibson, Dunn & Crutcher |
| Closing | Q1 2025 |
Strategic Context and Royalty Implications
The March 25 data event is the first clinical validation of the αvβ6 integrin-targeted siRNA delivery platform that underpins the entire Arrowhead collaboration. Positive proof-of-concept data across two programs simultaneously de-risks not just SRP-1001 and SRP-1003, but the broader platform thesis supporting all seven licensed programs and the discovery partnership---collectively representing up to $10 billion in potential milestone payments and low double-digit royalties to Arrowhead.
Sarepta's CEO Doug Ingram serves on Arrowhead's board of directors as part of the collaboration. Sarepta reported FY2025 revenue of $2.2 billion (+16% YoY), with its existing commercial portfolio comprising ELEVIDYS (delandistrogene moxeparvovec, gene therapy for Duchenne, $899M FY2025) and three PMO exon-skipping therapies ($966M FY2025). Cash and investments were $954 million at December 31, 2025. Sarepta underwent a strategic restructuring in July 2025 to reduce expenses by approximately $400 million annually starting in 2026, sharpening focus on the siRNA platform.
For royalty investors, the Arrowhead royalty stream—tiered up to low double-digits on commercial sales across a portfolio of programs addressing rare neuromuscular and neurodegenerative diseases with no approved disease-modifying therapies—represents one of the highest-potential siRNA royalty positions in the industry. The $200 million enrollment milestone triggered in November 2025, combined with today's positive platform data, signals that the near-term $300 million milestone tranche is substantially on track.
Beam Therapeutics: BEAM-302 Updated Phase 1/2 Data in Alpha-1 Antitrypsin Deficiency (March 25)
On March 25, 2026, Beam Therapeutics (NASDAQ: BEAM) reported updated data from 29 patients in the ongoing Phase 1/2 trial of BEAM-302, a liver-targeting lipid nanoparticle (LNP) base editing therapy designed to correct the PiZ mutation underlying the severe form of alpha-1 antitrypsin deficiency (AATD).
At the selected 60 mg dose, treatment produced mean steady-state total AAT of 16.1 uM (above the 11 uM protective threshold), with corrected M-AAT comprising 94% of total circulating AAT and an 84% reduction in toxic mutant Z-AAT, with durability demonstrated up to 12 months.
Notably, dynamic AAT induction was observed during a respiratory infection, with total AAT rising to 29.5 uM while maintaining 95% M-AAT composition---demonstrating that the corrected gene retains physiological regulation, a property not achievable with existing protein replacement therapies. Safety was favorable with no dose-limiting toxicities across single doses up to 75 mg.
Beam selected 60 mg as the optimal biological dose and plans to initiate a global pivotal cohort (~50 additional patients) in H2 2026, pursuing an FDA accelerated approval pathway based on 12-month biomarker endpoints, supported by RMAT designation.
BEAM-302 represents the first clinical demonstration of in vivo base editing correcting a disease-causing mutation in humans. Beam reported $1.25 billion in cash with runway into 2029. BEAM-302 is wholly owned by Beam with no external licensing or royalty arrangements disclosed on the primary asset.
However, under a 2024 settlement with a research institution, Beam owes up to $15 million in development/regulatory milestones per program plus $35 million in sales milestones and a 1% royalty through 2038.
Deeply Layered Academic Royalty Stack
Beam's SEC filings (10-K and various exhibits) reveal four overlapping IP obligations on its base editing products that create a significantly higher aggregate royalty burden than the 1% settlement alone:
| License | Key Terms | Estimated Remaining Exposure |
|---|---|---|
| Harvard License (June 2017, amended) | David Liu's foundational base editing IP; redacted royalty rates; milestone payments up to ~$68.8-74.0M per product; success payments tied to market cap multiples; 0-20% sublicense income sharing | Substantial milestones + ongoing royalties |
| Broad Institute License (May 2018, via Blink subsidiary) | CRISPR patent rights co-owned by MIT and Harvard; success payments $5M-$105M (up to ~$90M remaining after a $15M stock payment in 2021); redacted royalties with multi-patent-family reduction provisions | Up to ~$90M in success payments + ongoing royalties |
| Editas sublicense | Beam pays Editas an amount equal to what Editas owes Broad/Harvard under its head licenses plus a low-to-mid single-digit royalty | Stacked pass-through + royalty |
| Bio Palette cross-license (Kobe University spinout) | Additional obligations on base editing in certain fields | Undisclosed |
The aggregate stacked royalty burden on any BEAM-302 product is estimated at approximately 7-10% of net sales when all layers are combined (Harvard ~1-2%, Broad ~3-4%, Editas pass-through + royalty ~1-2%, Bio Palette ~1-2%, settlement 1%)---substantially higher than the 1% settlement royalty alone and representing a meaningful margin consideration for any acquirer or partner evaluating the asset. Individual rates are redacted in SEC filings; low-teens estimates circulating in some analyses likely overstate the aggregate burden absent evidence of additional undisclosed obligations.
The selection of a pivotal dose and advancement to registrational development may constitute a development milestone trigger under these agreements, though the specific definitions are redacted.
Eisai / BioArctic: New Lecanemab Real-World Data
On March 23, 2026, BioArctic announced the release of new real-world data from the AD/PD 2026 congress on lecanemab (Leqembi), including long-term treatment persistence data and four-year open-label extension results from the Clarity AD trial. Lecanemab is now approved in 53 countries. A supplemental BLA for subcutaneous initiation dosing carries a PDUFA date of May 24, 2026.
AAD 2026: Royalty and Licensing Context for Key Dermatology Readouts
The AAD 2026 annual meeting in Denver delivered three headline Phase 3 validations -- Alumis envudeucitinib and Takeda zasocitinib for psoriasis, and AbbVie Rinvoq for vitiligo -- each carrying meaningfully different upstream royalty profiles.
Alumis / envudeucitinib (ONWARD 1&2): Envudeucitinib is an allosteric TYK2 inhibitor (JH2 pseudokinase domain) discovered entirely internally by Alumis (founded 2020 as Esker Therapeutics). No upstream licensing arrangement with an external corporate or academic licensor has been publicly disclosed.
The compound's allosteric mechanism parallels BMS's deucravacitinib (Sotyktu, $1.5B+ franchise), raising potential freedom-to-operate considerations around BMS's allosteric TYK2 IP estate -- though Alumis's distinct scaffold likely provides separation. Critically, BMS holds foundational patents on allosteric TYK2 pseudokinase domain (JH2) inhibition, the mechanism shared by both deucravacitinib and envudeucitinib.
No patent litigation or licensing agreement between Alumis and BMS is publicly disclosed, representing a material FTO risk. Takeda's zasocitinib (also allosteric TYK2) faces identical exposure, suggesting industry-wide IP uncertainty across the entire allosteric TYK2 inhibitor class.
With 74% PASI 75 at Week 16 and an NDA targeted for H2 2026, envudeucitinib enters a $15B+ global psoriasis market with a potentially differentiated efficacy profile.
Royalty financing relevance: moderate. No identified upstream royalty to monetize from Alumis's perspective, but the company -- approaching its first NDA filing -- becomes a candidate for creating a synthetic royalty on product revenues as a non-dilutive financing mechanism ahead of launch.
Takeda / zasocitinib (LATITUDE): Zasocitinib was acquired when Takeda purchased Nimbus Lakshmi, Inc. (the TYK2 subsidiary of Nimbus Therapeutics) in December 2022 for $4.0 billion upfront plus up to $2.0 billion in CVRs.
The CVRs are held by former Nimbus Lakshmi shareholders and are tied to regulatory and commercial milestones; Schrödinger -- which held equity in Nimbus Lakshmi -- received approximately $100M from the upfront plus a pro-rata CVR entitlement estimated at up to ~$51M.
Critically, Schrödinger's economics are equity-based, not royalty-based: there is no ongoing percentage-of-sales royalty flowing to Schrödinger on zasocitinib net sales.
The CVR instruments -- up to $2 billion maximum -- are the most significant contingent exposure in the TYK2 dermatology space, but their binary, milestone-based structure makes them less relevant to traditional royalty financing models than a percentage-of-sales stream would be.
The LATITUDE Phase 3 success -- all 44 ranked endpoints met, NDA planned FY2026 -- advances zasocitinib toward commercialization and makes the CVR triggers increasingly probable. The positive data did not trigger a milestone payment; defined regulatory events (NDA acceptance, FDA approval) are the next trigger points.
AbbVie / upadacitinib (Rinvoq, Viti-Up): Upadacitinib was developed entirely internally by AbbVie (formerly Abbott). No material upstream royalty obligations to third parties have been identified in AbbVie's SEC filings for Rinvoq -- in contrast to Humira, which carried royalty obligations to Cambridge Antibody Technology/AstraZeneca (~2.688% on net sales).
The positive Phase 3 vitiligo data (both co-primaries met) expand Rinvoq's addressable market -- the drug generated approximately $4.0-4.5 billion in 2024 across six approved indications -- but trigger no milestone payments to external parties.
The primary competitor in vitiligo is Incyte's ruxolitinib cream (Opzelura, topical); upadacitinib would be a systemic oral alternative targeting more severe disease. Royalty financing relevance: low. No upstream royalty to monetize; AbbVie has no need for synthetic royalty financing at its scale.
MoonLake / sonelokimab (VELA, Phase 3 HS): Sonelokimab, a tri-specific Nanobody targeting IL-17A, IL-17F, and albumin, carries the heaviest upstream royalty burden of any W13 clinical readout. The compound was licensed from Merck Healthcare KGaA (Darmstadt, Germany) in December 2020. The Nanobody platform originated at Ablynx, which Sanofi acquired in 2018 for EUR 3.9B. The upstream IP chain runs Ablynx -> Merck KGaA collaboration -> MoonLake exclusive license.
Per MoonLake's 20-F disclosures, the license economics include: development and regulatory milestones of approximately EUR 45-50 million in aggregate; commercial/sales milestones of approximately EUR 150-200 million; and tiered royalties estimated in the high single-digit to low double-digit range (8-12%) on net sales. The positive Phase 3 VELA data in hidradenitis suppurativa (HiSCR75 primary met, n=838) could trigger a Phase 3 completion milestone payment to Merck KGaA, estimated at EUR 5-15 million.
Exact terms are partially subject to confidential treatment in SEC filings, but this royalty stack materially impacts MoonLake's long-term margin profile relative to wholly owned competitors in the same disease areas (compare Celldex barzolvolimab and Novartis remibrutinib, both wholly owned with zero upstream royalties).
Royalty financing relevance: moderate-to-high. The Merck KGaA royalty on sonelokimab net sales represents a well-defined, creditworthy counterparty stream that could be attractive for secondary royalty acquisition if MoonLake is acquired or monetizes the stream.
Biogen / litifilimab (AMETHYST, Phase 2 CLE): Litifilimab (BIIB059) was developed internally by Biogen, as indicated by the BIIB prefix in its compound designation. The antibody targets BDCA2 (CLEC4C) on plasmacytoid dendritic cells.
The scientific foundation draws from academic research on pDC biology, and Biogen may have modest academic license obligations (low single-digit royalties, small milestones), but there is no BMS license or royalty arrangement for this compound. Any prior attribution to Bristol-Myers Squibb is erroneous.
Sanofi / amlitelimab (COAST/SHORE, Phase 3 AD): Amlitelimab (formerly KY1005) was developed by Kymab Ltd. (Cambridge, UK). The "KY" prefix stands for Kymab. Sanofi acquired Kymab outright in January 2021 for up to ~$1.45 billion ($1.1B upfront plus ~$350M in contingent earn-out milestones tied to clinical, regulatory, and commercial events). Because this was a full acquisition rather than a license, there are no ongoing royalty obligations—only residual earn-out milestone payments to former Kymab shareholders.
Positive Phase 3 data could trigger a clinical milestone under the earn-out, potentially in the tens of millions. Kymab's IntelliSelect transgenic mouse platform (originating from Wellcome Trust Sanger Institute and Babraham Institute) carried upstream academic license obligations including low single-digit royalties and modest milestones, which transferred to Sanofi upon acquisition.
Nektar / rezpegaldesleukin (Phase 2b AD and alopecia areata): Now wholly owned by Nektar after Eli Lilly returned all rights in September 2023 following disappointing SLE Phase 2 results. The original 2017 Lilly collaboration ($150M upfront, up to $1.25B in milestones) is fully terminated. Nektar developed the compound using its proprietary PEGylation platform with no upstream obligations.
Connect Biopharma-Simcere / rademikibart (RADIANT-AD, Phase 3 AD): Rademikibart (CBP-201, anti-IL-4Ralpha) was developed internally by Connect Biopharma with no upstream third-party royalty. Greater China rights were out-licensed to Simcere Pharmaceutical in 2022 for ~$40M upfront, up to ~$125M development/regulatory milestones, ~$175M commercial milestones (~$340M total), plus tiered royalties from Simcere to Connect Biopharma on China net sales. Positive Phase 3 data likely triggers a $10-25M milestone FROM Simcere TO Connect Biopharma (not the reverse).
Celldex / barzolvolimab (anti-KIT, CSU): Phase 2 data showed up to 51% complete response (UAS7=0) at 12 weeks, deepening to 71% at 52 weeks; 41% maintained response 7 months post-last dose. Phase 3 EMBARQ-CSU enrolled ahead of schedule with topline expected Q4 2026. Barzolvolimab is wholly owned by Celldex with no disclosed upstream royalties. Royalty financing relevance: moderate-to-high given the large CSU addressable market ($5B+ globally) and potential for Phase 3 data to support a synthetic royalty transaction.
Eli Lilly / lebrikizumab (EBGLYSS): Four-year durability data in moderate-to-severe atopic dermatitis showing sustained skin clearance and itch relief through the ADlong Phase 3b interim analysis. Lebrikizumab was originally developed by Genentech/Roche; Lilly licensed it in October 2022 under a global agreement. Lilly pays Roche tiered royalties on global net sales.
Sun Pharma / tildrakizumab (ILUMYA): Phase 3b nail psoriasis data showed mNAPSI 75 response rising from 25.5% (week 28) to 41.2% at week 52. Tildrakizumab was licensed by Sun Pharma from Merck in 2014; Sun pays Merck mid-single-digit tiered royalties on US net sales under the October 2014 exclusive license.
Organon / tapinarof (VTAMA): Phase 3 ADORING pooled analysis in atopic dermatitis showed EASI75 ~55--59% vs. ~21--23% vehicle at week 8. Tapinarof was in-licensed from GSK through the Organon spinoff and the original Dermavant Sciences acquisition; upstream royalty obligations to GSK/Stiefel apply.
Astellas / setidegrasib (KRAS G12D PROTAC degrader): First-in-class data published simultaneously in NEJM (March 25) showing 36% ORR in NSCLC (N=45) with mPFS 8.3 months and 24% ORR in pancreatic cancer (N=21); confirmed 70.6% median KRAS G12D protein degradation in tumor biopsies. Setidegrasib was developed by C4 Therapeutics and licensed to Astellas. The NEJM publication marks the first clinical validation of targeted protein degradation for KRAS mutations.
Summit/Akeso / ivonescimab (HARMONi brain metastasis data): Intracranial PFS 10.1 vs. 6.5 months (HR 0.53, p=0.007) in EGFR-mutant NSCLC patients with brain metastases. Summit licensed ivonescimab from Akeso for ex-China rights under a $500 million upfront deal.
Summary of W13 AAD Upstream Royalty Profiles: The vast majority of W13 dermatology readouts involve wholly owned assets with clean IP (barzolvolimab, remibrutinib, povorcitinib, abrocitinib, rezpegaldesleukin, envudeucitinib, roflumilast cream, RLS-1496). Only three carry material upstream economics: sonelokimab (8-12% tiered royalties to Merck KGaA—the heaviest burden), lebrikizumab (tiered royalties to Roche), and tildrakizumab (mid-single-digit tiered royalties to Merck). Amlitelimab carries only residual earn-out milestones to former Kymab shareholders (no ongoing percentage-of-sales royalty).
Earendil Labs: $787 Million Financing for AI-Driven Biologics (March 20/23)
On March 20, 2026, Earendil Labs announced $787 million in financing---the largest private biopharma raise of the W13 window---to scale its AI-native biologics discovery and development platform. No specific Series label or valuation was disclosed.
Deal Structure
| Term | Detail |
|---|---|
| Company | Earendil Labs (Delaware; headquartered in Beijing) |
| Amount | $787 million |
| Key investors | Dimension Capital (Zavain Dar), DST Global, INCE Capital, Luminous Ventures, Miracle Capital, Sanofi (strategic), Biotech Development Fund (Hillhouse/Pfizer) |
| Pipeline | ~40 programs, ~20 drug candidates (antibodies, bispecifics, ADCs) |
| Lead asset | HXN-1001, half-life-extended anti-TL1A antibody for IBD (Phase 1 cohort 1 completed July 2025; Phase 2-ready) |
| CEO | Jian Peng, PhD (UIUC Associate Professor of Computer Science, 2020 ISCB Overton Prize) |
| Co-CEO/President | Zhenping Zhu, MD, PhD |
Helixon Therapeutics Affiliation and IP Provenance
Earendil Labs is the overseas-facing entity affiliated with Helixon Therapeutics (华深智药), a Beijing-based AI drug discovery company incubated at Tsinghua University's Institute for AI Industry Research and founded in June 2021. Both entities share the same leadership team. Pipeline compounds carry the HXN- prefix derived from Helixon's name. Helixon raised approximately $74.7 million in a Series A (June 2022) from 5Y Capital, Gaorong Capital, Neumann Capital, and Hillhouse Ventures.
The precise legal relationship between Earendil (Delaware) and Helixon (Beijing) is described only as "affiliate" in public disclosures---no IP licensing or transfer agreement has been made public. The Delaware incorporation appears designed to facilitate global partnering and regulatory access while R&D operations remain substantially in China.
Sanofi Strategic Collaborations
Two Sanofi deals anchor Earendil's partnering portfolio:
| Deal | Date | Structure | Key Programs |
|---|---|---|---|
| Bispecific antibody license | April 2025 | $125M upfront + up to $1.72B milestones + tiered royalties | HXN-1002 (α4β7/TL1A bispecific, UC/Crohn's) and HXN-1003 (TL1A/IL-23 bispecific, colitis/skin) |
| AI discovery collaboration | January 2026 | Up to $160M upfront/near-term + $2.56B total value + tiered royalties | Broader AI-driven antibody discovery across autoimmune and inflammatory diseases |
Combined Sanofi deal value: approximately $4.4 billion. Earendil also entered strategic collaborations with WuXi Biologics (March 2026, end-to-end biologics manufacturing) and WuXi XDC (February 2026, ADC payload-linker technology platform).
Geopolitical and Regulatory Risk Factors
The BIOSECURE Act (signed December 18, 2025 as NDAA Section 851) targets biotechnology companies of concern under foreign-adversary governance. Earendil/Helixon are not specifically named, but the company's Beijing headquarters, Tsinghua University incubation, Chinese venture backing, and active WuXi collaborations create material regulatory exposure. The WuXi entities specifically face BIOSECURE restrictions with compliance deadlines beginning in 2032, though exemptions may apply for existing contracts.
For royalty investors, the Sanofi royalty streams on HXN-1002 and HXN-1003 are the most commercially relevant assets, but they carry counterparty risk layered with geopolitical complexity. The IP provenance question---whether Earendil holds clean, independently enforceable IP or relies on technology developed at Helixon/Tsinghua---is a material diligence item for any downstream royalty transaction. No SEC filings exist for this private Delaware entity. CFIUS implications remain publicly unaddressed.
Royalty financing relevance: moderate, improving. The Sanofi royalty streams are high-quality counterparty obligations, but Phase 1 stage and unresolved IP/geopolitical questions make this premature for traditional royalty financing. Watch for Phase 2 data on HXN-1001 and regulatory clarity on the Earendil-Helixon IP structure.
Apogee Therapeutics: $403 Million Upsized Public Offering (March 26)
On March 26, 2026, Apogee Therapeutics (NASDAQ: APGE) closed an upsized underwritten public offering of 5,750,000 shares of common stock at $70.00 per share, including the full exercise of the underwriters' option to purchase 750,000 additional shares, for aggregate gross proceeds of approximately $403 million before deducting underwriting discounts, commissions, and expenses.
The offering was originally proposed on March 23 at $300 million, upsized to $350 million (5 million shares) at pricing on March 24, with the greenshoe exercised in full on March 25 and closing on March 26. Joint bookrunning managers were Jefferies, TD Cowen, Stifel, and Guggenheim Securities, with Wedbush PacGrow and BTIG as lead managers.
Apogee's stock had surged approximately 94% over the preceding six months and was trading near all-time highs at the time of pricing, driven by positive 52-week APEX Phase 2 data for zumilokibart (anti-OX40L antibody) in atopic dermatitis with Phase 3 planned for H2 2026.
The company is developing a pipeline of immunology assets including zumilokibart and APG808 (anti-IL-13 antibody). Royalty financing relevance: low. No external royalty or licensing obligations have been disclosed on Apogee's wholly owned pipeline. The offering capitalizes the company's transition from Phase 2 to pivotal development.
OnKure Therapeutics: $150 Million Oversubscribed Private Placement (March 27)
On March 27, 2026, OnKure Therapeutics (NASDAQ: OKUR) announced an oversubscribed $150 million private placement at $4.15 per share (26.7 million shares plus pre-funded warrants for 9.4 million additional shares).
| Term | Detail |
|---|---|
| Issuer | OnKure Therapeutics (NASDAQ: OKUR) |
| Amount | $150 million |
| Structure | Common stock at $4.15/share + pre-funded warrants |
| Lead investor | Access Biotechnology |
| Syndicate | BVF Partners, RA Capital, Trails Edge, Coastlands, StepStone, Vivo Capital, ADAR1, Foresite, Adage, Vestal Point, Acorn Bioventures, Logos |
| Placement agent | Leerink Partners |
| Lead program | OKI-219, pan-mutant-selective PI3Kα inhibitor (Phase 1 initiated February 2026) |
| Additional programs | OKI-345 and OKI-355 (IND filings planned H1 2027) |
| Cash runway | Into 2029 |
OnKure's pan-mutant-selective PI3Kα inhibitors target all clinically relevant PIK3CA mutations (including kinase domain and C2 domain variants) while sparing wild-type PI3Kα, addressing the hyperglycemia toxicity that has limited first-generation PI3K inhibitors.
The competitive landscape includes Novartis's recently acquired SNV4818 (Synnovation/Pikavation, $3 billion deal announced March 20), Lilly's STX-478 (acquired from Scorpion for $2.5 billion, January 2025), and Relay Therapeutics' zovegalisib. Royalty financing relevance: low. Early-stage pipeline with no disclosed upstream licensing or royalty obligations.
Zenas BioPharma: $300 Million Concurrent Convertible Notes and Equity Offering (March 27)
On March 27, 2026, Zenas BioPharma (NASDAQ: ZBIO) priced concurrent public offerings of 2.50% convertible senior notes due 2032 and common stock with aggregate gross proceeds of $300 million.
| Term | Detail |
|---|---|
| Issuer | Zenas BioPharma, Inc. (NASDAQ: ZBIO) |
| Convertible notes | $200 million principal amount, 2.50% coupon, due 2032 (conversion price $26.50, 32.5% premium) |
| Common stock | $100 million (5,000,000 shares at $20.00/share) |
| Total gross proceeds | $300 million (~$287.5 million net) |
| Joint bookrunners | Jefferies, Evercore ISI, Citigroup, Guggenheim Securities |
| Co-manager | Wedbush PacGrow |
| Expected close | March 31, 2026 |
Zenas BioPharma is a clinical-stage autoimmune and rare disease company. Proceeds will fund the U.S. commercial launch of obexelimab (bifunctional anti-CD19/FcγRIIb mAb for IgG4-related disease, BLA planned Q2 2026), Phase 3 orelabrutinib for progressive MS, and Phase 1/2 ZB021 (oral IL-17 inhibitor).
The dual offering structure—convertible debt plus equity—provides capital for pipeline advancement while limiting immediate dilution relative to a pure equity raise. Royalty financing relevance: low. Equity/debt financing mechanism with no licensing or royalty economics disclosed.
Debt Financings: CRISPR Therapeutics $550M Convertible Notes and Hansa Biopharma $30M Convertible Note
CRISPR Therapeutics (NASDAQ: CRSP) priced $550 million in convertible senior notes on March 11 (closed March 16), upsized from an initial $350 million offering. The notes carry a 1.125% effective coupon with a 45% conversion premium (~$76.56 conversion price) and mature in 2031. Goodwin Procter served as issuer counsel. Initial purchasers/book runners were not publicly named. The raise strengthens CRISPR's balance sheet as it commercializes Casgevy (exagamglogene autotemcel), the first approved CRISPR-based gene therapy, and advances its clinical pipeline.
Hansa Biopharma (NASDAQ STO: HNSA) closed a $30 million convertible note on March 20 with Athyrium Capital Management as sole lender. The note carries a 3% coupon, matures in March 2031, and has a conversion price of approximately SEK 43 per share. Both financings are borderline-period events (announced just before March 23) but appear in weekly roundups for this window.
Oryon Cell Therapies: $21 Million Series A Emergence
On March 23, 2026, Oryon Cell Therapies emerged from stealth with a $21 million new tranche of Series A financing, bringing total funding to $42 million (equity plus grants). Investors include Neuro.VC and Byers Capital. The company is led by CEO Ron Cohen, M.D. (founder of Acorda Therapeutics) and is developing autologous iPSC-derived dopaminergic neuron replacement therapy for Parkinson's disease.
The company's approach is mechanistically related to Aspen Neuroscience's ASPIRO program (12-month data presented at AD/PD 2026 in W12 showed symptom improvement in all eight patients), but Oryon focuses on a differentiated manufacturing and delivery approach. Phase 1b/2a data presented by Oryon showed 29-62% motor improvement in 5 patients at 6-18 months. The company plans to advance to a pivotal study.
Immutrin: $87 Million Series A for ATTR Amyloidosis Antibody
On March 24, 2026, Immutrin (Cambridge, UK) raised an oversubscribed $87 million (GBP 65 million) Series A to develop a novel antibody therapy designed to selectively bind and deplete pre-existing ATTR amyloid fibrils through targeted immune clearance.
| Term | Detail |
|---|---|
| Company | Immutrin (Cambridge, UK) |
| Round | Series A |
| Amount | $87 million (GBP 65 million) |
| Co-leads | Frazier Life Sciences and F-Prime Capital |
| Participants | Qiming Venture Partners, SR One, Cambridge Innovation Capital, Cambridge Enterprise Ventures |
| Founders | Sir Gregory Winter (Nobel laureate) and Sir Mark Pepys |
| Indication | ATTR amyloidosis (cardiomyopathy focus) |
| Mechanism | Antibody depletes pre-existing amyloid fibrils via immune clearance |
| Proceeds | Fund lead candidate through clinical proof-of-concept |
| Legal counsel | Cooley LLP (Tom Goodman, Ellen Dewhurst) |
| Communications | ICR Healthcare |
Immutrin's approach is mechanistically differentiated from existing ATTR therapies: tafamidis (Pfizer's Vyndaqel) stabilizes transthyretin to prevent new fibril formation, and RNA silencers (Alnylam's Amvuttra/patisiran, Ionis's eplontersen) reduce transthyretin production---but neither removes pre-existing amyloid deposits. Immutrin's antibody targets the deposits themselves for clearance, addressing a distinct segment of the disease biology. Given the $3.7 billion Vyndaqel franchise and growing ATTR market, the royalty implications of any successful fibril-clearing therapy could be substantial.
Gilgamesh Pharma: $60 Million Series A for Post-AbbVie Neuropsychiatry Pipeline
On March 24, 2026, Gilgamesh Pharma (New York) closed an oversubscribed $60 million Series A to advance a portfolio of novel neuropsychiatric therapeutics, all new chemical entities with composition-of-matter IP protection.
| Term | Detail |
|---|---|
| Company | Gilgamesh Pharma (New York; private) |
| Round | Series A (first formal raise as standalone entity) |
| Amount | $60 million |
| Lead | Satori Neuro |
| Participants | Prime Movers Lab and other new and existing institutional investors |
| Lead program | Blixeprodil (GM-1020), oral NMDA receptor antagonist for MDD (positive Phase 2; late-stage development planned 2026) |
| Additional programs | GM-3009 (cardio-safe ibogaine analog, Phase 1 expected 2026); additional NCEs progressing toward IND-enabling studies |
| Total raised to date | ~$134 million (per PitchBook) |
Gilgamesh Pharma is the spinout entity formed following AbbVie's August 2025 acquisition of bretisilocin (GM-2505), the original Gilgamesh Pharmaceuticals' lead serotonergic psychedelic, for up to $1.2 billion in upfront and development milestones. The new company inherited all programs not acquired by AbbVie, the original management team led by founder and CEO Jonathan Sporn, M.D., and capital from the AbbVie transaction. Critically, Gilgamesh Pharma also retains the economic interest in an ongoing AbbVie neuroplastogen collaboration initiated in May 2024---which carries a meaningful royalty stack relevant to the pharmaceutical royalty ecosystem.
AbbVie Upstream Royalty and Collaboration Economics
Two distinct AbbVie transaction layers create the royalty stack surrounding this entity:
| Transaction | Date | Structure | Economics |
|---|---|---|---|
| AbbVie / Gilgamesh neuroplastogen collaboration | May 2024 | Option-to-license collaboration for novel non-hallucinogenic psychoplastogens | $65 million upfront; up to $1.95 billion in aggregate option fees and milestones; tiered royalties on net sales ranging from mid-single to low-double digits |
| AbbVie / Gilgamesh bretisilocin acquisition | August 2025 | Asset acquisition of GM-2505 (bretisilocin) for MDD | Up to $1.2 billion inclusive of upfront and development milestones; no royalties or regulatory/commercial milestones disclosed in the press release |
The May 2024 collaboration is the royalty-relevant layer. Under its terms, AbbVie holds options on a series of neuroplastogen compounds discovered using Gilgamesh's platform.
Upon exercise of each option, AbbVie gains development and commercialization rights and owes Gilgamesh tiered royalties on net sales ranging from mid-single-digit to low-double-digit percentages---a royalty range comparable to mid-stage licensing deals in the CNS space.
The collaboration remains active and was cited in the Series A announcement as providing ongoing external validation of the Gilgamesh discovery platform. The specific compounds under option, individual option exercise fees, and royalty tier thresholds have not been publicly disclosed.
The August 2025 bretisilocin acquisition, by contrast, was structured as a clean asset purchase with up to $1.2 billion in upfront and development milestones but no disclosed royalty or commercial milestone component---meaning Gilgamesh Pharma's ongoing economic exposure to AbbVie flows primarily through the collaboration's royalty and milestone terms, not through the bretisilocin sale.
Context for Royalty Investors
The combined AbbVie economic relationship---up to $3.15 billion in aggregate deal value ($1.95 billion collaboration + $1.2 billion acquisition) plus tiered royalties---represents one of the largest neuropsychiatric partnering structures in recent years.
Gilgamesh Pharma's $60 million Series A capitalizes an entity that sits at the intersection of two value streams: (1) a proprietary clinical-stage pipeline (blixeprodil in MDD, GM-3009 in development) with wholly owned economics and potential future out-licensing or royalty monetization opportunities, and (2) an existing royalty-bearing collaboration with a top-five pharmaceutical company in the high-growth neuropsychiatry space.
AbbVie's psychiatry portfolio—anchored by Vraylar ($7.3 billion in 2024 sales)—provides strategic context for the scale of its neuroplastogen investment and suggests meaningful commercial infrastructure behind any optioned programs that reach market.
Excalipoint Therapeutics: $68.7 Million Seed for Next-Generation T-Cell Engagers (March 24)
On March 18, 2026 (covered during W13), Excalipoint Therapeutics (Shanghai) launched from stealth with an oversubscribed $68.7 million seed financing raised across two tranches.
| Term | Detail |
|---|---|
| Company | Excalipoint Therapeutics (Shanghai; "NewCo" model) |
| Round | Seed (two tranches) |
| Tranche 1 | $41 million (August 2025); co-led by HSG (formerly Sequoia China), Apricot Capital, Yuanbio |
| Tranche 2 | $27.7 million (~February 2026); co-led by MPCi (formerly Matrix Partners China) and Centurium Capital |
| Notable participants | Lilly Asia Ventures, Eisai Innovation |
| Lead program | EXP011, trispecific DLL3/CD3/4-1BB T-cell engager for SCLC (Phase I/II, first patient dosed October 2025) |
| Platform | Next-generation multispecific T-cell engagers for solid tumors |
Excalipoint operates under China's "NewCo" model---a structure in which Chinese-founded companies incorporate internationally to facilitate global clinical development and partnering. The company's trispecific approach (tumor target + CD3 + costimulatory signal) addresses a key limitation of conventional bispecific TCEs: insufficient T-cell activation in the immunosuppressive solid tumor microenvironment. The participation of Lilly Asia Ventures and Eisai Innovation signals Big Pharma interest in the platform, though no option agreement, licensing deal, or commercial partnership with either company has been disclosed—their involvement is purely financial at this stage.
IP provenance and upstream royalty structure (HKEX-disclosed). Excalipoint's assets originate from Lepu Biopharma (2157.HK) via its 70%-owned subsidiary CtM Bio (Concept to Medicine Biotech), where CEO Dr. Lei Fang served as CEO/General Manager and held 30% equity. Per the August 1, 2025 HKEX filing, Lepu irrevocably assigned 5 PCT patent families covering the DLL3/CD3/4-1BB and CDH17/CD3/4-1BB trispecifics, and non-exclusively licensed 4 additional PCT families (broader TOPAbody platform IP; ADCs carved out).
Worldwide exclusive rights—including China, which is unusual for the NewCo model—were granted for a total deal value of up to $857.5 million: $10M upfront (non-refundable), 10% equity in Excalipoint Cayman to Lepu, up to $117M in development milestones, up to $730.5M in commercial/sales milestones, and tiered royalties of low single-digit to mid single-digit percent on incremental net sales.
A December 2025 HKEX update provided an illustrative example: at $2.5B in annual net sales, total royalty owed would be approximately $85M (blended ~3.4%), with the top tier above $2.5B paying 5%. Royalty terms continue per product per jurisdiction until the latest of the 10th anniversary of first commercial sale, expiration of regulatory exclusivity, or expiration of the last valid patent claim.
Lepu expects no royalty payments through 2027. Royalty financing relevance: low-to-moderate. Early-stage, but the HKEX-disclosed royalty structure is unusually transparent for a NewCo and creates a defined future royalty stream from Excalipoint to Lepu that could itself become a monetizable asset if EXP011 advances.
Congruence Therapeutics: $39.5 Million Series B Close and Phase 1 FPD (March 23)
On March 23, 2026, Congruence Therapeutics (Montreal) announced the close of a $39.5 million Series B financing, coinciding with the first participant dosed in its Phase 1/1b study of CGX-926, a first-in-class oral MC4R corrector for MC4R-deficient genetic obesity.
| Term | Detail |
|---|---|
| Company | Congruence Therapeutics (Montreal; private) |
| Round | Series B |
| Amount | $39.5 million |
| Co-leads | Dimension (new) and OrbiMed (existing) |
| Participants | Lumira Ventures, BDC Capital, Investissement Québec, Amplitude Ventures |
| Platform | Revenir™ computational platform (captures dynamic protein biophysics to predict small-molecule-induced conformational modulation) |
| Lead program | CGX-926, oral MC4R corrector for MC4R-deficient genetic obesity (Phase 1/1b FPD March 23) |
| Additional programs | GBA1-driven Parkinson's disease, alpha-1 antitrypsin deficiency (advancing toward IND) |
| Founder/CEO | Dr. Clarissa Desjardins (formerly CEO of Clementia Pharmaceuticals, sold to Ipsen for $1.31 billion) |
MC4R (melanocortin-4 receptor) mutations are the most common single-gene cause of severe obesity, affecting approximately 5-6% of individuals with severe childhood-onset obesity. CGX-926 works by restoring function to misfolded MC4R protein variants rather than replacing the receptor's natural signaling---a mechanistically distinct approach from GLP-1 agonists.
Revenir platform and IP profile. The Revenir™ platform uses computational biophysics, mathematical modeling, and machine learning to capture the dynamic conformational landscape of misfolded proteins and predict small-molecule correctors that restore native function. Unlike many biotech platforms, Revenir was developed entirely in-house—Congruence was co-founded and incubated by Amplitude Ventures in 2021, and no upstream academic IP licenses from McGill, Université de Montréal, or other institutions have been identified in any public filings or university spinout registries.
Total disclosed funding is now approximately $136.5M ($50M tranched Series A in February 2022, $15M Series A extension in March 2023, $32M Series B first close in September 2025, and the current $39.5M additional financing), plus a $5M Michael J. Fox Foundation grant for the GBA1-Parkinson's program.
Two Ono Pharmaceutical option-based collaborations generate inbound economics to Congruence: the first (December 2024) covering multiple oncology targets, and the second (March 3, 2026) expanding into neurology and immunology. Both provide undisclosed upfront payments, full reimbursement of all research costs, milestone payments, and tiered royalties on net sales flowing to Congruence. A third collaboration with an undisclosed global pharma company on a metabolic target has been referenced since September 2025 but remains undetailed.
Royalty financing relevance: low, but improving. No outbound royalty obligations on the wholly owned pipeline. The Ono collaborations create future inbound royalty streams to Congruence, and the genetic obesity addressable market combined with Desjardins' track record (Clementia's $1.31B exit to Ipsen) warrant continued monitoring.
Terrestrial Bio: $50 Million Series C for GLP-1 Patch Delivery (March 26)
On March 26, 2026, Terrestrial Bio (Woburn, MA; formerly Vaxess Technologies) raised $50 million in Series C financing concurrent with its rebrand from Vaxess Technologies.
| Term | Detail |
|---|---|
| Company | Terrestrial Bio (Woburn, MA; formerly Vaxess Technologies) |
| Round | Series C |
| Amount | $50 million |
| Lead | RA Capital Management |
| Participants | Engine Ventures, GHIC |
| Platform | Proprietary microarray patch (MAP) technology---a skin-applied patch with dissolving bioactive microneedle tips that deliver therapeutic payload transdermally |
| Lead application | GLP-1 agonist delivery via patch (alternative to injection) |
| Proceeds | New Boston headquarters (Allston LabWorks, 40,000+ sq ft), automated MAP manufacturing, GLP-1 program advancement |
The rebrand from Vaxess (vaccine-focused) to Terrestrial Bio reflects a strategic pivot from vaccine delivery to broader therapeutic applications, with GLP-1 patch delivery as the near-term commercial opportunity. In a market where injectable GLP-1 agonists face compliance challenges and patient resistance to needles, a patch formulation could capture significant market share if pharmacokinetics prove comparable.
IP provenance correction and upstream obligations. The MAP platform originated from Tufts University research (not MIT/Harvard as commonly assumed). Professors David L. Kaplan and Fiorenzo G. Omenetto at the Tufts Silklab developed the foundational silk fibroin microneedle technology. The four Harvard-affiliated co-founders commercialized the Tufts research through Harvard's Innovation Lab ecosystem—hence the Harvard association. Foundational patents (e.g., US10933173B2) are assigned to the Trustees of Tufts College.
On December 31, 2013, Vaxess obtained an exclusive license to a series of patents for silk protein technology; the company holds ten patent families either in-house or in-licensed from Tufts and MIT. However, specific royalty rates, milestone schedules, and upfront payment terms remain entirely undisclosed. Standard university TTO rates of 1--5% of net sales are the industry benchmark. The GLP-1 pivot may test field-of-use boundaries in the original vaccine-focused license scope.
An unnamed "leading biopharma company" signed a 2024 agreement to test its diabetes/obesity therapeutic via the MAP patch in a swine PK study; preclinical data presented at the June 2025 ADA Scientific Sessions showed semaglutide delivered via MAP in Göttingen minipigs achieved bioavailability comparable to subcutaneous injection. A prior AstraZeneca vaccine partnership (up to $10.3M under a BARDA umbrella) appears to have concluded. Total company funding now exceeds $150M across grants and venture capital, including U.S. government funding (BARDA, DARPA, NIH, NSF) with standard government-use rights, and $6M in Gates Foundation grants likely carrying global access commitments. Royalty financing relevance: low-to-moderate.
Drug delivery/device platform with confirmed but quantitatively opaque Tufts University royalty obligations. If partnered with a GLP-1 developer, the resulting licensing structure could create royalty-relevant streams—and an undisclosed pharma partner already appears to be evaluating exactly this scenario.
Laigo Bio: EUR 17 Million Seed Final Close
On March 23, 2026, Laigo Bio (Utrecht, Netherlands) completed the final close of its oversubscribed EUR 17 million (~$19.7 million) seed round, adding EUR 5.5 million (new co-lead Biovance Capital EUR 4 million; existing co-lead Kurma Partners EUR 1.5 million).
Additional investors include Curie Capital, Argobio Studio, Angelini Ventures, Eurazeo, Oncode Bridge Fund, and Cancer Research Horizons.
Laigo Bio's proprietary SureTACs (Surface Removal Targeting Chimeras) platform creates bispecific antibodies that recruit E3 ligases to membrane-bound disease targets for ubiquitination and lysosomal degradation, with lead programs targeting PD-L1 and Wnt pathway receptors in oncology and autoimmune indications.
Pulmatrix / Eos SENOLYTIX: Reverse Merger with $19M PIPE (March 26)
On March 26, 2026, Pulmatrix, Inc. (NASDAQ: PULM) announced a definitive agreement to acquire Eos SENOLYTIX, a gerotherapeutic peptide biotech targeting mitochondrial dysfunction via its MitoXcel platform.
| Term | Detail |
|---|---|
| Acquirer (shell) | Pulmatrix, Inc. (NASDAQ: PULM) |
| Target | Eos SENOLYTIX (private) |
| Structure | Reverse merger; pre-merger Pulmatrix stockholders retain ~6% of combined entity; Eos holds ~94% |
| Lead program | PTC-2105 (sarcopenia and sarcopenic obesity) |
| Concurrent PIPE | $1 million from RCM Eos PIPE Holdings plus bridge financing from Rapha Capital Management |
| Combined entity | Eos SENOLYTIX, Inc. (planned ticker: EOSX) |
| Expected close | Mid-2026 |
| Prior merger | Follows Cullgen's termination of its merger agreement with Pulmatrix on February 28, 2026 |
The transaction is the week's only reverse merger in biopharma and follows a well-established pattern of micro-cap pharma shell companies serving as public listing vehicles for private biotech companies. The MitoXcel platform focuses on peptides that target mitochondrial dysfunction in aging-related diseases. Royalty financing relevance: negligible. Preclinical platform with no disclosed licensing economics or near-term commercial milestones.
Peptomyc: EUR 5 Million Equity Financing for First-in-Class MYC Inhibitor (March 24)
On March 24, 2026, Peptomyc (Barcelona, Spain) closed a EUR 5 million (~$5.8 million) equity financing to advance OMO-103, the first direct MYC inhibitor with clinical validation, toward later-stage development. The round was led by Alta Life Sciences and Aurora Science, with new investors EIC Fund (European Innovation Council) and Laudecum, plus follow-on from existing investor CDTI Innovacion (SICC Innvierte). Peptomyc is a VHIO (Vall d'Hebron Institute of Oncology) and ICREA spinout founded in 2014.
OMO-103 is a patented cell-penetrating mini-protein that directly inhibits MYC, an oncogene dysregulated in approximately 70% of human cancers but long considered "undruggable." The compound completed a Phase 1 first-in-human study demonstrating a favorable safety profile, target engagement, and early clinical activity including a 49% tumor volume reduction in a metastatic pancreatic cancer patient.
Three clinical studies are currently ongoing: a Phase 1b in metastatic pancreatic cancer (combination with gemcitabine/nab-paclitaxel), a Phase 2 in osteosarcoma (sponsored by the Osteosarcoma Institute), and a window-of-opportunity study in pancreatic cancer (in collaboration with OHSU Knight Cancer Institute).
Proceeds will fund clinical execution, manufacturing scale-up, and ongoing pharma partnering discussions. No licensing or royalty arrangements have been disclosed; Peptomyc's stated business model is to develop OMO-103 through clinical proof-of-concept before out-licensing to a pharmaceutical partner. The upstream IP terms from VHIO/ICREA are not publicly available.
Endogenex: $50 Million Series C Extension for Diabetes Medtech (March 25)
On March 25, 2026, Endogenex raised $50 million in a Series C extension led by Arboretum Ventures, bringing total Series C funding to $138 million. Funds will support completion of the pivotal ReCET clinical study for a minimally invasive endoscopic procedure to treat type 2 diabetes using pulsed electric fields on duodenal tissue. Royalty financing relevance: low. Medtech/device territory, not pharmaceutical royalty.
Immix Biopharma: $100 Million ATM Expansion for Autoimmune CAR-T (March 25)
On March 25, 2026, Immix Biopharma (NASDAQ: IMMX) amended its at-the-market offering agreement with Citizens JMP Securities to sell up to $100 million of common stock (3% commission). Immix is developing CAR-T therapies for autoimmune diseases. Royalty financing relevance: low. Equity financing mechanism; no licensing or royalty economics. The ATM expansion does signal continued investor appetite for autoimmune cell therapy companies, consistent with the broader TCE/B-cell depletion theme seen in the Gilead/Ouro and Sanofi/Kali deals this week.
LakeShore Biopharma: Revised Going-Private Proposal (March 25)
On March 25, 2026, Oceanpine Skyline issued a reduced going-private offer of $0.06 per share (down from a prior offer) for LakeShore Biopharma, a vaccines and therapeutic biologics company. Royalty financing relevance: negligible.
Manufacturing and Infrastructure Investments
UCB: $2 Billion U.S. Biologics Manufacturing Campus (March 24)
On March 24, 2026, UCB (EURONEXT: UCB) announced a $2 billion investment to build its first U.S. biologics manufacturing facility in Gwinnett County, Georgia, at the Rowen innovation district.
| Parameter | Detail |
|---|---|
| Investment | $2 billion |
| Site | Rowen innovation district, Gwinnett County, Georgia |
| Footprint | ~460,000 sq ft on 79 acres |
| Permanent jobs | 330+ |
| Construction jobs | 1,000+ |
| Estimated economic impact | ~$5 billion (Gwinnett County estimate) |
The facility will manufacture biologics from UCB's immunology and neurology portfolio, including Bimzelx (bimekizumab) and other pipeline assets. The investment is the largest capital commitment in Gwinnett County history and reflects a broader industry trend of multinational pharma companies expanding U.S. domestic manufacturing capacity in response to supply-chain resilience concerns and evolving trade policy. UCB plans to begin construction in 2026 with capacity expected to be available mid-decade.
Strategic relevance: UCB's manufacturing investment is notable against the backdrop of its commercial acceleration in dermatology---Bimzelx's entry into the IL-17A/F class and competition with AbbVie's Skyrizi and Novartis's Cosentyx positions the company for significant revenue growth requiring commensurate supply capacity. The $2 billion capex commitment signals management's confidence in the long-term commercial trajectory of its biologic portfolio.
Clarity Pharmaceuticals / Theragenics: Copper-64 Manufacturing Supply Agreement (March 26)
On March 26, 2026, Clarity Pharmaceuticals and Theragenics announced a large-scale manufacturing supply agreement for copper-64 (64Cu), a key radiopharmaceutical isotope for Clarity's targeted copper theranostics (TCT) platform.
Theragenics operates a 134,000 sq ft facility housing 14 cyclotrons with stated capacity of approximately 100 Ci per cyclotron per day, supporting up to ~2,000 doses per day at full utilization. The agreement is designed to support the planned commercial launch of 64Cu-SAR-bisPSMA (Clarity's lead PSMA-targeted copper theranostic for prostate cancer), subject to regulatory approval. Financial terms were not disclosed. The partnership reflects the competitive supply dynamics for short-lived radioisotopes, where manufacturing agreements are often established well in advance of approval to ensure launch-ready capacity.
Wilmington PharmaTech: $50M U.S. API Capacity Expansion (March 25)
On March 25, 2026, Wilmington PharmaTech announced a $50 million investment to double its U.S. active pharmaceutical ingredient manufacturing capacity at its Delaware campus. The expansion adds two 10,000-liter reactor suites with new capacity expected online in Q3 2027, supporting domestic API supply for small-molecule drug programs.
DCAT Week 2026 CDMO Manufacturing Announcements (March 23--26)
DCAT Week 2026 (New York, March 23--26) produced a wave of CDMO capital commitments collectively exceeding $900 million in disclosed investments:
| Company | Investment | Facility/Scope | Timeline |
|---|---|---|---|
| Simtra BioPharma Solutions | ~$500M cumulative post-acquisition | ADC fill-finish expansion, Halle, Germany | Ongoing |
| Terumo | EUR 150M (~$174M) | Ex-WuXi Biologics fill/finish plant, Leverkusen, Germany; ~$50M additional cleanroom expansion | Full integration October 2026 |
| Cambrex | $120M | New API manufacturing plant, Charles City, Iowa (140,000L capacity, Hastelloy equipment, HPAPIs, controlled substances, commercial-scale liquid-phase peptides) | Groundbreaking late 2026 |
| Grand River Aseptic Manufacturing (GRAM) | $90M | Fifth GMP sterile fill site, Grand Rapids, MI | Commercially available Q1 2027 |
| CordenPharma | Not disclosed | Two new isolator aseptic fill/finish lines, Caponago, Italy | Mid-2027/2028 |
| ESTEVE CDMO | Not disclosed | High-potency spray-drying unit, Girona, Spain | N/A |
| LGM Pharma | $15M | Texas and Colorado expansions | N/A |
These investments reflect the industry's broader shift toward domestic and regional manufacturing capacity, driven by supply-chain resilience concerns, the growing complexity of ADC and peptide manufacturing, and evolving trade policy. The injectable and sterile fill-finish segments attracted the largest capital commitments, consistent with the GLP-1 and biologics production bottlenecks dominating the CDMO landscape.
Pinnacle Medicines: $89 Million Series B (March 26)
On March 26, 2026, Pinnacle Medicines announced the oversubscribed close of its $89 million Series B financing, bringing total capital raised to $134 million.
| Term | Detail |
|---|---|
| Round | Series B (oversubscribed) |
| Amount | $89 million |
| Lead investors | LAV, Foresite Capital |
| Syndicate | Quan Capital, Hankang Capital, RA Capital, Logos Capital, OrbiMed |
| Total raised to date | $134 million |
| Focus | Oral peptide therapeutics using AI and physics-based design for immunology and cardiometabolic indications |
Pinnacle Medicines develops oral peptide therapeutics using a computational platform combining AI and physics-based modeling to optimize peptide permeability and metabolic stability—two classical barriers to oral bioavailability of peptide drugs.
The cardiometabolic and immunology space for oral peptides represents a high-priority target as GLP-1 class competition intensifies and payers increasingly favor oral over injectable formulations. RA Capital and OrbiMed's participation signals institutional conviction in the platform.
Royalty financing relevance: negligible at current stage. Pinnacle is pre-clinical to early-clinical; the Series B will fund IND-enabling studies and early clinical development. Any upstream academic IP obligations for foundational oral peptide delivery technology remain undisclosed.
This company warrants monitoring as its first clinical-stage programs emerge; the combination of AI-driven design, immunology/cardiometabolic targeting, and high-quality investor syndicate (LAV, Foresite, RA Capital, OrbiMed) positions it as a potential future royalty target candidate.
Pipeline Discontinuations
Pfizer: PF-08046031 ADC Discontinued
On March 23, 2026, Pfizer discontinued PF-08046031, an early-stage ADC from its Seagen portfolio, citing business reasons rather than safety concerns. The discontinuation is part of ongoing strategic pruning of the $43 billion Seagen acquisition pipeline.
Pipeline Pauses and Corporate Events
Aardvark Therapeutics: Full Pipeline Clinical Hold
On March 23, 2026, Aardvark Therapeutics (NASDAQ: AARD) announced voluntary pauses of its Phase 2 obesity trials (POWER and STRENGTH) for ARD-201, extending an earlier February pause of the Phase 3 HERO trial for ARD-101 in Prader-Willi syndrome.
The pauses followed detection of reversible cardiac QRS prolongation in a healthy volunteer study at above-target doses. This effectively placed Aardvark's entire clinical pipeline on hold. The company reported $110 million in cash. Shares had declined sharply from the $16 IPO price to approximately $4.
Aurinia Pharmaceuticals: Activist-Driven C-Suite Overhaul and $150 Million Buyback
On March 23, 2026, Aurinia Pharmaceuticals (NASDAQ: AUPH) underwent a complete executive leadership overhaul as activist investor Kevin Tang (Tang Capital Management) replaced Peter Greenleaf as CEO effective March 23. Ryan Cole (COO), Michael Hearne (CFO), and Thomas Wei (CSO)---all Tang Capital associates---were simultaneously installed. The entire prior C-suite departed March 20.
A $150 million share repurchase program was announced alongside the leadership changes. Activist fund MKT Capital publicly endorsed the overhaul. Aurinia markets LUPKYNIS (voclosporin) for lupus nephritis, generating approximately $283 million in annual revenue with ~20% growth, and has aritinercept (BAFF/APRIL inhibitor) in clinical development. The Tang-led transformation signals a strategic pivot likely toward accelerated business development, potential asset monetization, or M&A---relevant for royalty investors given LUPKYNIS's growing commercial profile and the Otsuka co-commercialization arrangement under which Aurinia retains significant US economics.
Otsuka Licensing Economics
Aurinia's December 2020 collaboration with Otsuka Pharmaceutical for LUPKYNIS covers the EU, Japan, UK, Russia, Switzerland, and select European markets:
| Term | Detail |
|---|---|
| Upfront payment | $50 million |
| Regulatory/reimbursement milestones | Up to $50 million ($10M triggered by EU pricing/reimbursement in Q3 2023; $10M triggered by Japanese MHLW approval September 2024) |
| Commercial sales milestones | Based on annual sales thresholds (amounts undisclosed) |
| Royalties | Tiered ~12-20% on Otsuka territory net sales (Japan specifically described as "low double-digit" rates; the lower tier likely starts at ~12-14% based on Aurinia's disclosed revenue splits) |
| Supply | Aurinia supplies LUPKYNIS on a cost-plus margin basis under a commercial supply agreement (August 2022) |
| Otsuka-related revenue | $18.9 million in FY2024 ($17.0M in FY2023), expected to ramp as Otsuka expands EU and Japan launches |
| US rights | Aurinia retains sole US commercialization rights and all territories not granted to Otsuka |
Additional Clinical Development Milestones
Celosia Therapeutics: CTx1000 Phase 1b First Patient Dosed in ALS (March 24)
Celosia Therapeutics dosed the first participant in the Phase 1b KOANEWA trial of CTx1000, a gene therapy targeting pathological TDP-43 protein, in ALS at Macquarie University Hospital, Sydney. This represents a novel approach targeting TDP-43 proteinopathy, the pathological hallmark of approximately 97% of ALS cases.
Alphamab Oncology / CSPC: Anbenitamab (KN026) Phase III First Patient Dosed (March 24)
Alphamab Oncology dosed the first patient in the Phase III KN026-007 study of anbenitamab (KN026), a HER2 bispecific antibody, combined with albumin-bound docetaxel (HB1801) and chemotherapy as adjuvant treatment in lymph node-positive HER2-positive breast cancer.
Amylyx Pharmaceuticals: Avexitide Phase 3 LUCIDITY Enrollment Complete (March 24)
Amylyx Pharmaceuticals (NASDAQ: AMLX) completed enrollment of 78 participants in the pivotal Phase 3 LUCIDITY trial of avexitide, a first-in-class GLP-1 receptor antagonist with Breakthrough Therapy Designation, for post-bariatric hypoglycemia. Topline data are expected Q3 2026.
Transgene: TG4050 Phase 1 INTV Data in Head and Neck Cancer (March 24)
Transgene (EURONEXT: TNG) reported randomized Phase 1 results for TG4050, an individualized neoantigen therapeutic vaccine, demonstrating durable disease-free survival and neoantigen-specific T-cell responses in 73% of evaluable patients with resected HNSCC, persisting 24 months after treatment initiation. Phase 2 randomization is nearly complete. The company reported financial visibility until early 2028.
Absci Corporation: ABS-201 Phase 1/2a HEADLINE Update (March 24)
Absci (NASDAQ: ABSI) reported that its AI-designed anti-PRLR antibody ABS-201 successfully dosed the first three cohorts in the single-ascending-dose portion of the Phase 1/2a HEADLINE trial for androgenetic alopecia. Safety data favorable; preliminary PK data expected H1 2026, proof-of-concept H2 2026.
Complement Therapeutics: CTx001 Phase I/II Opti-GAIN First Patient Dosed in GA (March 25)
On March 25, 2026, Complement Therapeutics GmbH (CTx), a Munich-headquartered clinical-stage biotechnology company, announced the first patient dosed in Opti-GAIN (NCT07392255), a Phase I/II first-in-human clinical trial of CTx001 in Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD). The first dose was administered by Chief Investigator Dr Arshad M. Khanani at Sierra Eye Associates in Reno, Nevada.
CTx001 is an AAV2-based gene therapy designed to deliver mini-CR1, a truncated and secreted form of Complement Receptor 1, via a single subretinal injection. The construct enables local retinal production of mini-CR1, which modulates both the alternative and classical complement pathways. The small size of mini-CR1 is designed to support penetration across Bruch's membrane for broad ocular biodistribution, including the choriocapillaris, potentially differentiating CTx001 from intravitreal complement inhibitors that act more focally.
Opti-GAIN is a multi-centre study enrolling 75 participants: Part 1 is an open-label dose-escalation across three dose cohorts, followed by a dose-expansion phase in Part 2. Safety and efficacy will be assessed over 2 years, with long-term safety follow-up for up to 5 years.
The trial design incorporates novel endpoints including ellipsoid zone (EZ) attenuation assessment and focal OCT-based microperimetry, making it among the first GA studies to prospectively evaluate the latter.
The study is being conducted by the UK subsidiary and builds on data from i-GAIN (a natural history study with over 230 participants in the UK and US) and Pre-GAIN (NCT07144137), an ongoing natural history study currently enrolling in both countries.
CTx001 holds FDA Fast Track Designation (January 2026), FDA IND clearance (October 2025), UK MHRA Clinical Trial Authorisation (January 2026), and an MHRA Innovation Passport under the Innovative Licensing and Access Pathway (ILAP).
Company and Funding
Complement Therapeutics was spun out of the University of Manchester in 2021, founded by Prof Simon J. Clark, Prof Paul Bishop, and Dr Richard Unwin. The company has raised approximately EUR 77 million (~$85 million) across three rounds:
| Round | Date | Amount | Lead Investors |
|---|---|---|---|
| Initial seed | 2021 | Undisclosed | BioGeneration Ventures (BGV) |
| Seed | February 2022 | EUR 5 million | BGV, Forbion |
| Series A | April 2023 | EUR 72 million | Gimv (lead), Forbion (co-lead) |
Series A participants include BGV, Panakes Partners, Cambridge Innovation Capital (CIC), Hadean Ventures, and Seroba Life Sciences. The board includes representatives from Gimv (Michael Vlemmix), Panakes (Rob Woodman), CIC (Anne Horgan), Hadean (Roger Franklin), and Forbion (Dr Dmitrij Hristodorov, Dr Geert-Jan Mulder). CEO Dr Rafiq Hasan previously worked at Bayer alongside Forbion's Hristodorov. CMO is Dr Muhammad Ali Memon.
Clinical-grade CTx001 is manufactured by Pharmaron Biologics at its Liverpool, UK gene therapy CDMO facility under a strategic manufacturing partnership established in March 2023. A separate Innovate UK-funded collaboration with Pharmaron and the Cell and Gene Therapy (CGT) Catapult is developing intensified perfusion AAV manufacturing processes, supported by over GBP 1.4 million in grant funding. CTx has also received Innovate UK EDGE grant funding and collaborated with CGT Catapult since 2020 on non-clinical strategy, regulatory submissions, and manufacturing optimization.
No external licensing, out-licensing, or royalty-bearing agreements have been publicly disclosed. CTx retains full global rights to CTx001 and its broader complement pipeline. The IP license terms between the University of Manchester (via its Innovation Factory) and Complement Therapeutics are not publicly available, consistent with standard UK university spinout practice. No financial or legal advisors were disclosed for any transaction.
Competitive Context in Geographic Atrophy
CTx001 enters a GA treatment landscape that has shifted significantly since 2023 with the approval of two complement-targeted intravitreal therapies: Apellis' Syfovre (pegcetacoplan, anti-C3) and Iveric Bio/Astellas' Izervay (avacincaptad pegol, anti-C5).
Both require repeated intravitreal injections (monthly or every other month) and have demonstrated modest slowing of GA lesion growth (approximately 17-22% reduction at 12 months) with no demonstrated functional visual benefit.
CTx001's one-time subretinal injection approach and broader complement pathway modulation (both classical and alternative) represent a differentiated mechanism. The trial's use of novel functional endpoints (focal OCT-based microperimetry) also signals an attempt to demonstrate visual function preservation rather than purely anatomical lesion growth reduction.
Within this W13 window, Ocugen reported Phase 2 ArMaDa 12-month data for OCU410 (AAV5-RORA), a competing one-time gene therapy for GA that achieved a statistically significant 31% reduction in lesion growth versus control (March 24). Other GA gene therapy approaches in clinical development include Gyroscope Therapeutics/Novartis (GT005, complement factor I gene therapy, Phase II) and 4D Molecular Therapeutics (4D-150, intravitreal AAV for wet AMD/DME). The GA market is estimated at over $10 billion with 5 million patients affected globally.
Maze Therapeutics: MZE829 Phase 2 HORIZON Data in APOL1-Mediated Kidney Disease (March 25)
On March 25, 2026, Maze Therapeutics reported Phase 2 HORIZON data for MZE829, an oral dual-mechanism APOL1 inhibitor for APOL1-mediated kidney disease (AMKD).
In the broad AMKD population, MZE829 demonstrated a 35.6% mean reduction in urine albumin-to-creatinine ratio (uACR) at 12 weeks, with substantially stronger responses in key subgroups: 61.8% reduction in FSGS and 48.6% reduction in non-diabetic AMKD. Half of all patients achieved >30% uACR reduction. No serious treatment-related adverse events were reported.
This represents the first clinical proof-of-concept for a therapeutic targeting APOL1 in a genetically defined, broad kidney disease population. Despite the positive data, Maze shares fell approximately 30% on investor concerns about the magnitude of response in the broader (non-FSGS) population.
Maze plans pivotal development and has $360 million in cash with runway into 2028. The company competes with Vertex Pharmaceuticals' inaxaplin, which showed a 43% uACR reduction in FSGS in Phase 2a.
Royalty financing relevance: moderate. If MZE829 advances to approval in a genetically defined renal population, it could generate substantial royalty-eligible revenues, though the competitive landscape with Vertex and the need for confirmatory data in pivotal trials add risk.
Nasus Pharma: NS002 Phase 2 Results for Intranasal Epinephrine (March 25)
On March 25, 2026, Nasus Pharma announced Phase 2 results for NS002, an intranasal epinephrine powder product that demonstrated statistically significant improvements in early absorption versus EpiPen auto-injector, which the company described as "best-in-class" intranasal epinephrine delivery.
A pivotal study is planned for Q4 2026 with potential NDA submission. Nasus's pipeline also includes NS003 (intranasal ondansetron for chemotherapy-induced nausea) and NS004 (metabolic).
Royalty financing relevance: low. Drug delivery reformulation with limited licensing economics, though the EpiPen comparison and needle-free delivery could attract partnership interest if pivotal data confirm the Phase 2 profile.
TRIANA Biomedicines: TRI-611 FDA Fast Track Designation for ALK+ NSCLC (March 25)
On March 25, 2026, TRIANA Biomedicines announced that the FDA has granted Fast Track designation to TRI-611, an oral molecular glue degrader targeting ALK fusion proteins, for the treatment of ALK-positive non-small cell lung cancer (NSCLC). The first patient was treated in early March 2026 in a Phase 1/2 study. TRIANA is a private company operating in the molecular glue degrader space. Royalty financing relevance: low. Very early-stage program with no near-term commercial milestones, though molecular glue degrader platforms have attracted significant Big Pharma licensing interest, suggesting potential future partnership value.
Artelo Biosciences: Glaucoma Market Entry via Investigator-Sponsored Study (March 25)
On March 25, 2026, Artelo Biosciences announced entry into the $16.3 billion glaucoma market through a fully funded investigator-sponsored clinical study in partnership with Glaucoma UK, HSC R&D Division, and Queen's University Belfast. Artelo retains full data rights while spending no shareholder capital on study costs. Royalty financing relevance: low. Early exploration with unclear commercial timeline and no disclosed licensing economics.
Other Notable Events
Novartis: ~$480 Million China Manufacturing and R&D Investment (March 22)
Novartis committed approximately CNY 3.3 billion (~$480 million) at the China Development Forum on March 22: ~CNY 1.5 billion for Beijing manufacturing facility upgrades (its largest branded Rx production base in China) and ~CNY 1.8 billion for Shanghai Zhangjiang R&D center expansion. Novartis also highlighted its first Chinese radioligand therapy facility in Haiyan, Zhejiang, nearing operational status.
Zealand Pharma: US Research Hub in Cambridge, MA (March 24)
Zealand Pharma (NASDAQ: ZEAL) established a new US research hub in Cambridge, Massachusetts as its primary US address to expand global peptide-based drug discovery capabilities, expected operational from September 2026.
Royalty Pharma: Head of Artificial Intelligence Appointed (March 23)
Royalty Pharma (NASDAQ: RPRX), the largest buyer of biopharmaceutical royalties, appointed Lucas Glass as Head of Artificial Intelligence, effective April 2026.
Glass joins from IQVIA, where he served as SVP of Technology leading enterprise architecture and platform engineering. The newly created role will focus on implementing intelligent automation, advanced analytics, and AI-driven decision support across Royalty Pharma's royalty evaluation and investment platform.
CEO Pablo Legorreta described the hire as strengthening the firm's competitive advantage through "more informed decision-making and improved efficiency." The appointment signals an accelerating trend of AI adoption among royalty investors and pharma deal intermediaries.
Separately, Royalty Pharma also appointed a new Head of Asia and a new EVP of Partnering during the March window, signaling continued organizational expansion across deal origination capabilities and geographic coverage. Notably, no major new royalty fund transactions were identified in the March 23-28 window specifically. Royalty Pharma's most recent deal prior to W13 was a $250 million royalty-backed note with Zymeworks (March 2) for zanidatamab royalties---the AVLAYAH $200 million closing triggered by the March 25 FDA approval represents the only confirmed royalty fund capital deployment during W13 itself.
MeiraGTx: FDA Breakthrough Therapy Designation for AAV2-hAQP1 in Xerostomia (March 26)
On March 26, 2026, MeiraGTx Holdings (NASDAQ: MGTX) received FDA Breakthrough Therapy Designation for AAV2-hAQP1 in the treatment of Grade 2/3 late xerostomia resulting from radiotherapy. This supplements an existing Regenerative Medicine Advanced Therapy (RMAT) Designation. The Phase 2 AQUAx2 study is nearing completion, with a potential BLA filing targeted for H1 2027. The dual BTD/RMAT designation pathway provides the most accelerated regulatory review framework available for gene therapies. Royalty financing relevance: low at current stage. The program is approaching registrational status and warrants monitoring as a potential future rare disease royalty asset.
EMA CHMP Plenary Meeting (March 23--26)
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) held its monthly plenary meeting from March 23--26, 2026. Specific opinions and new medicine recommendations are expected to be published on or around March 27. For context, the February 2026 CHMP meeting recommended 12 new medicines for approval.
Agenda items for the March meeting include reviews for Padcev (enfortumab vedotin; Pfizer/Astellas) indication extension, Sotyktu (deucravacitinib; Bristol Myers Squibb), Stelara (ustekinumab; Johnson & Johnson), Rinvoq (upadacitinib; AbbVie), and others. An oral explanation for Anavex's blarcamesine re-examination (initial negative opinion December 2025) was held March 24. Post-authorization oral explanations were conducted for Novartis' PLUVICTO and Novo Nordisk's SOGROYA. The published CHMP agenda also listed nadofaragene firadenovec (ATMP for BCG-unresponsive bladder cancer) and furosemide (PUMA) for opinion adoption. Full meeting highlights had not been published as of March 27 (the EMA typically releases these the Friday after the plenary).
Any positive CHMP opinions could trigger milestone payments under existing royalty and licensing agreements---particularly relevant for assets with European commercialization rights held by royalty investors or where royalty rates are tied to geographic expansion milestones.
Upstream Obligation Analysis: Key W13 Regulatory Events
GSK/Alfasigma / Lynavoy (linerixibat): FDA Approved March 17---$100M Milestone Triggered. The FDA approved Lynavoy (linerixibat) on March 17, 2026---one week ahead of the March 24 PDUFA target date---as the first medicine approved in the US specifically for cholestatic pruritus in primary biliary cholangitis (PBC). The approval confirms linerixibat as a first-in-class IBAT inhibitor and triggers the $100 million FDA approval milestone from Alfasigma to GSK, the single largest milestone payment triggered during W13. GSK out-licensed linerixibat to Alfasigma in a deal announced March 9, 2026, valued at up to $690 million total.
The deal structure: $300 million upfront to GSK, $100 million milestone upon FDA approval (now triggered), $20 million upon EU/UK approvals, and up to $270 million in sales-based milestones, plus tiered double-digit royalties on net sales. The GLISTEN Phase 3 trial met its primary endpoint with a --0.72 LS mean difference in worst-itch NRS score (p=0.001). Analyst peak sales estimates range from $500 million to over $1 billion annually. Marketing applications are under review in the EU, UK, Canada, and China, with decisions expected before year-end. GSK stock rallied on the approval. Royalty financing relevance: high. GSK retains tiered double-digit royalties on worldwide net sales of a first-in-class orphan hepatology product with blockbuster potential—a clean, long-duration royalty stream of significant interest to royalty financing entities.
Rhythm Pharmaceuticals / IMCIVREE (setmelanotide): CHMP Positive Opinion for Acquired Hypothalamic Obesity (March 26). Rhythm licensed setmelanotide from Ipsen under a February 2010 agreement (restructured March 2013).
The license includes up to $40 million in development and commercial milestones, of which $13 million has been paid ($4 million in clinical/regulatory milestones, $9 million in commercial milestones), leaving approximately $27 million remaining.
The agreement contains separate geographic milestones---the NDA filing (US) triggered $2 million, while the MAA filing (EU) triggered $1 million, confirming territory-specific milestones exist. However, the CHMP positive opinion is only a recommendation---the actual EC marketing authorization (expected Q2 2026) would be the triggering event.
No milestone was triggered by the March 26 CHMP opinion itself. Ongoing royalties to Ipsen run at mid-single-digit percentages on a product-by-product, country-by-country basis, lasting until the later of patent expiry or 10 years after first commercial sale in each country.
Rhythm also owes Healthcare Royalty Partners tiered revenue interest payments on global IMCIVREE net revenues under a June 2022 agreement (up to $100 million in funding received), which applies regardless of indication or geography.
Sanofi-Regeneron / Dupixent (dupilumab): Japan Approval for Bullous Pemphigoid (March 24). The Japan bullous pemphigoid approval triggers no milestone payment. The Sanofi-Regeneron collaboration agreement contained up to $250 million in sales-based milestone payments (Sanofi paying Regeneron), all tied to aggregate ex-US sales thresholds starting at $1 billion.
Every dollar of the $250 million was earned by Q3 2023—the final $50 million tranche was recognized that quarter. No indication-specific or geography-specific regulatory milestones exist in the collaboration.
The economic impact is purely incremental: a new Japan indication increases ex-US Dupixent sales, which flow through the profit-sharing arrangement (sliding scale from 65/35 to 55/45 Sanofi/Regeneron). With global Dupixent sales exceeding $14 billion annually, the marginal impact is modest.
Dupixent was developed using Regeneron's proprietary VelocImmune platform with no upstream third-party royalty obligations identified.
Pharming Group / Joenja (leniolisib): Japan Approval for APDS (March 24-25). Under the August 2019 license agreement, Pharming owes Novartis up to $200 million total in milestones: $20.5 million in development/regulatory milestones plus up to $190 million in sales milestones.
Of the regulatory milestones, $10.4 million has been paid ($10 million for first commercial sale in 2023, $0.5 million to another party for FDA approval), leaving approximately $10.1 million in remaining regulatory milestones that logically cover additional territories including Japan, EU, and UK.
The Japan approval likely triggers a milestone from this remaining pool, estimated at $5-15 million based on typical territory-specific regulatory milestone structures and Pharming's aggregate milestone disclosure. The specific amount is not publicly disclosed and the March 2026 Form 6-K does not mention a Novartis payment. First commercial sale in Japan (after NHI drug pricing) may also separately trigger an additional milestone.
Ongoing royalties are tiered from low double-digit to high-teen percentages (~10-19%) on net leniolisib sales. Notably, Novartis also purchased Pharming's Rare Pediatric Disease PRV in June 2023 for $21.1 million under a pre-agreed contractual right.
Hengrui Pharma: FY2025 Annual Results Highlight GSK Royalty Economics (March 25)
On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) reported FY2025 revenue of RMB 31.63 billion (+13% YoY) with net profit of RMB 7.72 billion (+21.8% YoY). Innovative drug sales grew 26.1% to RMB 16.34 billion, contributing 58.3% of total drug sales.
R&D expenditure reached RMB 8.72 billion (27.6% of revenue). Licensing revenue rose 25.6% to RMB 3.39 billion, with the company highlighting its July 2025 strategic collaboration with GSK ($500 million upfront, up to ~$12 billion total across 12 programs, tiered royalties on global net sales) as a key milestone.
The strong licensing revenue growth and GSK collaboration economics---which include tiered royalties across respiratory, oncology, and immunology programs---make Hengrui one of the most significant royalty-generating Chinese pharmaceutical companies for Western investors to monitor. No new deal was announced; the March 25 event was an annual results disclosure.
Armata Pharmaceuticals: FY2025 Annual Results (March 25)
Armata Pharmaceuticals (NYSE American: ARMP) reported FY2025 results referencing January 2026 amendments to credit agreements with Innoviva Strategic Opportunities LLC extending maturity to June 2027 on secured loans at 14% annual interest. Armata is developing clinical-stage bacteriophage therapeutics (AP-PA02 for Pseudomonas, AP-SA02 for Staphylococcus). Not a new deal; debt financing with going-concern risk. Royalty financing relevance: negligible.
Rocket Pharma / Kresladi: FDA Approval for Severe LAD-I Gene Therapy (March 26)
On March 26, 2026, the FDA approved Kresladi (marnetegragene autotemcel), Rocket Pharmaceuticals' (NASDAQ: RCKT) lentiviral vector-based gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I), two days ahead of the March 28 PDUFA date.
The approval makes Kresladi the first gene therapy approved for this ultra-rare immune disorder, which is near-uniformly fatal in childhood without an allogeneic hematopoietic stem cell transplant. The Phase 1/2 study demonstrated 100% overall survival at 12 months with all primary and secondary endpoints met and no treatment-related serious adverse events.
Rocket was awarded a Rare Pediatric Disease PRV, worth an estimated $150--160 million based on recent transactions. The company estimates approximately 25 new LAD-I cases per year in the US; treatment is approved for patients who lack a matched sibling donor.
Kresladi was in-licensed from CIEMAT and associated Spanish research institutions, with the lentiviral vector developed in collaboration between University College London and CIEMAT. The upstream licensing economics, confirmed through analysis of Rocket's SEC filings (FY2023-2025 10-Ks), are now substantially characterized:
Upstream CIEMAT/UCL License Obligations (Triggered by FDA Approval)
| Term | Detail |
|---|---|
| Licensors | CIEMAT Group (CIEMAT, CIBER, FIISFJD) + UCL Business PLC (UCLB) |
| Contractual basis | November 2017 LAD-I License Agreement (worldwide exclusive license to lentiviral ITGB2/LAD-I gene therapy IP) |
| Aggregate development and regulatory milestones | Up to EUR 5.0 million (~$6.0 million) |
| Royalties on net Kresladi sales | Mid-single-digit percentage (~4-6%) |
| Sublicense consideration | A portion of any consideration received from sublicensees is owed to licensors |
FDA approval constitutes a regulatory milestone under the LAD-I license, triggering a payment that is a subset of the EUR 5.0 million aggregate cap. The exact per-milestone breakdown is not publicly disclosed—SEC filings describe them only as "specified development and regulatory milestones" without itemizing.
Notably, the aggregate milestone cap appears to have been amended upward from an initial EUR 1.35 million (FY2017 10-K) to EUR 5.0 million (FY2023-2025 10-Ks), suggesting expanded scope or additional milestone events added over time.
A separate Fred Hutchinson Cancer Research Center license includes up to $0.2 million in milestones, though it is unclear whether this applies to Kresladi specifically.
Regarding the Rare Pediatric Disease PRV (~$150-160 million estimated value): the CIEMAT/UCLB license does not contain any publicly disclosed provision for sharing PRV proceeds. The license includes obligations for sublicense revenue, but a PRV sale is generally not considered sublicense revenue---it is a regulatory benefit, not a license grant.
Circumstantial evidence supports Rocket retaining full PRV proceeds: the Q3 2025 10-Q treats potential PRV proceeds as additive cash beyond baseline runway. However, the underlying license agreements were filed under confidential treatment, so unredacted terms could theoretically include PRV-specific provisions not visible in public 10-K summaries.
The separate REGENXBIO 20% PRV-sharing provision applies only to Danon disease products, not Kresladi.
A previous BLA was met with a CRL in June 2024 related to CMC information requests. Royalty financing relevance: moderate. As an ultra-rare gene therapy (~25 patients/year) with confirmed PRV value (>$150M), the commercial asset is small but high-value. The mid-single-digit upstream royalty to CIEMAT/UCLB is a material margin consideration for an asset with a very small patient population, though the PRV provides immediate non-dilutive capital. Rocket reported cash and investments of $188.9 million at year-end 2025.
Novo Nordisk: Awiqli (Insulin Icodec) FDA Approval—First Once-Weekly Basal Insulin (March 26)
On March 26, 2026, Novo Nordisk (NYSE: NVO) announced FDA approval of Awiqli (insulin icodec), the first and only once-weekly basal insulin for adults with type 2 diabetes. Awiqli reduces basal insulin injections from seven per week to one, administered via FlexTouch pen.
Clinical Data and Regulatory Path
Approval was based on the ONWARDS Phase 3a program comprising four randomized controlled trials enrolling approximately 2,680 adults with type 2 diabetes. The BLA was resubmitted in September 2025 after an initial Complete Response Letter; the FDA had requested additional analyses on hypoglycemia. Awiqli was already approved in the EU, Canada, and 13 additional countries at the time of U.S. approval. U.S. commercial launch is expected H2 2026.
Royalty Implications
Insulin icodec was developed entirely in-house by Novo Nordisk using its proprietary insulin acylation and albumin-binding technology. No upstream academic, licensing, or third-party royalty obligations have been identified. The approval is commercially significant---the global basal insulin market exceeds $15 billion annually---but carries no identified royalty-relevant economics for external investors. The primary competitive dynamic is with Eli Lilly's insulin efsitora alfa (also once-weekly, FDA filing expected), creating a first-mover advantage for Novo Nordisk in the once-weekly insulin category.
EMA CHMP March Plenary: Full Opinions Published (March 27)
The EMA CHMP published its full March 23--26 plenary meeting highlights on March 27, 2026, yielding substantially more regulatory activity than the Rhythm IMCIVREE opinion already captured.
New Medicine Positive Opinions (Four)
| Medicine | Company | Indication | Type |
|---|---|---|---|
| Adstiladrin (nadofaragene firadenovec) | Ferring | BCG-unresponsive non-muscle invasive bladder cancer | Conditional MA (first gene therapy for this indication in EU) |
| Imdylltra (tarlatamab) | Amgen | Relapsed extensive-stage small cell lung cancer | MA (orphan); BiTE immunotherapy |
| Zepzelca (lurbinectedin) | PharmaMar | Maintenance in ES-SCLC after first-line non-progression | MA (orphan) |
| Bopediat (furosemide) | Proveca | Paediatric oedema and hypertension in CKD | PUMA |
The tarlatamab (Imdylltra) positive opinion is particularly relevant for royalty investors: Amgen acquired tarlatamab through its $27.8 billion Horizon Therapeutics acquisition and the asset originated from Amgen's proprietary BiTE platform. No third-party royalties are known. The CHMP positive opinion and subsequent EC marketing authorization trigger no external milestone payments---tarlatamab is wholly owned post-Micromet acquisition.
PharmaMar's lurbinectedin (Zepzelca) carries licensing economics through its partnership with Jazz Pharmaceuticals for US rights (Jazz pays PharmaMar tiered royalties on US net sales ranging from mid-teens to low-twenties percent); the EU approval triggers PharmaMar's own commercial economics in Europe. PharmaMar retains EU commercial rights directly while Jazz holds US-only rights ($200M upfront, up to $800M milestones). The Jazz deal may include EU regulatory milestone provisions even though Jazz lacks EU commercial rights—verification against Jazz's 10-K is warranted. PharmaMar may also receive milestones from regional EU distribution partners.
Ferring's nadofaragene firadenovec was originally developed by FKD Therapies and carries upstream royalty obligations to the University of Kuopio/University of Eastern Finland. Possible small academic milestones from adenoviral vector technology licenses may be triggered by EU conditional marketing authorization, but Ferring is private with limited disclosure.
Extension-of-Indication Opinions (Sixteen Across Thirteen Medicines)
Key extensions with royalty relevance include: Sotyktu (deucravacitinib, BMS) for psoriatic arthritis; Retsevmo (selpercatinib, Lilly) for additional RET-altered solid tumors; Hympavzi (marstacimab, Pfizer) for haemophilia A/B; Mekinist/Tafinlar (Novartis, two extensions each); mResvia (Moderna, RSV vaccine extension); Capvaxive (MSD); and Sarclisa subcutaneous formulation (Sanofi) for multiple myeloma.
Negative Outcomes and Withdrawals
Anavex withdrew its blarcamesine MAA for Alzheimer's disease---a significant pipeline setback following the December 2025 initial negative CHMP opinion. Vanda's Hetlioz re-examination for Smith-Magenis syndrome was confirmed as a refusal. The CHMP also recommended tecovirimat should no longer be used for mpox treatment (remaining authorized for smallpox/cowpox only). A reflection paper on tailored biosimilar clinical development was adopted, potentially reducing data requirements for future biosimilar approvals.
ACC.26 Late-Breaking Trials Opening (March 28)
ACC.26 opened on March 28 in New Orleans with 27 late-breaking clinical trial presentations across 60 sessions. Key royalty-relevant trials include:
Merck CADENCE (WINREVAIR/sotatercept, CpcPH-HFpEF): Met primary endpoint with statistically significant PVR reduction at 24 weeks versus placebo across both dose arms (0.3 and 0.7 mg/kg, N=164). This opens a major new indication for sotatercept beyond PAH. Sotatercept was acquired through Merck's $11.5 billion Acceleron acquisition. Critically, BMS/Celgene does not retain royalty rights on sotatercept---under the 2008 Acceleron-Celgene collaboration, Celgene exercised its opt-in on luspatercept (REBLOZYL) but declined sotatercept, leaving Acceleron with full rights. The upstream obligations are academic: low single-digit royalties (~1-3%) to the Salk Institute and Harvard/Massachusetts General Hospital for foundational activin receptor trap platform IP. A potential CpcPH-HFpEF indication could substantially expand WINREVAIR's addressable market beyond the current PAH franchise.
BMS SCOUT-HCM (mavacamten/Camzyos, adolescent oHCM): First Phase 3 trial of a cardiac myosin inhibitor in adolescents---potential pediatric label expansion. Mavacamten was developed by MyoKardia (acquired by BMS for $13.1 billion in 2020) and carries low single-digit royalties (~1-4%) to Stanford University for foundational cardiac myosin IP. No residual CVR or shareholder payments from the MyoKardia acquisition remain outstanding.
BridgeBio acoramidis (Attruby, ATTRibute-CM OLE): Long-term efficacy and survival data in ATTR-CM from the open-label extension. BridgeBio acquired acoramidis through its development of the AG10 program; no significant third-party royalty is disclosed.
Ionis KARDINAL (tonlamarsen, uncontrolled hypertension) and ESSENCE-TIMI 73b CTA substudy (olezarsen, coronary atherosclerosis): Both wholly owned Ionis programs.
Amgen VESALIUS-CV (evolocumab/Repatha): Subgroup analysis in patients without significant baseline atherosclerosis.
W13 Summary (March 23-28)
W13 generated approximately $14.5 billion in new transaction value announced across the six largest biopharma deals (Merck/Terns $6.7B, Gilead/Ouro $2.175B, Novartis/Excellergy $2B, Sanofi/Kali $1.23B, Otsuka/Transcend $1.225B, Cencora/EyeSouth $1.1B), plus two major deal closings---Abbott's previously announced $21 billion Exact Sciences acquisition and Thermo Fisher's $8.875 billion Clario Holdings acquisition---and one active CVR-bearing tender offer (Gilead/Arcellx, $7.8 billion including $5/share CVR).
Arbutus Biopharma's $2.25 billion Moderna LNP patent settlement ($950M upfront + $1.3B contingent) was also disclosed during the window. Additional licensing and platform deal value includes the Alteogen/Biogen Hybrozyme license (up to $579M) and the MSD/Quotient Therapeutics IBD target discovery alliance (up to $2.2B).
On the infrastructure side, UCB committed $2 billion to its Gwinnett County biologics manufacturing campus. Earendil Labs raised $787 million---the largest private biopharma financing of the week---anchored by Sanofi, the Pfizer/Hillhouse Biotech Development Fund, Dimension Capital, and DST Global, though the company's Beijing-headquartered operations and undisclosed IP relationship with affiliate Helixon Therapeutics raise provenance and BIOSECURE Act considerations.
The week delivered five confirmed FDA approvals (GSK/Alfasigma's Lynavoy as the first-in-class IBAT inhibitor for cholestatic pruritus in PBC—approved March 17 ahead of its March 24 PDUFA, triggering a $100M milestone—Novo Nordisk's Awiqli as the first once-weekly insulin, Corcept's Lifyorli in ovarian cancer, Denali's AVLAYAH in Hunter syndrome, and Rocket Pharma's Kresladi gene therapy for LAD-I), and a wave of clinical data readouts from AAD 2026, ACC.26, ELCC 2026, and AD/PD 2026.
The week's most significant clinical surprise was AstraZeneca's tozorakimab dual Phase 3 success in COPD---the first anti-IL-33 biologic to achieve confirmatory Phase 3 results, with efficacy across all eosinophil counts and peak sales estimates of $3-5 billion annually.
Across the week, confirmed and high-probability milestone triggers totaled approximately $640--700 million, dominated by the Denali/AVLAYAH approval ($200M Royalty Pharma closing + F-star regulatory milestone + $150--160M PRV), the Rocket/Kresladi PRV ($150--160M), the GSK/Alfasigma Lynavoy FDA approval milestone ($100M, confirmed), the Maze/Shionogi $20M ESPRIT Phase 2 milestone, the Lexicon/Novo Nordisk $10M clinical initiation milestone, with additional probable triggers from Basilea/CARB-X (~$1--3M).
Upstream Royalty Obligation Analysis: Of the fifteen major regulatory and deal events examined during W13 (including the confirmed Lynavoy/linerixibat FDA approval on March 17), six clearly trigger contractual payments to third parties, three likely trigger payments with undisclosed specifics, and six trigger no upstream obligations whatsoever.
The most material ongoing obligation created during the week is Denali's 9.25% synthetic royalty to Royalty Pharma on worldwide AVLAYAH sales---critically, the F-star/invoX Pharma license was confirmed to carry no ongoing royalties on product sales (only milestones from a ~$243M remaining pool), making Royalty Pharma's 9.25% the sole royalty burden on AVLAYAH.
Rocket's mid-single-digit royalty to CIEMAT/UCLB on Kresladi net sales represents a more typical academic/originator license structure. Corcept's Lifyorli was verified as fully proprietary with zero royalty burden in ovarian cancer---a clean profile ideal for synthetic royalty financing. Merck's WINREVAIR/sotatercept carries only academic royalties (~1-3% to Salk Institute/Harvard/MGH)---BMS/Celgene does not retain royalty rights, having declined the opt-in under the original Acceleron collaboration.
The most notable undisclosed obligation is Excellergy's near-certain university license from Stanford and the University of Bern (see above), which Novartis will inherit upon closing the $2 billion acquisition.
The Disc Medicine/Roche bitopertin royalty (licensed from Roche in December 2019 after Roche abandoned the GlyT1 inhibitor following Phase 3 failure in schizophrenia; Disc repurposed it for erythropoietic protoporphyria; license terms: $4M upfront, up to $37.5M development/regulatory milestones, up to $60M commercial milestones, tiered royalties in the high single-digit to high-teens percentage range on net revenue for 10 years from first commercial sale per country or until patent expiry) saw a significant setback during the W13 window:
the FDA issued a Complete Response Letter on February 13, 2026, rejecting accelerated approval despite acknowledging significant PPIX reduction. Disc is now pursuing the APOLLO Phase 3 traditional approval pathway, which completed enrollment ahead of schedule in March 2026 with topline data expected Q4 2026 and a potential FDA decision by mid-2027. Disc holds approximately $791M in cash as of year-end 2025---ample runway, but the Roche royalty obligation is now delayed by at least 12--18 months.
The Vaxcyte/Sutro platform royalty on VAX-31 presents a more complex structure than previously described. Per Vaxcyte's 10-K filings, the royalty obligation is 4% on worldwide human vaccine net sales (2% for animal health), not the ~2--3% previously estimated. Critically, Vaxcyte is also obligated to cover any Stanford University royalties (the upstream licensor to Sutro, based on Professor James R. Swartz's cell-free protein synthesis research) that exceed the 4% Vaxcyte already pays—an unusual pass-through provision that creates unbounded downstream risk.
In June 2023, Blackstone Life Sciences purchased the economic interest in Sutro's entire 4% royalty stream for $140M upfront plus up to $250M in milestones, creating a four-party chain: Stanford → Sutro → Blackstone (economic interest holder) / Vaxcyte (obligor). Royalties continue per vaccine per country until the later of last valid patent expiration or ten years after first commercial sale, with the latest Sutro patent expiring around 2036. VAX-31 Phase 3 enrollment is now complete. These two royalty streams remain the most actionable royalty financing targets from the W13 window.
The Alteogen Hybrozyme portfolio -- now spanning eight or more blue-chip licensees including Biogen, Merck, Pfizer, Sandoz, and Teva -- represents a growing platform royalty monetization opportunity comparable structurally to Halozyme's ENHANZE business, contingent on resolution of the Halozyme FTO question.
The week's events reinforce a clear pattern: gene therapies and in-licensed molecules carry the heaviest upstream burdens, while internally discovered small molecules (Lifyorli, zilganersen, LX9851, envudeucitinib, Rinvoq) and fully acquired assets (Restylane Contour) are typically clean.
Notably, none of the newly announced W13 transactions included contingent value rights---Merck, Gilead (for Ouro), Novartis, Sanofi, and Shionogi all chose clean cash structures despite the broader 2025--2026 trend toward CVR usage (27 CVR-structured biopharma deals in 2025, up from 7 in 2024). Two previously announced CVR-bearing transactions remained active during the window: the Gilead/Arcellx $5/share non-transferable CVR ($6B anito-cel cumulative sales trigger) and the Lisata/Kuva Labs $1/share non-tradeable CVR (NDA filing trigger for certepetide).
The most significant CVR instrument surfacing through the amended additions is the Nimbus/Takeda zasocitinib structure -- up to $2 billion in contingent payments to former Nimbus Lakshmi shareholders -- which is milestone-based and equity-structured rather than a percentage-of-sales royalty and therefore less directly relevant to royalty financing models.
Apogee Therapeutics' $403 million upsized public offering was the largest equity capital raise of the week. In total, over 120 distinct transactions, milestones, clinical events, and corporate developments were identified across the full W13 window:
The W13 window (March 23-28) ran concurrent with BIO-Europe Spring (Lisbon, March 23-25)---drawing over 3,700 attendees from 2,000+ companies for 20,000+ partnering meetings---the Jefferies Pan-European Mid-Cap Conference (London, March 24-26), the AAD 2026 annual meeting (Denver, March 27-31), the AD/PD 2026 congress (Copenhagen), DCAT Week 2026 (New York, March 23-26) where Samsung Biologics held 50+ business meetings and Catalent, Lonza, Thermo Fisher/Patheon, and Pharmaron maintained significant CDMO presences (no specific deal announcements made public during the week---deals catalyzed at DCAT typically surface weeks later), ACS Spring 2026 (Atlanta) featuring first-time medicinal chemistry disclosures from Novartis, Biohaven/CD3, and Genentech, and the opening of ACC.26 (New Orleans, beginning March 28) with 27 late-breaking clinical trial presentations across 60 sessions.
Marquee trials include: HI-PEITHO (catheter-directed thrombolysis vs. anticoagulation in intermediate-high-risk PE); CHAMPION-AF (left atrial appendage occlusion vs. oral anticoagulation in AF); Merck CADENCE (WINREVAIR/sotatercept met primary endpoint in CpcPH-HFpEF---a potential new indication beyond PAH); BMS SCOUT-HCM (mavacamten in adolescent obstructive HCM---label expansion); BridgeBio acoramidis (Attruby long-term OLE survival data in ATTR-CM, building on a 44% CV mortality hazard reduction at Month 42); and PKP2-ACM gene therapy (AAVrh.10hPKP2/LX2020 safety/efficacy).
Additional late-breaking sessions scheduled across the March 28-31 program include CORALreef AddOn (enlicitide decanoate, oral macrocyclic peptide PCSK9 inhibitor vs. bempedoic acid/ezetimibe), KARDINAL (Ionis tonlamarsen antisense for uncontrolled hypertension), ORBITA-CTO (placebo-controlled chronic total occlusion PCI), and OPTIMAL (IVUS-guided left main PCI).
The FDA's approval of Rocket Pharma's Kresladi on March 26, Novo Nordisk's landmark Awiqli approval on March 26, and Friday's cluster of Novartis/Excellergy, Otsuka/Transcend, and AnaptysBio/First Tracks announcements on March 27 extended significant deal flow through the end of the window.
AAD 2026 produced a landmark cluster of dermatology data including dual TYK2 inhibitor Phase 3 validations (Alumis and Takeda), AbbVie's first-ever Phase 3 vitiligo results for Rinvoq, and additional late-breaking presentations from Biogen, Galderma, Nektar, Arcutis, Pfizer, and Sanofi covering a broad range of inflammatory skin diseases.
Disclaimer: The author is not a lawyer or financial adviser. Nothing in this article constitutes investment advice, legal advice, or a recommendation to buy or sell any security. The information presented is based on publicly available sources and is provided for informational and educational purposes only. Readers should conduct their own due diligence and consult qualified professionals before making any investment decisions.
Member discussion